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CHAPTER 1
INTRODUCTION AND OUTLINE OF THE THESIS
Chapter 1
Introduction
The three mechanisms that are considered to be most important for failure after radiotherapy 
are intrinsic radio-resistance, rapid proliferation o f tumor cells and tumor cell hypoxia. In 
recent years many studies have been undertaken to analyze and to minimize the negative 
effects of these three mechanisms on treatment outcome.
Intrinsic radio-resistance has been studied mainly with clonogenic assays. Tumor cells are 
cultured and exposed to radiation. Only surviving cells are able to form macro-colonies, 
therefore the number o f colonies is a reflection o f the intrinsic radio-sensitivity [15,40]. 
DNA double strand break repair, chromosome break analysis and micronucleus formation 
can also be used to study intrinsic radio-sensitivity [1]. Different tumor categories have been 
identified on the basis o f intrinsic radio-sensitivity [12]. However, it is still impossible to 
modify radiotherapy for individual patients based only on differences derived from intrinsic 
radio-sensitivity assays alone. Clinical studies were undertaken to overcome the negative 
effect o f intrinsic radio-resistance on treatment outcome for different tumor groups. These 
studies include dose escalation in combination with conformal radiotherapy, intensity 
modulated radiotherapy or hyperfractionated radiotherapy and the use of radio-sensitizers 
[41,46,48,59]. Several o f these treatment modifications have not yet been tested in 
randomized trials [41,45,59]. The combination o f radiotherapy with cis-platin used as 
radiosensitiser has resulted in an increase in loco-regional tumor control and survival in non­
small cell lung cancer [48].
The proliferation rate o f cells can be analyzed with proliferation markers such as the 
thymidine analogues bromodeoxyuridine and iododeoxyuridine (BrdUrd and IdUrd) [18]. 
BrdUrd is incorporated into the DNA of cells that are in S-phase o f the cell cycle. After 
immunohistochemical or immunocytochemical detection, the labeling index (LI) as 
determinant o f the proliferative activity, can be calculated in tissue sections or by flow 
cytometry (FCM) as the number o f BrdUrd labeled cells versus the total number o f cells 
[2,28]. In various tumors, including those o f the brain and the head and neck area, it was 
shown that a high LI was correlated with poor loco-regional tumor control [3,14]. 
Retrospective analysis of clinical trials demonstrated that a prolonged overall treatment time 
was associated with a reduced loco-regional tumor control rate [58]. It was postulated that 
an increase in the tumor cell proliferation rate, induced by radiation, accounts for this loss of 
treatment effect [58]. It was subsequently shown in several trials in head and neck cancer
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patients and in patients with non-small cell lung cancer that reduction of the overall treatment 
time resulted in an increase in loco-regional tumor control and survival [9,13,26,39,47,49].
The oxygenation status o f malignant tumors plays a crucial role in cancer treatment and 
prognosis. The fact that the mutation frequency in cultured cells under hypoxic conditions is 
elevated, makes it likely that hypoxic cells play an important role in malignant tumor 
progression [45]. This is supported by clinical studies showing an increased incidence of 
distant metastases in hypoxic soft tissue sarcomas and hypoxic carcinomas o f the uterine 
cervix [5,51]. The same mechanism might explain the association between hypoxia and 
poor local control after surgical treatment in cancer o f the uterine cervix and soft tissue 
sarcomas [24,25,37].
The above mentioned consequences o f hypoxia may play an important role in the outcome 
after radiotherapy as well. Furthermore, it has been known for decades that hypoxic cells 
are more resistant to irradiation than normoxic cells [19,34]. The oxygen enhancement ratio 
(OER) is the ratio o f the radiation dose needed to induce the same level o f cell kill under 
hypoxic conditions and normoxic conditions. For most cell cultures the OER is close to 3. 
This phenomenon is explained by the oxygen fixation hypothesis. According to this 
hypothesis free radicals are produced in the nucleus by direct or indirect action o f radiation 
and cause local damage to the DNA. This damage can be repaired under hypoxic conditions 
but is fixed in the presence o f oxygen [21,27].
Two forms o f tumor cell hypoxia were identified in tumors: diffusion limited or 'chronic' 
hypoxia and perfusion limited or 'acute' hypoxia. In the classic description o f hypoxia, 
tumor cells at a certain distance from blood vessels (100 to 150 ^m) are beyond the 
maximum diffusion distance o f oxygen and become chronically hypoxic [52]. The second 
form o f hypoxia is caused by transiently opening and closing o f blood vessels producing 
fluctuations in blood perfusion o f tumor regions and resulting in changes in the oxygen 
tension [7]. In tumor tissue this rhythmic opening and closing o f vessels was observed with 
laser Doppler blood flow measurements [22]. Tumors have their own characteristic vascular 
network that differs from that o f normal tissues with respect to vessel diameter, inter 
vascular and inter branch distances [4,31]. The combination o f fluctuations in tumor blood 
perfusion together with an inadequate vascular network will cause tumor cells to be exposed 
to a combination o f chronic and acute hypoxia.
There are several methods available to analyze tumor cell hypoxia [50]. Most assays are 
designed to determine the oxygenation status at a certain moment in time. The classical way
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for calculating the hypoxic fraction is with the paired survival-curve method [35,54]. With 
this method the results o f a clonogenic assay under normoxic conditions are compared with 
a clonogenic assay under anoxic conditions. From these two clonogenic assays the 
parameters are derived to calculate the radiobiological hypoxic fraction. Another way to 
study the radiobiological hypoxic fraction is with the comet assay. In this assay differences 
in DNA double strand breaks between hypoxic and normoxic cells are used to calculate the 
hypoxic fraction [38].
Tumor cell hypoxia can also be studied with the use o f bio-reductive chemical markers such 
as the 2-nitroimidazoles [30,32,43,44]. Following injection and bio-chemical reduction of 
these markers under hypoxic conditions, adducts are irreversibly bound in hypoxic cells. 
There are now several bio-reductive markers available such as pimonidazole, EF5, NITP 
and CCI-103F. Pimonidazole and EF5 are now being applied in clinical studies [10,29,57]. 
With immunohistochemical techniques bio-reductive marker adducts can be visualized. The 
ratio o f cells positive for the hypoxic marker and the total number o f cells determine the 
hypoxic fraction. Calculation o f this ratio is based on the analysis o f tissue sections or by 
flow cytometry [29,56].
The tissue oxygen (pO2) tension can be measured directly with polarographic needle 
electrodes (Eppendorf™) [55]. Clinical studies with polarographic needle electrodes clearly 
showed that loco-regional tumor control after radiotherapy is worse for hypoxic tumors as 
compared to better oxygenated tumors [6,36]. The disadvantage o f pO2 measurements with 
polarographic needles is that for these measurements small amounts o f oxygen are 
consumed. This is the reason why it is not possible to measure at one position in a tumor 
over a prolonged period o f time [8,20].
Recently a fiber-optic probe was developed for pO2 measurements based on time-resolved 
luminescence. These probes and the associated equipment is now commercially available 
(OxyLite™) [8,60,61]. Because there is no oxygen consumption involved in these 
measurements, tumor pO2 can be recorded over a prolonged period o f time at the same 
position in a tumor. Other methodologies that can give dynamic information on tumor 
oxygenation include electron paramagnetic resonance (EPR) oximetry [16,17], 
cryospectrophotometry of intra-vascular oxyhemoglobin (HbO2) saturation profiles [11] and 
spin-lattice relaxation of fluorinated Magnetic Resonance (MR) agents [33]. These methods 
are not available yet for clinical use.
Failure to respond to irradiation and other forms of anti-cancer therapy is not caused by one 
o f these mechanisms in isolation, therefore intensifying and modulating treatment has to be 
aimed at several of the above mentioned radio-resistance mechanisms.
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Assays for selection o f patients for intensified treatment combinations should be developed 
into two directions. First, assays are needed to study a combination o f tumor 
microenvironmental parameters that are considered to be o f importance for treatment 
outcome. This can be illustrated with unexpected effects occurring in the tumor 
microenvironment after carbogen (95% O2, 5% CO2) breathing. Initially carbogen breathing 
was chosen over 100% O2 because 100% O2 may have a negative effect on tumor blood 
flow. The addition o f 5% CO2 would result in relaxation o f the vascular system and tumor 
blood perfusion would then not be reduced if  oxygen were given in combination with CO2 
[23]. Laser Doppler flow measurements as well as analysis o f tumor blood perfusion by 
gadolinium DTPA M R has shown that carbogen by itself had different effects on tumor 
blood flow. An increase as well as an unexpected decrease o f tumor blood flow after 
carbogen breathing was reported in several studies [42,53].
Secondly, new assays should be designed that can assess the effect o f certain treatment 
modifications in individual patient's tumors before the treatment is actually started. In the 
example o f oxygen modification, assays should be used that directly measure the effect of 
test doses o f vaso-active drugs or the breathing o f oxygen enriched gas mixtures over time 
in a given patient. In this way only the patients that respond favorably to the treatment 
modification can be selected for these approaches.
The aim o f the studies described in this thesis was to further develop and test methods to 
measure tumor microenvironmental parameters in relation to the tissue architecture. The 
oxygenation status together with other parameters, were analyzed with fiber-optic oxygen 
sensors and with bio-reductive hypoxic markers in combination with cell proliferation 
markers and blood perfusion markers. Effects o f carbogen, nicotinamide and irradiation on 
these parameters were analyzed.
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Outline of the thesis
The introduction to this thesis is given in chapter 1. The three main radiation resistance 
mechanisms, intrinsic radio-resistance, rapid tumor cell proliferation and tumor cell 
hypoxia, are discussed. Examples are given of how these resistance mechanisms can be 
studied and modified.
The focus of this thesis is on the measurement and modification of the tumor oxygenation 
status in relation to other microenvironmental parameters such as vascular architecture, 
tumor blood perfusion and tumor cell proliferation. New methods to study the combination 
of these parameters at the microscopic level and to measure changes in pO2 in response to 
carbogen, nicotinamide and irradiation dynamically are presented.
In chapter 2 the clinical results of accelerated radiotherapy given in combination with 
carbogen breathing and nicotinamide (ARCON) for treatment of advanced stages of head 
and neck cancer are presented.
Experimental studies showed an almost two-fold increase in effectiveness if accelerated 
radiotherapy combined with carbogen and nicotinamide was compared with standard 
radiotherapy. This combination was chosen to overcome repopulation of clonogenic tumor 
cells during radiotherapy and to minimize radio-resistance due to tumor cell hypoxia.
A total of 124 patients with stage III or IV head and neck squamous cell carcinomas received 
the ARCON-treatment. Loco-regional control and toxicity are described for larynx 
carcinomas, hypopharynx carcinomas and for oral cavity and oropharynx carcinomas.
Despite the high loco-regional control rates, still some patients fail after treatment. This, in 
combination with an increase of toxicity, indicates the need for optimal selection of patients 
for this type of treatment intensification. This has led to the development and the 
standardization of a multi-parameter assay for the analysis of tumor vascular architecture, 
tumor blood perfusion and tumor cell proliferation, which is presented in chapter 3.
Whole cross-sections of human larynx carcinoma and glioblastoma xenografts were studied. 
Hoechst 33342 and BrdUrd were used as perfusion and proliferation markers and the anti­
endothelial antibody 9F1 was used to delineate vascular structures. The sections were 
analyzed by a multi-step immune-staining and computer-controlled microscope scanning 
method. The various vascular and proliferation parameters were quantitated and related by 
analysis of the computerized images.
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In chapter 4 the assay for multi parameter analysis of tumor microenvironmental parameters 
was expanded to include analysis of tumor cell hypoxia with a bio-reductive hypoxic cell 
marker (NITP). The effects of carbogen and nicotinamide on tumor hypoxia, proliferation 
and perfusion in relation to the vascular architecture of two human laryngeal squamous cell 
carcinoma xenograft lines were studied. The results showed improvement of the 
oxygenation status by treatment with carbogen. Carbogen breathing was very effective in 
reducing diffusion limited ('chronic') hypoxia and had an additional anti-proliferative effect. 
In one of the two tested tumor lines a reduction of tumor blood perfusion occurred after 
carbogen breathing which was reversed by nicotinamide, indicating that the addition of 
nicotinamide may be important to compensate for this undesired effect of carbogen in certain 
tumors. This also demonstrates that tumors originating from the same anatomical site with 
similar histology may respond differently to oxygenation modifying treatments.
The above-described method for multi-parameter analysis of the tumor microenvironment 
has many advantages such as a high spatial resolution. However, temporal changes in for 
instance pO2 in the same tumor can not be measured. To add dynamic information on pO2, 
bio-reductive hypoxic marker binding was related to fiber-optic pO2 measurements in 
chapter 5. The newly developed fiber-optic oxygen sensing device, OxyLite™, was further 
standardized. Tumor pO2 measurements were compared with bio-reductive hypoxic marker 
binding (pimonidazole) in three human tumor xenograft lines.
Temporal changes in tumor pO2 resulting from carbogen breathing and nicotinamide 
administration were studied in three human xenograft lines with the OxyLite™ system in 
chapter 6 . Bio-reductive hypoxic cell marker binding in combination with OxyLite™ pO2 
determination gives spatial information about the distribution patterns of tumor hypoxia at 
the microscopic level together with the possibility to continuously measure changes in pO2 
in specific tumor areas.
The effect of irradiation depends on the oxygenation status of a tissue, while irradiation 
itself also changes the oxygenation and perfusion status of tissues. A better understanding 
of these changes will allow a better planning of radiotherapy in combination with modifiers 
of blood flow and hypoxia. Studies on the effect of irradiation on tumor hypoxia are 
presented in chapter 7.
Vasculature, perfusion and hypoxia were studied in a human laryngeal squamous cell 
carcinoma xenograft line after a single dose of 10 Gy X-rays.
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These experiments showed that irradiation causes rapid changes in the tumor oxygenation 
status and the tumor blood perfusion. This may have consequences for the optimal timing of 
radiotherapy schedules employing multiple fractions per day and the introduction of 
oxygenation and perfusion modifying drugs.
In chapter 8 the summary and conclusion of this thesis are given.
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Abstract
Introduction. Experimental studies have shown an almost twofold increase in effectiveness 
if accelerated radiotherapy combined with carbogen and nicotinamide (ARCON) was 
compared with standard radiotherapy. This combination was chosen in order to overcome 
repopulation of clonogens during radiotherapy and to minimize tumor hypoxia. Analysis of 
microenvironmental parameters is required to identify tumors that can benefit from this new 
treatment approach.
Materials and methods. In this study 124 patients with stage III or IV head and neck 
squamous cell carcinomas received ARCON treatment. Vascular architecture, perfusion, 
proliferation and oxygenation were studied in two human laryngeal squamous cell 
carcinoma xenograft lines and the effects of carbogen and nicotinamide were analyzed. 
Results. Loco-regional control for stage III-IV larynx carcinomas was 85%, for 
hypopharynx carcinomas 50% and for oral cavity and oropharynx carcinomas 65%. In the 
experimental studies, carbogen treatment resulted in one tumor line in a decrease of blood 
perfusion, which was reversed if nicotinamide was added. The other tumor line showed no 
perfusion changes after carbogen or nicotinamide treatment. Both tumor lines showed a 
drastic reduction of hypoxia after carbogen breathing only or carbogen breathing plus 
nicotinamide.
Conclusion. The ARCON schedule results in high loco-regional tumor control rates. 
Analysis of tumor microenvironmental parameters showed differences in response to 
carbogen and nicotinamide between different tumor lines of similar histology and site of 
origin. This indicates that it may be advantageous to base the selection of patients for 
oxygenation modifying treatment on microenvironmental tumor characteristics.
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Introduction
Radiotherapy is often preferred to surgery for the treatment o f head and neck cancer, 
because o f the good results in loco-regional control combined with preservation o f organ 
function. The treatment of early laryngeal cancer with radiotherapy alone, for example, can 
achieve cure rates o f 66-93% [1]. However, there has also been on-going work aiming to 
improve the results of radiotherapy for more advanced local disease.
Advanced local disease can only be treated successfully if  radiotherapy is given in 
combination with a strategy to overcome the effect o f radiation-resistance mechanisms. The 
three radio-resistance mechanisms that are considered to be most important for radiation 
treatment failure are: intrinsic radio-resistance, tumor cell repopulation during treatment and 
tumor hypoxia. Overcoming these resistance mechanisms almost always results also in an 
increase in side effects. It is therefore important to aim at treatment intensification in 
combination with careful selection of patients for new treatment modalities.
To overcome treatment failure due to intrinsic radio-resistance the tumor dose has to be 
increased. This can be achieved by dose escalation with hyperfractionation or with 3-D 
planned conformal radiotherapy [18,41].
The second mechanism that is known to be important for failure o f loco-regional tumor 
control is cellular repopulation during treatment. It has now been recognized as an important 
cause for radiation treatment failure in various cancers, particularly in squamous cell 
carcinomas [11,24,37,46]. One week o f prolongation o f the overall treatment time during a 
course o f fractionated radiotherapy can result in a 3-25% loss o f local control [14]. 
Randomized clinical studies have shown that patients with head and neck and bronchus 
carcinomas benefit from reducing the overall treatment time to counteract repopulation of 
clonogenic tum or cells during treatment [11,24,37,46].
The third mechanism that can be a cause o f treatment failure is tumor hypoxia. A meta­
analysis of 72 randomized clinical trials showed that the combination o f radiotherapy with a 
treatment to modify tumor oxygenation resulted in an improvement o f loco-regional control 
and survival compared to radiotherapy alone [36]. This meta-analysis included, for 
example, randomized studies on the use o f hyperbaric oxygen in head and neck carcinoma 
and in carcinoma of the uterine cervix, which demonstrated an improvement in loco-regional 
control and survival if  irradiation took place under hyperbaric conditions relative to treatment 
in air [20,52]. In a recently published randomized study, an increase in tumor control and 
survival was found in patients with supraglottic and pharynx carcinomas with the hypoxic 
radiosensitiser nimorazole [38].
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Often in the above-mentioned studies there were groups o f patients showing a better 
response to the modified treatment than other groups. For example in the meta-analysis by 
Overgaard and Horsman the improvement was dominated by head and neck tumors [36].
Because o f the difference in response between categories o f patients to certain treatment 
modifications it is important to select patients before treatment is started. This selection 
needs to be based on the factors that the treatment modification is aiming at. Predictive 
assays for the various resistance mechanisms have been developed and the potential value of 
some o f these assays has been shown in clinical radiotherapy studies.
Intrinsic radio-resistance
Assessment o f the radio-sensitivity o f tumor cells by a clonogenic survival assay gives a 
direct measure o f the fraction o f cells capable o f forming colonies after a given dose of 
irradiation. However, clonogenic assays are not feasible if  cells fail to proliferate in a tissue 
culture system or, as in the case in some primary and early passage cultures, if  the tumor 
consists o f several sublines with differences in growth rate and/or intrinsic radio-sensitivity. 
Mechanism based assays o f intrinsic radio-sensitivity are being proposed and tested to use 
instead. The relative degrees o f chromosome and DNA break induction and repair, and the 
subsequent clonogenic cell survival does not only depend on the cell type, but also changes 
throughout the cell cycle. This means that non-clonogenic endpoints o f radiation sensitivity 
must be used with caution [5].
The intrinsic radio-sensitivity of squamous cell carcinomas analyzed by clonogenic assays is 
intermediate relative to tumors o f other histology [13]. Differences in parameters derived 
from clonogenic assays are correlated with the probability o f loco-regional control in head 
and neck cancer [16]. However, it is not possible to select individual patients based on 
intrinsic radio-sensitivity testing alone, because the discriminating power is not sufficient 
and often a clonogenic assay is not fast enough for clinical application.
Tumor cell proliferation kinetics
The fraction o f cells in S-phase can be analyzed after labeling with thymidine analogues 
such as bromodeoxyuridine (BrdUrd). The fraction o f labeled cells is the Labeling Index 
(LI), which is a measure o f the proliferative activity o f a cell population. The LI can be 
determined either by counting under the microscope [26] or by flow cytometry (FCM) [12]. 
Data collected from 10 different European trials showed that the pre-treatment LI, analyzed 
by flow cytometry, is correlated with local control after conventional radiotherapy [10]. The 
tissue architecture is lost because o f the processing for flow cytometry, which is a
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disadvantage because it precludes analysis o f histological patterns o f proliferation and 
relations with other structures such as blood vessels. Analysis o f whole tissue sections 
shows various differences in distribution patterns o f proliferating cells even though the 
overall LI is the same [3]. The spatial information o f proliferation patterns can give 
additional information which can help in selecting patients for accelerated treatment in certain 
tumors more than overall LI based on flow cytometry alone [3]. Recently, we presented a 
semi-automatic computer-controlled method for the analysis o f tumor cell proliferation and 
tumor blood perfusion in relation to tissue architecture in whole tissue sections [6].
Tumor oxygenation
Well-oxygenated cells are more radiosensitive than hypoxic cells [17]. In the classical model 
o f Thomlinson and Gray, hypoxic cells are located at a relatively constant distance from 
blood vessels, which is dependent on the diffusion capacity o f oxygen in tissues ('chronic' 
or 'diffusion-limited' hypoxia) [50]. Another form o f hypoxia is induced by local and 
temporary fluctuations o f tumor blood perfusion, this has become known as 'acute' or 
'transient' hypoxia [4]. It has been demonstrated that hypoxia is present to various degrees 
in most rodent and xenografted tumors [42]. Estimates o f the amount o f hypoxia in tumors 
range from 1% to 98%. These estimates depend on several factors including the method 
used for measuring hypoxia, tumor size, transplantation site and characteristics o f the host. 
In clinical studies measurement o f tumor hypoxia has been shown to predict for the 
treatment outcome o f patients receiving radiotherapy for carcinomas o f the uterine cervix, 
head and neck carcinomas and for soft tissue sarcomas [15,21,34,35]. The most commonly 
used methods for measuring the oxygenation status o f tumors and tissues are oxygen 
electrodes and, more recently, time resolved luminescence measurements for direct 
measurement o f pO2 . Another way to quantitate hypoxia is by using immunohistochemical 
staining o f bio-reductive chemical probes such as the 2-nitroimidazoles [32,40]. After 
injection and staining they can be analyzed by flow cytometry [22] or visualized in tissue 
sections [31]. In situ detection o f hypoxic probes has been used to analyze the distribution 
o f tumor hypoxia in whole tissue sections [7].
The improvement of loco-regional tumor control is in the order o f 5 to 20% if  the treatment 
is modified to counteract one o f the above mentioned radio-resistance mechanisms 
[11,20,23,24,37,38,46,52]. Even though these are important improvements, many 
individual patients will still remain uncontrolled. It is likely that a combination o f these 
treatment modifications will lead to an additive effect. The DAHANCA trials studied the 
combination of shortening the overall treatment time o f radiotherapy together with a hypoxic
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cell sensitizer. Significant increases in local control and survival were found after first 
adding the hypoxic cell sensitizer nimorazole and, secondly, reducing the overall treatment 
time by giving 6 instead of 5 treatments per week [37,38].
The combination o f Accelerated Radiotherapy with CarbOgen breathing and Nicotinamide 
(ARCON) that was first proposed by Rojas et al. is applied in the present study [43,44]. 
Carbogen (95% O2 and 5% CO2) breathing causes a rise o f the oxygen partial pressure in 
blood and tissues and reduces chronic hypoxia. In patients with head and neck cancer this 
effect was shown by direct measurements with oxygen electrodes in metastatic lymph nodes 
[33]. Nicotinamide, the amide derivative o f vitamin B 3, can reduce the intermittent closure 
o f blood vessels in experimental rodent tumors and consequently decreases transient 
hypoxia [8,25].
With carbogen alone, a TCD-50 enhancement ratio o f 1.5 was obtained in mouse tumors 
with irradiation doses close to those used clinically [44]. Addition o f nicotinamide gave 
further radio-sensitization to an enhancement ratio o f 1.7 [44]. Finally, when also 
accelerated fractionation was incorporated the complete ARCON treatment resulted in an 
enhancement ratio of 1.9, indicating an almost two-fold increase o f the effectiveness o f this 
treatment relative to conventional radiotherapy alone [44]. These promising results justified 
testing of this treatment in the clinic.
It is clear that it is necessary to combine treatment modalities in order to increase tumor 
control. Often this will lead to an increase o f side effects. Therefore, in parallel with 
treatment modifications, predictive tests are being developed to select patients or categories 
o f patients that are more likely to benefit from these new treatment approaches. In our 
microenvironmental study we aim to combine tumor architecture, vascularization, tumor cell 
proliferation and hypoxia into one predictive profile. This profile will enable us in the future 
to identify patients or categories o f patients for these new treatment combinations.
In this paper the results o f the ARCON treatment for head and neck cancer and the recent 
advances in the development o f predictive profiles to select patients for this treatment are 
presented.
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Materials and methods
Clinical study
Study design and patients
Patients with squamous cell carcinomas o f four major head and neck sites: oral cavity, 
oropharynx, larynx and hypopharynx, were included in this study. All patients had 
advanced disease, i.e. stage III or IV. Also voluminous stage II hypopharyngeal lesions 
were eligible.
Between October 1993 and May 1998 124 patients received the ARCON treatment. The 
study started with larynx carcinoma patients only, but from November 1995 patients with 
hypopharynx, oral cavity and oropharynx carcinomas were also eligible. The distribution by 
tumor site and TNM-stage [UICC 1992] is shown in Table 1.
The study was approved by the local ethics committee.
Accelerated Radiotherapy
The treatment started with giving one fraction o f 2 Gy per day, five times a week. During 
the last 1.5 weeks, treatments were given twice daily (2 Gy per fraction) with an interval 
between the fractions of at least 6 h. The overall treatment time was 36-38 days. Total dose 
was 68 Gy for gross disease and 44 Gy for the nodal areas treated electively. Sensitization 
o f the laryngeal cartilage has been reported after radiotherapy in hyperbaric oxygen. A 10% 
reduction of the total dose in a subsequent study o f hyperbaric oxygen reduced the laryngeal 
complications to a level seen with treatment in air [20]. Since a similar effect might be 
expected from normobaric carbogen with nicotinamide, the maximal permissible dose to the 
larynx was reduced from 70 to 64 Gy and, as a consequence, the dose for primary tumors 
o f the larynx and hypopharynx did not exceed this limit. Involved nodes received 68 Gy. 
Because a decrease in the tolerance o f the rat spinal cord o f ~20% was observed when 
radiation was combined with carbogen and nicotinamide [19], total dose to the spinal cord 
was not higher than 40 Gy.
Carbogen breathing
Scuba-diving equipment was used for carbogen delivery. Details o f this breathing system 
have been described earlier [28]. Carbogen breathing commenced 4 min before start of 
irradiation and was continued throughout the treatment.
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Nicotinamide
Nicotinamide was administered orally as a liquid formulation, 1.5 h before irradiation. On 
days when two fractions were given, only one dose of nicotinamide was taken before the 
first treatment. Initially, the daily dose was 6 g. Based on pharmacokinetic studies [47], this 
was changed to a weight-adjusted dose o f 80 mg/kg with a maximum of 6 g from April 
1994 and the interval between intake and irradiation was reduced to 1 h from November 
1995. Also from November 1995, a dose reduction to 60 mg/kg was introduced for those 
patients who experienced severe side effects.
Chemotherapy
A total o f 23 patients received chemotherapy prior to radiation treatment. This consisted of 
cis-platin weekly for 1-6 courses. All these patients had far advanced unresectable tumors. 
None of the patients with laryngeal tumors received chemotherapy.
Table 1. Patients treated with the ARCON regimen.
Distribution by tumor site and TNM-stage [UICC 1992].
larynx
N0 N1 N2 N3 Total
T1 -- -- 1 1 2
T2 -- 4 6 -- 10
T3 22 9 7 -- 38
T4 11 -- 2 -- 13
Total 33 13 16 1 63
hypopharynx
N0 N1 N2 N3 Total
T1 -- 1 -- -- 1
T2 3 4 7 1 15
T3 -- 2 3 -- 5
T4 1 3 7 1 12
Total 4 10 17 2 33
oral cavity / oropharynx
N0 N1 N2 N3 Total
T1 -- -- 1 -- 1
T2 -- -- -- -- --
T3 1 4 7 -- 12
T4 2 4 7 2 15
Total 3 8 15 2 28
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Tumor vasculature and microenvironment
Two tumor lines (SCCNij3 and SCCNij19) derived from different primary human 
squamous cell carcinomas o f the larynx were studied. Tumor vasculature (endothelium 
marker 9F1), blood perfusion (Hoechst 33342), hypoxia (NITP) and proliferation (BrdUrd) 
were studied in whole tissue sections. For details o f the staining procedure see Bussink et 
al. [6,7]. The effects o f carbogen breathing and nicotinamide on these parameters and the 
differences in response between the two tumor lines where analyzed.
The tissue sections were analyzed with an image processing system after 
immunohistochemical staining o f NITP, BrdUrd and vasculature. A high-resolution 
intensified solid-state camera on a fluorescence microscope (Zeiss Axioskop) with a 
computer-controlled motorized stepping stage was used. A detailed description o f the 
scanning method has been given by Rijken et al. [45]. Tumor cross sections were 
sequentially scanned three to four times, using different filters for the different fluorescent 
signals. After each scan o f complete tissue sections, one composite image was reconstructed 
o f the different fluorescent images. As a final step, the tumor area was delineated by 
drawing a contour line. This area was used as a mask in further image analysis excluding 
non-tumor tissue and necrotic areas from the analysis.
Quantitative data o f perfusion and vascularity were derived from the Hoechst and 9F1 
images. The area o f perfused vascular structures divided by the total vascular area o f the 
tissue section yielded the perfusion fraction [45].
The labeling index (LI) was determined from the ratio o f the BrdUrd positive surface 
(FITC) and the total nuclear surface (Fast Blue) [6].
For analysis o f the relationship between proliferation and vascularity, functional units, so 
called 'vascular domains' were calculated. Delineation o f these domains is based on 
imaginary lines which are equidistant from adjacent vessels and which are determined by 
computerized image processing [6].
In order to describe the distribution o f hypoxic regions in relation to the vasculature, the 
relative amount o f hypoxia was calculated as the fraction o f NITP-stained area in different 
zones around a perfused vessel (= relative hypoxic area) (Rijken et al. personal 
communication).
- 31 -
Chapter 2
Results
Clinical study
Carbogen and nicotinamide, compliance
Full compliance with carbogen breathing was 76%. Some patients experienced sensations of 
suffocation and/or hyperventilation and were not able to cope with the breathing procedure. 
The most common side-effects o f nicotinamide were nausea and vomiting, which occurred 
in 61% and 30% of the patients, respectively. Thirty percent o f the patients discontinued the 
drug intake and 13% required a dose reduction because of severe symptoms.
Early reactions of mucosa and skin
With the ARCON treatment 69% of the patients developed moist desquamation o f the skin 
with a mean duration o f 2.5 ± 2 weeks (SD). Healing was always complete.
Confluent mucositis occurred in 95% of the patients with larynx and hypopharynx tumors 
and in 90% of the patients with oral cavity and oropharynx tumors. Mean duration of 
confluent mucositis was 6.0 ± 3.2 weeks (SD) in larynx and hypopharynx tumors and 6.7 
± 4.0 weeks (SD) for oral cavity and oropharynx tumors. Healing was always complete.
Loco-regional tumor control
Median follow-up at the time o f analysis was 22 months for larynx carcinomas, 11 months 
for hypopharynx carcinomas and 11 months for oral cavity and oropharynx carcinomas. N o 
patients have been lost to follow-up. The actuarial loco-regional control rate at three years 
for larynx carcinomas was 85%, for hypopharynx carcinomas 50% and for oral cavity and 
oropharynx carcinomas 65% (at two years). Loco-regional tumor control for the various 
sites is shown in Figure 1.
Tumor vasculature and microenvironment
The semi-automatic method for computer-controlled quantitative analysis o f whole tissue 
sections allows studying architectural patterns o f proliferation, vascularization and 
oxygenation o f tumors. Perfused and non-perfused vessels can be distinguished and 
specific regions of interest can be analyzed separately [6,7].
Perfusion
SCCNij19 showed no changes in tumor blood perfusion after carbogen or nicotinamide 
treatment. For SCCNij3 a decrease o f tumor blood perfusion o f 11% was found after
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carbogen breathing only (from 66% to 55%). The combination o f carbogen and 
nicotinamide resulted in a 12% increase of the perfusion fraction to 78%.
Proliferation
Nicotinamide treatment resulted in an increase in LI. SCCNij3 showed an increase in LI 
from 10.7% to 14.1% and for SCCNij19 an increase from 12.6% to 14.5% was found. 
Carbogen treatment resulted in both tumor lines in a decrease o f the LI: for SCCNij3 from 
10.7% to 6.8% and for SCCNij19 from 12.6% to 5.2%.
The combination of carbogen and nicotinamide resulted in a different effect on the LI in the 
two tumor lines: for SCCNij3 the LI decreased to a level close the carbogen only group 
(5.7%), but for SCCNij19 the LI stayed close to the level o f the control tumors (10.8%).
loco-regional 
control (%)
follow-up (months)
Figure 1. Actuarial loco-regional tumor control after treatment according to the ARCON 
schedule for larynx, hypopharynx and oral cavity and oropharynx carcinoma.
Hypoxia
The NITP stained area was drastically reduced if  tumors were treated with carbogen or 
carbogen in combination with nicotinamide. At an increasing distance from 150 ^m to 300
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^m from the nearest perfused vessel the hypoxic fraction o f untreated tumors increased from 
3.5% to 11% in SCCNij3 and from 3.5% to 6% in SCCNij19.
After carbogen breathing the hypoxic fraction was reduced to 1.5% or less from 150 to 300 
^m from the nearest perfused vessel in both tumor lines. Treatment with nicotinamide alone 
did not significantly change the NITP-staining pattern in either tumor line.
As an example, figure 2 shows the binary images o f untreated and treated tumors 
(SCCNij3). There is an almost complete disappearance o f hypoxia after treatment with 
carbogen alone (not shown) or carbogen in combination with nicotinamide (top right). The 
bottom images show the decrease in proliferation after treatment with carbogen and 
nicotinamide (right) relative to the untreated tumor (left).
Discussion
Failure o f a tumor to respond to radiotherapy has been attributed mainly to three radio­
resistance mechanisms: intrinsic radio-sensitivity, accelerated repopulation during 
radiotherapy and tumor hypoxia. This paper focuses on treatment modification to overcome 
the latter two. Both the clinical response o f the ARCON treatment and the development of 
pre-treatment testing to select patients that can benefit from this new treatment approach are 
presented. The changes in the tumor microenvironment after carbogen breathing and 
nicotinamide are described.
Clinical study
Patients with squamous cell carcinomas o f the head and neck were selected because there 
was already evidence that this category o f patients can benefit both from acceleration and 
from hypoxic modification. Additional arguments were that the loco-regional control rate for 
the more advanced cases is not yet satisfactory and that organ preservation in the head and 
neck region is o f great value. This region is easily accessible for assessment o f normal 
tissue reactions and tumor response. Finally, hypoxic modification and treatment 
acceleration increases loco-regional control [20,38].
In the present study patients were treated with a combination o f accelerated radiotherapy, 
nicotinamide and carbogen. This approach has led to a loco-regional control rate for stage 
III-IV larynx carcinomas of 85% at 3 years, which is considerably higher than the control 
rates o f 23-53% that are obtained with conventional irradiation schedules [2,49,51]. In fact, 
better results have not previously been reported. The results of the ARCON treatment for 
hypopharynx and oral cavity and oropharynx tumors are not as high as for the larynx
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carcinomas. However, these patients had more voluminous tumors with 70% of the 
hypopharynx tumors and 82% of the oral cavity and oropharynx tumors being stage IV (see 
Table 1). Most o f the patients with oral cavity and oropharynx tumors had unresectable 
disease and were referred for palliative treatment. A 65% 2-year loco-regional control rate 
for this category o f patients is certainly very encouraging.
Although these results are very promising, an increase in mainly acute toxicity is observed. 
Both early skin and mucosal reactions were increased with acceleration and hypoxic 
modification. A gradual increase o f the severity and duration o f these reactions occurred 
with successive addition o f the three components: acceleration, carbogen and nicotinamide 
[27,29,30]. This emphasizes the need for predictive testing, in order to select patients who 
are likely to benefit from the intensified treatments. Patients with sensitive tumors who are 
likely to do well with conventional treatment can thus be spared the enhanced toxicity.
Tumor vasculature and microenvironment
Multiple staining of the same tissue section is a difficult procedure. For instance antibodies 
used for visualizing one antigen can be damaged if  visualization o f the next antigen needs 
aggressive treatment, such as acid to expose BrdUrd-labeled DNA. Image analysis with the 
semi-automatic method for quantitative analysis as described, enabled us to perform triple 
and quadruple staining o f sections. In order to preserve optimal staining quality and signal 
to noise ratio, tissue sections were scanned between the staining sessions, i.e. each 
fluorescent signal was captured before the staining o f the next marker (antigen) was 
commenced. Proliferation and hypoxia can be analyzed in whole tissue sections but also as a 
distribution pattern throughout the tissue section or in relation to vasculature [6,7].
The two tumor lines that were used in these studies, SCCNij3 and SCCNij19, were both 
derived from male patients with advanced laryngeal carcinoma (both clinical stage 
T4N2cM0). The differentiation grades o f both squamous cell carcinomas were similar 
(SCCNij3 moderately to well differentiated, SCCNij19 moderately differentiated). 
However, the vascular pattern, proliferation characteristics and the effect o f carbogen and 
nicotinamide on the tumor microenvironment were different.
Hypoxia and perfusion
Carbogen breathing gave a different response in the two tumor lines. In SCCNij3 there was 
a decrease in perfusion, whereas SCCNij19 showed no change in perfusion after carbogen 
treatment. Tumor-dependent changes in blood perfusion during carbogen breathing were 
also observed by other investigators [39]. A difference in response to carbogen or
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nicotinamide may be related to endogenous vasoconstrictors (e.g. endothelin-1) and 
vasodilators (e.g. NO) that are oxygen dependent and tumor dependent [9].
The absence of a significant increase o f tumor blood perfusion after nicotinamide treatment 
may be attributed to a high baseline perfusion fraction in these tumors that can not be much 
further increased by nicotinamide. If, however, tumor blood perfusion is not at the 
maximum level due to carbogen treatment, nicotinamide can compensate and cause an 
increase in the perfusion fraction, which was shown for SCCNij3.
Proliferation
The decrease in LI after carbogen treatment may be caused by a cell cycle delay in S-phase 
as a result o f glucose and other nutrient deprivation (both lines showed a reduced perfusion 
after carbogen), or a G2 delay caused by reperfusion injury to previously poorly oxygenated 
cells by the overall increased pO2 . The decrease o f the extra-cellular pH after carbogen 
breathing does not result in a change o f intra-cellular pH [48], the consequences o f this for 
the proliferative activity o f tumor cells is unclear at the moment. The observed anti­
proliferative effect o f carbogen could complement the radiation modifying effects on the 
hypoxic compartment o f tumors by also reducing the proliferative activity o f tumor cells 
during a course o f fractionated radiotherapy. However, the anti-proliferative effect in 
SCCNij19 was reversed by nicotinamide, which suggests that the anti-proliferative effect of 
carbogen may not be obtained in all tumors with the full ARCON treatment.
The differences in response to nicotinamide and carbogen between the two tumor lines that 
were analyzed show that even in tumors o f the same site and histology a pre-treatment 
analysis may in the future help to select patients for treatments that reduce tumor hypoxia.
Figure 2. Binary images o f tumor sections o f a human laryngeal squamous cell 
carcinoma xenograft tumor line (SCCNij3), showing microenvironmental 
changes after oxygenation modifying treatment. Left images: control; right 
images: combination o f carbogen and nicotinamide. Top images; scanned at 
100 X  magnification for analysis o f tumor blood perfusion (Hoechst, blue), 
vascular structures (9F1, red) and tumor hypoxia (NITP, green). Bottom 
images: scanned at 200X magnification for analysis o f proliferation 
characteristics (BrdUrd, green) in relation to vasculature (9F1, red) and 
tumor blood perfusion (Hoechst, blue). The boxes in the top images show 
the area that is shown at 200X magnification in the bottom image 
(consecutive tissue section).
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The goal o f the microenvironmental study is to develop an assay that can aid the selection of 
patients or patient categories that may benefit from radiotherapy treatment modification. 
Recently, we have started a study that applies most o f the described methodology directly to 
primary human tumor material. Patients are injected with a hypoxic marker (pimonidazole) 
and a proliferation marker (IdUrd or BrdUrd), after which diagnostic biopsies are taken and 
analyzed. Initial results indeed show large differences o f microenvironmental parameters 
between individual patients.
Conclusion
The clinical outcome o f the treatment of head and neck cancer patients with advanced disease 
according to the ARCON schedule results in high loco-regional tumor control rates. The 
microenvironmental study shows that the analysis o f multiple parameters related to the 
tumor tissue architecture can reveal different responses to carbogen and nicotinamide, even 
in tumor lines o f similar histology. This indicates that a pre-treatment analysis o f tumor 
characteristics may aid the selection o f patients who can benefit from accelerated fractionated 
radiotherapy and oxygenation modification.
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Abstract
A method is presented in this report for concurrent analysis o f vascular architecture, blood 
perfusion and proliferation characteristics in whole-tumor cross-sections o f human larynx 
carcinoma and glioblastoma xenografts.
Tumors were implanted subcutaneously in nude mice. After i.v. injection with Hoechst 33342 
and bromodeoxyuridine (BrdUrd) as perfusion and proliferation markers, animals were killed. 
An anti-endothelial antibody (9F1) was used to delineate vascular structures. Cross-sections 
were analyzed by a multi-step immune-staining and computer-controlled microscope scanning 
method. Each tumor section was stained and scanned four times (Hoechst, 9F1, BrdUrd and 
Fast Blue for all nuclei). When these images were combined, vasculature, perfusion and 
proliferation parameters were analyzed.
The labeling index (LI) was defined as the ratio o f the BrdUrd-labeled area to the total nuclear 
area. The LI based on manual counting and the LI calculated by flow cytometry (FCM) were 
both in good agreement with the LI based on surface analysis.
LI decreased at increasing distance from its nearest vessel. In the vicinity o f perfused vessels 
the LI was 30-70% higher than near non-perfused vessels.
This method shows that both vasculature/perfusion and proliferation characteristics can be 
measured in the same whole-tumor section in a semi-automatic way. This could be applied 
in clinical practice to identify combined human tumor characteristics that predict for a 
favorable response to treatment modifications.
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Introduction
The radiation response o f tumors is determined by several well-recognized factors, 
including intrinsic radio sensitivity, cell kinetics and the degree o f tumor oxygenation and 
perfusion. There is increasing recognition that a combination o f these mechanisms may be 
responsible for treatment failure in certain tumor types.
The prognostic relevance o f intrinsic radio sensitivity, measured by clonogenic assays, has 
been demonstrated for cancer of the uterine cervix [25] and for head and neck cancer [14]. 
Another cause for radiation treatment failure is tumor cell repopulation, which compensates 
for radiation induced cell kill. The longer the overall treatment time o f fractionated radiation 
treatments, the greater the opportunity for tumor cell repopulation. Withers et al. have 
reviewed 59 clinical studies on head and neck cancer and have demonstrated that the 
outcome was worse with longer treatment schedules [38]. Preliminary results from four 
randomized studies in head and neck cancer and one in bronchus carcinoma demonstrate that 
tumor control rates can be improved with shortened radiation treatment schedules delivering 
two or more radiation fractions per day relative to once-a-day treatments with conventional 
radiotherapy [1,19,29,33].
Begg et al. measured the potential doubling time (Tpot) in biopsies of head and neck 
carcinomas by flow cytometry (FCM) and showed that this could be predictive for treatment 
outcome. A trend was shown for the fast proliferating tumors to perform worse on a 
conventional treatment schedule than slow proliferating tumors. The outcome o f the fast 
proliferating tumors was improved with accelerated radiotherapy, although the differences 
were not statistically significant [4]. In data collected from 10 different European trials, 
Begg showed that the pre-treatment kinetic parameters, analyzed by flow cytometry can 
predict local control after conventional radiotherapy [10]. Bennett et al. categorized 
squamous cell carcinomas by histological proliferation patterns that appeared to be correlated 
with radiation treatment outcome [5].
A third factor determining the effect o f radiotherapy is oxygenation. Radiotherapy is less 
effective under hypoxic conditions [15,26]. Hypoxia exists in varying degrees in nearly all 
tumors. In advanced cancer o f the uterine cervix and in nodal metastases o f head and neck 
tumors, tumor pO2 as detected by polarographic measurements, predicted for survival 
[13,18,27].
A variety o f procedures have been developed to overcome hypoxic radiation resistance 
including high oxygen content gas breathing under normo- or hyperbaric conditions, 
hypoxic cell radio-sensitizers, blood transfusions and use of vaso-active drugs.
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Figure 1. The principle o f vascular domains: the tissue section is divided into areas on 
the basis o f vascular structure, domains. The boundaries o f these domains 
are equidistant to adjacent vessels.
Figure 2. The process of staining and scanning o f the same tissue section (squamous 
cell carcinoma tumor line SCCNij3). Binary reconstructed image after 
scanning a tissue section four times. Hoechst for perfusion (blue), 9F1 
TRITC for vascular structures (red), BrdUrd FITC for proliferation 
(green). The Fast blue signal for the total nuclear surface is not shown. 
Note non-perfused vascular structures (arrow) and perfused vascular 
structures and the decrease in LI at increasing distance from vessels.
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A meta-analysis o f 83 randomized clinical trials showed that both local control and survival 
can be improved by reduction o f hypoxia [28].
Tumor hypoxia is the result o f a chaotically organized vascular network and an insufficient 
and heterogeneous blood supply. A detailed understanding o f the vascular architecture and 
perfusion status o f tumors is necessary to develop and assess methods for tumor 
oxygenation modification in an effort to improve radiation response. In addition, it has been 
shown that the metastatic potential o f tumors is related to certain vascular parameters [36]. 
The morphological aspects are commonly analyzed using stereological principles such as the 
point counting method [9,11]. Information on vascular function is obtained using 
radioactive and fluorescent perfusion markers [21].
Bernsen et al. presented a method to analyze quantitatively both morphological parameters 
o f vascular architecture and perfusion using an automated image analysis system [6]. This 
paper presents a further development o f this method that includes the simultaneous 
measurement of kinetic parameters.
The aim o f this study was to standardize a method for quantitative analysis o f vasculature, 
blood perfusion and proliferation in the same tissue section. This could be applied in clinical 
practice to identify the combined human tumor characteristics that predict for a favorable 
response to treatment modifications, including oxygen modification, altered fractionation 
schedules and combinations o f these approaches.
Materials and methods 
Tumors
Tumors were derived from different primary human high-grade gliomas and head and neck 
squamous cell carcinomas (moderately to well differentiated). Viable 1 mm3 tumor pieces 
were transplanted subcutaneously in nude mice (Balb/c nu/nu mouse). Tumors were 
passaged when they reached a diameter o f 1-1.5 cm. For the analysis o f vascular and kinetic 
parameters tumors with a diameter o f 0.6 to 1.0 cm were used.
Markers o f proliferation and perfusion
The S-phase marker bromodeoxyuridine (BrdUrd) (Sigma Chemical Co., St. Louis, MO) 
was given at a dose of 100 mg/kg intra-peritoneally, 15 min before the animals were killed. 
In experiments in which the in situ analysis is compared with flow cytometry (FCM), 
BrdUrd was injected 5 hours before killing the animals, to allow calculation o f the potential
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doubling time (Tpot) by the relative movement method [3]. Two minutes before killing the 
animals, Hoechst 33342 was given intra-venously via one o f the tail veins as a marker of 
perfusion. Tumor specimens were cut in two: one half was stored in liquid nitrogen until 
frozen sections were cut, which were then stored at -80 oC until staining and the other half 
was fixed in 70% ethanol for FCM  analysis.
Immunohistochemical staining
After thawing, sections of 5 ^m thickness were fixed in acetone for 10 min and slides were 
then rinsed and mounted in phosphate buffered saline (PBS). Then the tissue sections were 
scanned for the Hoechst signal. The starting point and the resulted composite binary image 
with perfused tissue areas were both stored in the computer. Details on the scanning 
procedure are given below.
The same sections were then stained for endothelial structures. First they were incubated for 
45 min at room temperature with undiluted 9F1 (rat monoclonal antibody to mouse 
endothelium, Department o f Pathology, University Hospital Nijmegen, The Netherlands). 
After rinsing, the sections were then incubated for 30 min at room temperature with 
tetramethyl rhodamine isothiocyanate (TRITC)-conjugated rabbit anti-rat antibodies 
(Organon Teknick W est Chester, PA, USA) diluted 1:100 in PBS with 10% normal mouse 
serum. This was followed by rinsing and 30 min incubation at room temperature with 
TRITC-conjugated goat anti-rabbit antibodies (Tago, Burlingame, CA, USA) diluted 1:50 in 
PBS with 1% BSA. Then the sections were rinsed again.
Next, BrdUrd was immuno-histochemically visualized. The DNA of the tissue sections was 
denatured by incubation with 2 N  HCl for 10 min. To neutralize the pH, sections were 
rinsed in 0.1 M  borax for 10 min followed by rinsing in PBS. The sections were then 
incubated for 60 min at 37 oC with Br-3 (mouse monoclonal to BrdUrd, Caltag 
Laboratories S. San Francisco, CA, USA) 1:50 in PBT (PBS with 1% BSA and 0.5% 
Tween-20). Next, after rinsing with PBS again, the sections were incubated for 45 min at 
room temperature with fluorescein isothiocyanate (FITC)-conjugated rat anti-mouse 
antibodies (DAKO Denmark) diluted 1:25 in PBT.
As a final step all nuclei were stained with Fast Blue (Sigma) diluted 1:1000 in PBS for 15 
min at room temperature and finally rinsed again.
Scanning o f tumor sections and image processing
The tumor sections were scanned by a computer-controlled procedure using a high­
resolution intensified solid-state camera for quantitative analysis on a Zeiss microscope. A 
detailed description o f this scanning method was given by Rijken et al. [30]. Each tumor
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section was sequentially scanned four times, at 200X magnification, using different filters 
(TRITC signal, 510-560 nm excitation and 690 nm emission filter; FITC, 450-490 nm 
excitation and 520 nm emission filter; Hoechst and Fast Blue, 365 nm excitation and 420 
nm emission filter). After processing all fields (scanning in 8 times 8 steps, i.e. 64 fields 
with a field size o f 0.31 mm2), the scanned area was reconstructed from the separate 
processed images into one large composite image. The result o f this scanning procedure is 
four composite images: one showing the perfused areas (Hoechst), one showing vascular 
structures (9F1), one showing proliferating nuclei (BrdUrd) and one showing all nuclei 
(Fast Blue). As a final step, the tumor area was determined by drawing a contour line. This 
area was used as a mask in further image analysis, excluding non-tumor tissue and necrotic 
areas from the analysis. Stromal cells that are close to tumor cells or embedded in the tumor 
tissue (for instance near vascular structures) can not be excluded from the analysis.
Analysis o f vascular and kinetic parameters
The vascular parameters can be derived from the first two composite images (Hoechst and 
9F1) [6]. W hen these two images are combined, the overlapping structures represent those 
vascular structures that were perfused at the time o f injection o f Hoechst: the vascular 
structures which have no corresponding Hoechst staining o f adjacent nuclei represent non­
perfused vessels. The area o f perfused vascular structures divided by the total vascular area 
o f the tissue section yields the perfusion fraction, indicating the fraction o f vascular 
structures that was perfused at the time o f Hoechst injection.
Because o f the high cellular density o f most tumors in the tissue sections, nuclei are often 
abutting or overlapping and individual nuclei cannot always be discriminated by the 
scanning system. It is therefore not possible to calculate the labeling index (LI), which is the 
number of BrdUrd-positive nuclei relative to the total number o f nuclei, based on the count 
o f individual labeled and unlabeled nuclei. Therefore, the LI was determined from the ratio 
o f the BrdUrd-positive surface (FITC) to the total nuclear surface (Fast Blue). To validate 
this method, the same microscopic fields were analyzed by the computer-controlled analysis 
system and by manual counting, both at 400X magnification. With the manual count, at 
least 200 nuclei were counted in 15 microscope fields o f a glioblastoma tumor line. The LI 
obtained by the two methods were compared.
The heterogeneity o f distribution o f proliferating cells within a tumor section was assessed 
by dividing the composite image in 16x16 fields, thus yielding 256 arbitrary tissue areas of 
0.076 mm2 each, corresponding to approximately one high-power microscope field of
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400X magnification. For each o f these individual areas the LI was calculated and the mean 
LI o f the 256 tissue areas with standard deviation were obtained for each tissue section. In 
addition, the overall LI for the whole section was calculated.
For a better understanding o f the relationship between proliferation and vascularity, the 
composite images were subdivided into functional units, so called 'vascular domains'. A 
domain was constructed around each vascular structure in a separate image. The boundaries 
o f these domains were defined such that they were equidistant to adjacent vessels (Figure 
1). In the recorded composite images, the LI was calculated in four arbitrary zones at 
increasing distance from the surface of the vessel in each domain: 0 to 15 |im, 15 to 30 |im, 
30 to 70 ^m and more than 70 ^m from the nearest vessel. The LI was analyzed for every 
individual domain, distinguishing perfused and non-perfused domains.
Flow cytometry
The method o f staining and analysis using FCM has been described elsewhere [5]. Briefly, 
ethanol-fixed tissue fragments were digested into nuclei using 0.4 mg/ml pepsin in 0.1 M 
HCl for 30 min at 37 oC. DNA was denatured with 2 M  HCl for 12 min at room 
temperature. The nuclei were incubated with Br-3 FITC conjugate (mouse monoclonal to 
BrdUrd, Caltag Laboratories S. San Francisco, CA) in PBS containing 0.5% Tween-20 and 
0.5% normal goat serum for 2 h at room temperature. Total DNA was stained using 10 
Mg/ml propidium iodide and the samples were analyzed by FCM.
Samples were run on a Becton Dickinson FACScan with a single excitation wavelength of 
488 nm. Doublets were excluded by gating on the width and area signals from the FL3 
channel. Ten thousand events were collected. The data derived from the FCM profiles were 
the DNA index, the LI o f all cells and o f the aneuploid sub compartment in appropriate 
tumors making a correction for cell division [37]. The DNA synthesis time ( T s )  was 
calculated using the method o f Begg et al. [3] and the Tpot was derived using the formula: 
Tpot = A x T s  / LI, with A =0.8.
Statistics
The LI obtained by the scanning method based on labeled surface analysis was compared 
with the LI obtained by manual counting and by FCM by linear least squares regression 
analysis. The t-test was used to compare LI in perfused domains with the LI in non­
perfused domains. For analysis o f the decrease o f LI at increasing distance from vascular 
structures, MANCOVA was used for all data points. To determine where these differences
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in the means o f any two distance intervals were present, the post-hoc Tukey honest 
significant difference (HSD) test for multiple comparisons was applied.
Results
Images
Figure 2 shows the composite binary image obtained after the scanning procedure for a 
representative tumor section. The combination o f the Hoechst, 9F1 and BrdUrd images 
clearly shows the distribution o f proliferating cells throughout the tissue section and the 
relation to vascular structures (Figure 2). Note perfused and non-perfused vascular 
structures and the decrease in LI at increasing distance from vessels.
BrdUrd LI: comparing three methods
Calculation o f LI based on computerized in situ analysis as the ratio o f BrdUrd-labeled 
nuclear surface to the total nuclear surface was compared with manual counting and with 
FCM  results.
For 12 tumors from 7 different tumor lines, the LI obtained by FCM  was compared with the 
computerized in situ method. From 3 samples it was not possible to obtain a reliable result 
by computerized in situ analysis because o f heavy background staining that made it 
impossible to analyze the tumor section. One tumor consisted almost completely o f necrosis 
and could not be analyzed by either computerized in situ analysis or FCM. In 9 out o f these 
12 tumors both in situ and FCM  results were available, showing a good correlation between 
the two methods (correlation coefficient 0.81, Figure 3). Only 6 o f these tumors were 
aneuploid: o f these 6 the correlation with the computerized in situ analysis showed a 
correlation coefficient o f 0.90. Analysis by FCM  also yielded Tpot values, which are given 
in Table 1.
A good correlation was observed between the computerized surface-based LI and the LI 
based on manual count (correlation coefficient 0.89, p<0.05, Figure 4).
Distribution o f LI and relation to vasculature
Both the inter- and intra-tumor variability o f LI are large (Table 1). As an example o f intra­
tumor variability the distribution profile o f the LI in a high-grade glioma is given in Figure 5 
(number 1 in Table 1).
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LI by computerized in situ analysis
Figure 3. LI after computerized in situ analysis versus FCM; the samples o f the 
aneuploid tumors are indicated by *.
After construction o f the vascular domains, the LI was calculated at different distances from 
the surface o f the nearest vessel. Figure 6 shows the results obtained in three different 
squamous cell carcinoma tumor lines. Each panel represents the average LI o f four to five 
tumors o f the same tumor line. At increasing distance from the nearest vessel, the LI 
decreases both in perfused and non-perfused vascular domains. The LI calculated for the 
cells that are nearest to the vessel is based on the area that also includes the extra-vascular 
matrix. In this matrix slower proliferating cells, such as fibroblasts, are present, this is the 
reason for the lower LI in the 0-15 |im range. There is a statistically significant decrease in 
LI at increasing distance in all three tumor lines with p-values < 0.05 if  the LI from 15-30 
^m is compared with the interval > 70 ^m (Tukey HSD test).
Overall, the LI is lower in non-perfused domains than in perfused domains (Figure 7). 
Discussion
This paper describes how the semi-automatic method for quantitative analysis o f tumor 
perfusion and vasculature, as described by Rijken et al. [30], was further developed to
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allow also quantitation o f proliferative activity in the same tumor section. Without disturbing 
tissue architecture, the proliferative patterns o f tumors can be studied and related to 
vascularity with the possibility o f distinguishing between functional and non-functional 
vessels.
LI by computerized in situ analysis
Figure 4. LI after computerized in situ analysis versus manual count.
For detection o f vascular structures the newly developed anti-mouse endothelium antibody, 
9F1, was used. It recognizes the same vascular structures as the more commonly used 
collagen IV antibody (Bernsen et al. submitted for publication). In the squamous cell 
carcinoma xenografts, however, the collagen IV antibody produces significant background 
staining because o f considerable amounts o f collagen in the extra-cellular compartment of 
these tumors. This background staining is less with the 9F1 antibody, which is therefore 
more suitable for the automated image analysis.
The LI based on computerized surface analysis is in good agreement with the LI based on 
manual counting and FCM analysis. Other studies have also found a good correlation 
between LI based on FCM  and manual counting [5,8,12].
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Table 1. FCM analysis versus computerized in situ analysis.
flow cytometry computerized in situ analysis
tumor Tpot
(d)$
LI all 
cells
LI aneu­
ploid cells
LI in 
situ#
mean@ SD@ range@
1 GM2 2.6 0.13 0.11 0.11 0.07 0 - 0.32
2 GM2 - - 0.06 0.03 0.03 0 - 0.16
3 GM34 7.0 0.04 0.06 0.05 0.04 0.03 0 - 0.17
4 GM34 - - 0.02 0.02 0.03 0 - 0.11
5 GM49 3.3 0.09 0.09 0.06 0.05 0.04 0 - 0.17
6 GM106 3.7 0.08 0.09 0.10 0.10 0.11 0 - 0.40
7 GM106 2.0 0.12 0.15 0.16 0.18 0.08 0 - 0.36
8 GM182 2.6 0.09 0.11 - - - -
9 GM192 8.9 0.03 0.04 0.03 0.03 0 - 0.14
10 SCCNij3p3 - - 0.04 0.02 0.01 0 - 0.39
11 SCCNij3p3 - - 0.02 0.01 0.02 0 - 0.06
12 SCCNij20 5.2 0.05 0.05 0.05 0.03 0.03 0 - 0.12
13 SCCNij18 - - - - - -
14 SCCNijp4 1.8 0.10 - - - -
15 SCCNij3p4 8.3 0.03 0.06 0.06 0.05 0 - 0.21
16 SCCNij3p4 5.6 0.06 0.08 0.07 0.01 0 - 0.26
17 SCCNij3p4 3.1 0.08 - - - -
18 SCCNij3p4 - - 0.04 0.02 0.03 0 - 0.09
GM, glioblastoma multiforme;
SCCNij, Squamous cell carcinoma Nijmegen; p is the number of transplantation.
# Overall LI o f a whole tissue section.
@ M ean LI, standard deviation (SD) and range of 256 tissue areas o f one tissue section.
$ Tpot is calculated on the basis o f the aneuploid cells if  present, otherwise on the diploid 
cell population.
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Figure 5. Example o f the distribution o f LI in 256 fields each representing 0.076 
mm2 of a glioblastoma tissue section.
FCM  has the advantage that large cell numbers can be counted. However, this method 
produces an average LI for the entire tissue sample and information on spatial heterogeneity 
o f proliferative activity within a tumor is lost. In addition, in diploid tumors FCM can not 
distinguish tumor cells from normal cells, which may significantly influence the analysis. 
Assessment o f LI by computerized surface analysis gives a lower LI than manual counting 
o f labeled nuclei (difference approximately 0.05, Figure 3). This difference was also seen 
when the LI o f tumor sections was compared with the LI obtained by FCM [5]. This 
difference could be caused by non-tumor cells in the tumor section. Assessment o f LI by 
computerized surface analysis can be influenced by the thresholding o f the FITC signal. If 
the threshold is set too high, BrdUrd-positive cells are not identified and will result in a 
lower LI. This can also introduce a systemic difference between FCM measurements and 
our method.
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Figure
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6. LI versus distance from the nearest vessel, mean o f five tumors with SEM. 
SCCNij3, SCCNij15 and SCCNij19 are different human laryngeal squamous 
cell carcinoma tumor lines.
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0
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Figure 7. Mean LI o f 4 (SCCNij19) or 5 (SCCNij3 and SCCNij15) tumors. Perfused 
domains (rn) and non-perfused domains (rn) at 4 different zones around 
vessels: 0-15 jm  (top, left), 15-30 jm  (top, right), 30-70 jim (bottom, left) 
and>70 jm  (bottom right). Error bars indicate SEM(* t-test, p<0.05).
*
*
Another advantage o f the immunohistochemical method over FCM is that it allows the study 
o f tumor cell kinetics in relation to histology. It has been suggested that the histological 
proliferation pattern can be a stronger predictor for clinical outcome than the LI or Tpot 
[5,37].
Manual counting in tissue sections is time-consuming however, and only limited cell 
numbers can be analyzed. In addition, there is an element o f subjectivity with inter-observer 
variations. The computer-controlled scanning method combines the strengths o f FCM  and 
manual counting: proliferation patterns can be analyzed rapidly in complete tissue sections. 
In addition, the translation into binary images greatly facilitates quantitation o f any o f the 
parameters being studied (proliferation, vascular patterns and perfusion). Two-dimensional 
analysis allows spatial study o f relationships between (functional) vessels and cell 
proliferation. Areas o f interest can be chosen for detailed analysis and non-tumor tissue and 
necrotic areas can be easily excluded. FCM  allows calculation o f Tpot because it gives also
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information on the DNA content o f nuclei [3]. Calculation o f Tpot with the 
immunohistochemical method would require two consecutive injections with thymidine 
analogues, e.g. BrdUrd and IdUrd, to allow estimation o f S-phase duration [2]. We have 
attempted this, but with the computer analysis system double-labeled nuclei are not always 
reliably distinguished from single-labeled nuclei and technical improvements are required to 
enable estimation o f Tpot by this method. In contrast, there is currently some debate as to 
whether Tpot has any additional value over LI as a predictor o f radiotherapy outcome. In 
data collected from 10 different European trials, Begg et al. showed that although both the 
LI and Tpot correlate with local control, the LI was the strongest predictor [10].
The analysis o f tumor cell proliferation in relation to the nearest vessel and its perfusion 
status shows a decrease in LI with increasing distance from the vessel. This was also noted 
in other studies [17,23,31]. One might argue that this could be an artifact because BrdUrd, 
the proliferation indicator, is transported to the tissues by the bloodstream and a decrease in 
labeling away from the vessels might simply reflect a limited diffusion capacity o f the 
compound. However, although decreased, we did observe labeled nuclei at a greater 
distance from the vessels and dosage o f the compound is such that cellular uptake cannot be 
a limiting factor. In addition, we have also analyzed the proliferation patterns with the MIB-
1 antibody, which binds to nuclear associated antigens that are naturally present only in 
proliferating cells, and found similar results (data not shown). The most plausible 
explanation for this phenomenon is that the availability o f oxygen and nutrients decreases at 
a greater distance from the vessels. The observation that the LI is lower in non-perfused 
domains is in agreement with this. However, the LI close to non-perfused vessels is still 
significantly higher than the LI at a greater distance from perfused vessels.
Because both BrdUrd and Hoechst 33342 are bound in the DNA by replacement of 
nucleotides, one could argue that the signal o f BrdUrd might quench the Hoechst signal. 
The half-life o f BrdUrd is relatively short (minutes). BrdUrd is only incorporated in the 
DNA of S-phase cells. Hoechst 33342 will be visible in all nuclei surrounding perfused 
vessels. I f  any disturbance of the Hoechst signal by BrdUrd incorporation would occur, this 
would only be in a minority o f cells (S-phase). As an example, Figure 2 shows that the LI is 
higher near perfused than non-perfused vessels (the arrow in Figure 2 indicates an area with 
no perfusion and a low LI).
It has been shown [21,34] that tumor blood vessels transiently open and close in a non- 
physiological pattern. Vessels that are observed as non-functioning at a certain time may be 
functional at some other time. This has been demonstrated with the use o f two different 
fluorescent perfusion markers injected at different times [34]. These fluctuations in tumor
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blood perfusion may explain why there is considerable proliferative activity around 
apparently closed blood vessels. An alternative explanation can be that the 'non-perfused' 
domains are supplied by nearby vessels that are located just above or below the plane o f the 
tissue section being studied. Obviously, a limitation o f our image analysis system is that it 
allows only a two-dimensional study. The technique does allow construction o f a three­
dimensional image by simply scanning several consecutive slides o f the same tumor. 
However, this is laborious and it requires a powerful computer and further development of 
the software.
In a future study, we will address the issue o f the potential sampling error. This is of 
relevance when the method is taken into the clinic, because only relatively small biopsies can 
be obtained from most cancer patients. Haustermans et al. showed that for oesophageal 
cancer increasing the number o f biopsies from one to five allowed better discrimination 
between slower and faster proliferating tumors [16].
A future aim of our study is to incorporate a further step in the analysis to directly indicate 
hypoxic areas in tumor sections. The use o f Hoechst as a perfusion marker is an indirect 
measure for the oxygenation status. Hypoxic cells can be identified directly by bio-reductive 
chemical probes with immuno-recogni sable side chains e.g. 7-(4'-(2-nitroimidazole-1-yl)- 
butyl)-theophylline (NITP) [35]. The metabolism o f these compounds involves the 
generation o f a free radical which is so reactive towards oxygen that further metabolism is 
inhibited in well-oxygenated cells.
The ultimate goal is to design an assay that can be helpful in selecting patients or patient 
categories that can benefit from novel radiotherapy treatments including altered fractionation 
schedules, oxygenation modification or hypoxia-specific toxins [7,20,22,24,32].
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Abstract
Background and purpose. A better understanding of the vascular architecture and the 
microenvironmental parameters (VAMP) will allow the identification of tumors that can be 
more effectively treated by intensified fractionated radiotherapy or modifiers of blood flow 
and oxygenation or combinations of these approaches.
Materials and methods. Proliferation (BrdUrd), vascular architecture (endothelial marker), 
perfusion (Hoechst 33342) and oxygenation (NITP) were studied in two human laryngeal 
squamous cell carcinoma tumor lines grown as xenografts in nude mice. The effects of 
carbogen and nicotinamide on these parameters were evaluated.
Results. Carbogen treatment resulted in a decrease of the number of perfused blood vessels 
from 66% to 55% in one of the two tumor lines. In this tumor line nicotinamide prevented 
this reduction of tumor blood flow by carbogen. In both tumor lines the labeling index (LI) 
decreased after treatment with carbogen for 1 h, from 11-13% to 5-7%. Both tumor lines 
showed a drastic reduction of hypoxia by carbogen alone or by carbogen plus nicotinamide. 
Conclusions. In both laryngeal squamous cell carcinoma xenograft tumor lines carbogen 
was very effective in reducing diffusion limited hypoxia. Only in one of the two tested 
tumor lines carbogen also caused a reduction of tumor blood perfusion, which could be 
compensated for by nicotinamide. In addition, carbogen reduced tumor cell proliferation. 
The fact that differences in response to nicotinamide and carbogen were observed and that 
they can be studied in vivo provides a basis for further development of a 'predictive profile', 
which will guide the clinician to select the optimal treatment for individual patients or groups 
of patients.
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Introduction
There is good evidence that tumor cell proliferation, tumor oxygenation and perfusion 
strongly influence the response of tumors to anti-cancer treatment. This has been 
demonstrated best in squamous cell carcinomas of the cervix and of the head and neck 
region [1,7,9,12,16,27,30,43].
After Gratzner had developed a monoclonal antibody against the thymidine analogue 
bromodeoxyuridine (BrdUrd) [10], the method of incorporation and visualization of 
BrdUrd with immuno staining techniques has become the standard for the detection of 
proliferating cells in culture and in tissue sections. The fraction of cells in S-phase at the 
time of BrdUrd administration is calculated by the ratio of BrdUrd labeled nuclei versus the 
total number of nuclei (labeling index, LI). This ratio can be determined either by counting 
under the microscope [20] or by flow cytometry (FCM) [8].
Both methods have limitations. Analysis by flow cytometry allows measurement of kinetic 
information but implies loss of tissue architecture when processing the tissue fragments. 
This precludes analysis of histological patterns of proliferation and relations with other 
structures e.g. blood vessels. Immunohistochemical analysis by manual counting is, on the 
other hand, laborious and limited in scope.
Various methods are available for measuring the oxygenation status of tumors and tissues. 
Oxygen electrodes are being used for direct measurement of pO2 in human tumors in situ. In 
advanced cancer of the uterine cervix and in nodal metastases of head and neck tumors a 
good correlation between pre-treatment pO2 and loco-regional control [9,27] and survival 
[12] was observed. Another approach for estimating the hypoxic tumor fraction is by using 
bio-reductive chemical probes. The 2-nitroimidazoles are the most successful hypoxia 
markers in vivo and nitroimidazoles with immuno-recognisable side chains were developed 
[25,33]. After injection and staining they can be analyzed by flow cytometry [13,40,41] or 
visualized in tissue sections [23].
Radiation treatment strategies which try to overcome both the negative effects of 
compensatory proliferation and tumor hypoxia are now under investigation in clinical phase
II trials: accelerated radiotherapy is combined with carbogen breathing and nicotinamide 
(ARCON) [21]. The first results of a study in patients with laryngeal cancer showed an 
actuarial local control rate at two years of 92% (stage III-IV tumors). This is higher than any 
previous report in the literature for this category of patients [22]. The associated increase in
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toxicity indicates the importance of developing tests to select patients who may benefit from 
these intensified treatment schedules.
It is becoming clear that the radiation response of tumors cannot be predicted by the value of 
a single parameter such as surviving fraction at 2 Gy (SF2) or potential doubling time 
(Tpot). A better understanding o f the vascular architecture and the microenvironmental 
parameters (VAMP) may allow identification o f tumors or classes o f tumors that can be 
more effectively treated by combinations o f new fractionation schedules with modifiers of 
blood flow and oxygenation.
Recently we have published a method for concurrent analysis o f vascular architecture, blood 
perfusion and proliferation characteristics in whole tissue sections [4]. Tissue sections were 
analyzed by a multi-step immuno staining and computer-controlled microscope scanning 
method. Proliferative activity was analyzed by BrdUrd labeling. The BrdUrd LI based on 
computerized analysis was in good agreement with the LI based on manual counting and the 
LI calculated by FCM. The advantage of this method is that tissue architecture is maintained 
so that proliferative activity can be described in relation to vascular architecture and 
perfusion.
The aim o f the present study was to further incorporate analysis o f tissue hypoxia in this 
computerized method to allow simultaneous quantitative analysis o f architectural patterns of 
proliferation, vascularization, blood perfusion and oxygenation. NITP, which in our study 
is used as hypoxia marker, is not approved for clinical use. Other hypoxic markers, such as 
pimonidazole and EF5, which can also be visualized immunohistochemically, are approved 
for clinical use. A clinically approved perfusion marker is not yet available.
This method may then be applied to obtain a 'predictive profile', which can guide the 
clinician to select the optimal treatment for individual patients or categories o f patients. We 
have used this method to analyze the effects o f carbogen breathing and nicotinamide on 
proliferation, vascular parameters and hypoxia in two recently established human squamous 
cell carcinoma xenograft lines o f the larynx (SCCNij3 and SCCNij19).
Materials and methods
Tumors
Two tumor lines (SCCNij3 and SCCNij19) derived from different primary human 
squamous cell carcinomas o f the larynx (SCCNij3 moderately to well differentiated and
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SCCNij19 moderately differentiated) were used in this study. Viable 1 mm3 tumor pieces 
from resection specimens were transplanted subcutaneously in nude mice (Balb/c ABom nu 
mouse). Tumors were passaged when they reached a diameter of 1.0 cm. For the analysis 
of vascular and kinetic parameters, tumors transplanted at the hind leg with a diameter of 0.6 
to 0.8 cm were used.
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines.
Markers of hypoxia, proliferation and perfusion
As marker of hypoxia 7-(4'-(2-nitroimidazole-1-yl)-butyl)-theophylline (NITP) (Gray 
Laboratory, Northwood, Middlesex UK) was used. NITP is a bio-reductive chemical probe 
with an immuno recognizable side chain (theophylline). The metabolism of this compound 
involves the generation of a free radical which is so reactive towards oxygen that further 
metabolism is inhibited in well oxygenated cells [40]. In V79 cell cultures the value for half 
the hypoxic : oxic differential of metabolic binding was found to be 1400 p.p.m. [13], 
which was similar to the 'K' value for the dependence of radiosensitivity on oxygenation. 
NITP was injected intra-peritoneally: 70 mg NITP in 0.5 ml dimethyl sulfoxide (DMSO) 
with 4.5 ml peanut oil, 0.3 ml per animal (155 mg/kg). The S-phase marker 
bromodeoxyuridine (BrdUrd) (Sigma Immuno Chemicals, St Louis, MO, USA) was given 
at a dose of 100 mg/kg in 0.5 ml saline intra-peritoneally. As marker of perfusion the 
fluorescent dye Hoechst 33342 (Serva, Heidelberg, Germany) dissolved in saline was given 
intra-venously via one of the tail veins at a dose of 25 mg/kg in 0.1 ml.
NITP was injected 55 min, BrdUrd 15 min and Hoechst 33342 one min prior to killing the 
animals (Figure 1).
Tumor specimens were removed within approximately one min after killing the animals and 
directly stored in liquid nitrogen until frozen sections of 5 ^m thickness were cut, which 
were then stored at -80 oC until staining.
Nicotinamide and carbogen breathing
Nicotinamide (Sigma) was dissolved in saline and injected intra-peritoneally at a 
concentration of 500 mg/kg, 75 min before killing the animals. The plasma peak 
concentration is observed within one hour after injection [36].
For carbogen (95% O2, 5% CO2, Hoek Loos, Schiedam, The Netherlands) breathing, 
animals were placed in a perspex box with a continuous carbogen flow of 5-7 l/min. 
Carbogen breathing started 60 min before killing the animals (Figure 1).
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Control animals were injected with NITP, BrdUrd and Hoechst and kept under ambient 
conditions. The effects of nicotinamide alone, carbogen alone and the combination of both 
were analyzed.
time (min)
Figure 1. Treatment schedule and experimental design. See text for details. NITP, 7-(4'- 
(2-nitroimidazole-1-yl)-butyl)-theophylline; BrdUrd, bromodeoxyuridine and 
Hoechst, Hoechst 33342. Animals are killed at time '0'.
Immunohistochemical staining
After thawing, sections were fixed in acetone for 10 min. Slides were then rinsed and 
mounted in phosphate buffered saline (PBS) for scanning of the Hoechst signal prior to 
immunohistochemical staining of the other markers. Details of the scanning procedure are 
given below.
Between all the consecutive steps of the staining procedure the sections were rinsed three 
times 2 min in PBS.
Endothelial structures
After the first scanning procedure for the Hoechst signal, sections were incubated for 45 
min at room temperature with undiluted 9F1 (rat monoclonal to mouse endothelium [31,42]) 
(Department of Pathology, University Hospital Nijmegen, The Netherlands). Sections were 
then incubated for 30 min at room temperature with tetramethyl rhodamine isothiocyanate 
(TRITC)-conjugated goat anti-rat antibodies (Jackson Immuno Research Laboratories, West 
Grove, PA, USA) diluted 1:50 in PBS-B (PBS with 0.5% bovine serum albumin). This
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was followed by 30 min incubation at room temperature with TRITC-conjugated donkey 
anti-goat antibodies (Jackson Immuno Research Laboratories) diluted 1:50 in PBS-B.
S-phase marker BrdUrd
The DNA in the tissue sections was denatured by incubation with 2 N hydrochloric acid for 
10 min. To neutralize the pH, sections were rinsed in 0.1 M borax for 10 min. The sections 
were then incubated for 60 min at 37 oC with Br-3 (mouse monoclonal to BrdUrd, Caltag 
Laboratories, S. San Francisco, CA, USA) diluted 1:50 in PBS-B. Next, the sections were 
incubated for 45 min at room temperature with fluorescein isothiocyanate (FITC)-conjugated 
rabbit anti-mouse antibodies (DAKO, Denmark) 1:25 in PBS-B. Finally, all nuclei were 
stained with Fast Blue (Sigma) diluted 1:1000 in PBS for 15 min at room temperature.
Hypoxic marker NITP
For staining of NITP the tissue sections were incubated overnight at 4 oC with rabbit anti­
theophylline antibodies (Sigma) diluted 1:10 in PBS-B. Next, slides were incubated with 
donkey anti-rabbit FITC-conjugated whole IgG (Jackson Immuno Research Laboratories) 
diluted 1:100 in PBS-B 60 min at room temperature.
Figure 2. Composite binary images o f a representative tumor section (SCCNij19). The 
left binary image shows the Hoechst (blue), endothelium (9F1, red) and 
NITP (green) distribution in a tissue section (scanned at 100X  
magnification). The binary image o f the consecutive tissue section (right) 
shows the combination o f Hoechst, endothelium and BrdUrd (green). The 
threshold for Hoechst has not been the same. The box in the left image 
indicates the area o f the consecutive tissue section that is analyzed for BrdUrd 
labeling.
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Scanning of tumor sections and image processing
The tumor sections were scanned for quantitative analysis by a computerized digital image 
processing system using a high-resolution intensified solid-state camera on a fluorescence 
microscope (Zeiss Axioskop) with a computer-controlled motorized stepping stage. A 
detailed description of the scanning method has been given by Rijken et al. [34]. Tumor 
cross-sections were sequentially scanned four times at 200X magnification, using different 
filters (TRITC signal: 510-560 nm excitation and 690 nm emission filter; FITC: 450-490 nm 
excitation and 520 nm emission filter and for Hoechst and Fast Blue: 365 nm excitation and 
420 nm emission filter). After each scan, which consisted of 64 fields (8 x 8, field size 0.31 
mm2), one composite image was reconstructed from the individual microscope images. The 
whole scanning procedure thus yielded four composite images from each tumor cross­
section: one showing the perfused areas (Hoechst), one showing vascular structures (9F1), 
one showing proliferating nuclei (BrdUrd), and one showing all nuclei (Fast Blue). As a 
final step, the tumor area was delineated by drawing a contour line in another binary image 
which was stored with the corresponding composite images. This area was used as a mask 
in further image analysis excluding non-tumor tissue and necrotic areas from the analysis. 
From each tumor a second, consecutive, tissue section was sequentially scanned three times 
at 100X magnification using the above mentioned filters, first for the Hoechst signal then 
for the NITP-FITC signal and finally for the 9F1-TRITC signal. This second scanning 
procedure resulted in three composite images, one showing the perfused areas (Hoechst), 
one showing hypoxic areas (NITP) and one showing vascular structures (9F1). Finally the 
tumor area was delineated again by drawing a contour line.
Analysis of vascular and kinetic parameters
Quantitative data of perfusion and vascularity were derived from the Hoechst and 9F1 
images. When these two images were combined the overlapping structures represented 
those vascular structures that were perfused at the time of Hoechst injection. The vascular 
structures that had no corresponding zone of Hoechst stained nuclei represented non­
perfused vessels. The area of perfused vascular structures divided by the total vascular area 
of the tissue section yielded the perfusion fraction. The relative vascular volume was 
calculated as the ratio of the 9F1-positive surface and the total tumor surface [34].
The labeling index (LI) was determined from the ratio of the BrdUrd positive surface 
(FITC) and the total nuclear surface (Fast Blue). Validation of this method was described 
previously [4].
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For analysis of the relationship between proliferation and vascularity, first functional units, 
so called 'vascular domains' were calculated. Delineation of domains is based on imaginary 
lines at equidistance between adjacent vessels and determined by image processing [4]. LI 
was calculated in three arbitrary zones at increasing distance from the surface of the vessel in 
each domain: 15-30 ^m, 30-70 |im and >70 ^m. LI in the 0-15 ^m range is based on the 
area that also includes the extra-vascular matrix. In this matrix slower proliferating non­
tumor cells, like fibroblasts, are present and therefore this zone was excluded from the 
analysis [4].
The LI was analyzed for all the individual domains, distinguishing perfused and non­
perfused domains.
Analysis of hypoxic parameters
Delineation of domains in the analysis of tumor hypoxia was also based on the vascular 
network. Only now, in contrast to calculation of the proliferation parameters, the domains 
were calculated based on perfused vessels only, including the whole tissue section. In order 
to quantitate the distribution of hypoxic regions in relation to the vasculature the relative 
amount of hypoxia was calculated as the fraction of NITP-stained area in different zones 
around a perfused vessel (= relative hypoxic area). These zones were chosen arbitrarily at 
increasing distance from the surface of the nearest perfused vessel: 50-100 ^m, 100-150 
^m, 150-200 |im, 200-250 |im and 250-300 |im (Rijken et al, submitted for publication). 
The zones <150 ^m were excluded from the analysis because of the almost complete 
absence of NITP-staining. The zones >300 ^m were excluded from analysis because of low 
amounts of NITP-staining due to necrotic tumor tissue, which was checked by light 
microscopy.
Statistics
All data points represent the average of five tumors with the standard error of the mean 
(SEM). For analysis of the differences of LI and the relative amount of hypoxia at 
increasing distance from vascular structures the analysis of variance was used for all data 
points. To determine where these differences in the means of any two distance intervals or 
treatment was present, the post hoc Tukey honest significant difference (HSD) test for 
multiple comparisons was applied. The t-test was used to compare the overall LI between 
different treatment modalities. The statistical analyses were done on a Macintosh computer 
using the Statistica 4.0 software package.
- 75 -
Chapter 4
LI
LI
Figure 3.
0.25
0.2
0.15
0.1
0.05
0
- •  — all domains 
-■—  perfused domains 
-♦—  non perfused domains
20 40 60 80 100 120
0.25
0.2
0.15
0.1
0.05
20 40 60 80
distance (|J.m)
100 120
BrdUrd LI as a function o f distance from the nearest vessel in two different 
squamous cell carcinoma tumor lines, SCCNij3 (top) and SCCNij19 
(bottom). Each graph represents the mean LI o f five tumors o f the same 
tumor line with standard errors o f the mean.
0
0
0
- 76 -
Carbogen, nicotinamide and the microenvironment
Results
Images
Figure 2 shows a detail of a combined composite image obtained after the scanning 
procedure of a representative tumor section (SCCNij19). The left image of Figure 2 shows 
the Hoechst, 9F1 and NITP distribution (100X magnification). The combination of 
Hoechst, 9F1, and BrdUrd (Figure 2, right image) clearly show the spatial distribution of 
proliferating cells throughout the tissue section and the relation to vascular structures (200X 
magnification). The threshold for Hoechst was not the same between the left and right 
image. A difference in the threshold for Hoechst signals does not influence the estimate of 
the perfusion fraction. Hypoxic areas are present at some distance from vessels, beyond the 
zone of proliferative activity. At even greater distance from the vessels necrotic areas are 
characterized by the absence of any staining.
Proliferation in perfused areas versus non-perfused areas
After defining perfused and non-perfused vascular domains, the LI was calculated at 
different distances from the surface of the nearest vessel. Figure 3 shows the results for the 
two different squamous cell carcinoma tumor lines. At increasing distance from the blood 
vessel the LI decreases both in perfused and non-perfused vascular domains. Overall the LI 
was lower in non-perfused domains compared to perfused domains, at zones from 15-30 
^m and from 30-70 ^m the difference reached statistical significance (p < 0.05). The 
reduction in LI as a function of distance from the nearest blood vessel was more pronounced 
in SCCNij19 than in SCCNij3. The difference in labeling index for perfused compared with 
non-perfused domains was also greater for SCCNij19 compared with SCCNij3.
Effects of carbogen and nicotinamide
After one hour of carbogen breathing and 75 min after nicotinamide administration the 
tumors were harvested. The vascular architecture and the changes in microenvironmental 
parameters after the oxygenation/perfusion modifying treatment were then analyzed.
Vascular structures and perfusion
The baseline perfusion fraction of SCCNij19 was higher than SCCNij3 (80% versus 66%) 
(Table 1). There were no obvious changes in the perfusion fraction in SCCNij19 with 
carbogen or nicotinamide. In SCCNij3, after carbogen treatment the perfusion fraction 
decreased from 66% to 55%. Nicotinamide treatment resulted in an increase of the perfusion 
fraction to 72%. Adding carbogen to this treatment resulted in an increase of the perfusion
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fraction to 78%. For SCCNij3 the relative vascular volume decreased significantly (p<0.05) 
after carbogen treatment but there was no change in relative vascular volume after 
nicotinamide treatment or the combination of both (Table 1).
L I ° .25 r ---• — carbogen and nicotinamide
---■ -  nicotinamide
---♦ carbogen
0.2 - ---- A— control
0
0 20 40 60 80 100 120
distance (|J.m)
Figure 4. BrdUrd LI as a function o f distance from the nearest vessel after treatment 
with carbogen, nicotinamide or the combination o f both in two different 
squamous cell carcinoma tumor lines, SCCNij3 (top) and SCCNij19 
(bottom). Each graph represents the mean LI o f five tumors o f the same 
tumor line with standard errors o f the mean.
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Figure 5. Relative hypoxic area, after treatment with carbogen, nicotinamide or the 
combination o f both in two different squamous cell carcinoma tumor lines, 
SCCNij3 (top) and SCCNij19 (bottom). The mean o f five tumors is given 
with standard errors o f the mean. (* p  < 0.05, relative to the control, Tukey 
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Figure 6. Example o f binary images o f tumor sections o f line SCCNij3 after scanning 
for the Hoechst signal (blue), vascular structures (9F1, red) and hypoxia 
(NITP, green). Control tumor (top, left) and after treatment with carbogen 
alone (top, right), nicotinamide alone (bottom, left) and the combination o f  
both (bottom, right).
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Proliferation
In both tumor lines the LI decreased significantly after treatment with carbogen (Table 1). In 
SCCNij19 this was largely compensated when nicotinamide was added. This effect of 
nicotinamide was not observed in SCCNij3. Nicotinamide alone caused an increase in LI in 
both tumor lines which was statistically significant only for SCCNij3.
LI as a function of distance from the vessels and the effects of carbogen and nicotinamide 
are shown in Figure 4. For all treatments LI decreased at increasing distance from the 
nearest vessel.
Table 1. Microenvironmental parameters o f two different tumor lines after treatment with 
carbogen and nicotinamide.
SCCNij3
Treatment Overall LI Perfusion Relative vascular
fraction (%) volume
Control 10.7 (1.0) 66 (6.9) 0.065 (0.010)
NAM 14.1s (0.6) 72 (5.6) 0.070 (0.006)
Carbogen 6.8s (1.3) 55 (9.2) 0.044 (0 .004)
NAM + carbogen 5.7s (1.1) 78 (4.6) 0.061 (0.005)
SCCNij19
Treatment Overall LI Perfusion Relative vascular
fraction (%) volume
Control 12.6 (1.5) 80 (5.7) 0.058 (0.005)
NAM 14.5 (1.5) 84 (3.0) 0.069 (0.016)
Carbogen 5.2s (1.0) 85 (5.4) 0.068 (0.007)
NAM + carbogen 10.8 (3.1) 76 (3.8) 0.067 (0.004)
s change relative to control, p<0.05 (t- test).
Mean of 5 tumors (SEM).
Hypoxia.
Hypoxia was analyzed in zones from 150 to 300 ^m around perfused vessels. The relative 
hypoxic area at a distance between 150 and 300 ^m from a perfused vessel ranged from 3 to 
10% in both tumor lines. Both tumor lines showed a drastic reduction of NITP-stained 
tumor cells after carbogen treatment (Figure 5). Nicotinamide alone did not change the
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NITP-staining pattern in either tumor line although there was a trend for a decrease in 
hypoxia at distances from 200 to 300 ^m. The combination of carbogen and nicotinamide 
resulted in a similar decrease in hypoxic cell fraction as for carbogen only in SCCNij3. 
SCCNij19 showed a hypoxic fraction that was lower for carbogen alone than for carbogen 
in combination with nicotinamide (Figure 5). As an example figure 6 shows the binary 
images of untreated and treated tumors (SCCNij3). There was an almost complete 
disappearance of hypoxia after treatment with carbogen alone or carbogen in combination 
with nicotinamide. The decrease in perfusion fraction after carbogen treatment (more 
vascular structures without Hoechst stain) did not occur if carbogen was given in 
combination with nicotinamide.
Discussion
This paper describes further development of the semi-automatic method for quantitative 
analysis of tumor perfusion, vasculature and proliferation as described earlier [2,4,34], to 
include quantitation of hypoxia. The advantage of this system is that it allows to study 
architectural patterns of proliferation, vascularization and oxygenation of tumors in 
combination with the possibility to distinguish between perfused and non-perfused vessels. 
The method can only be used if a clear discrimination between stained and non-stained areas 
is obtained. The setting of the threshold is a subjective, but nevertheless remarkably robust 
and reproducible procedure. In a previously published paper Rijken et al. [34] showed that 
there was only a small variation in outcome of the analysis of vascular volume calculation 
and determination of the perfusion fraction if the threshold was changed. Setting of the 
threshold implies that the signal is reduced to 'on' or 'off in a binary way. This implies that 
if  a gradient in the staining intensity is present, changes in areas that are considered positive 
or negative will depend on the threshold. In unpublished experiments we found that the 
effect of thresholding on the calculation of proliferation indices was low. The effects of 
thresholding are minimized if the staining quality is optimized, with a high signal-to-noise 
ratio.
Promising results of the combination treatment of accelerated radiotherapy, carbogen 
breathing and nicotinamide (ARCON), in patients treated for squamous cell carcinoma of the 
larynx have been reported [22]. Therefore, two squamous cell carcinoma tumor lines of the 
larynx with different tumor and vascular architecture (Figure 2 versus Figure 6) were
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compared with respect to the changes in oxygenation and proliferation patterns after 
treatment with carbogen and nicotinamide.
Perfusion and vascular volume
The antibody used for staining vascular structures (9F1) has been compared with the anti­
mouse endothelium specific monoclonal antibody MEC 7.46 which showed in xenografts to 
react only with endothelial cells [42]. Anti-collagen IV monoclonal antibody as marker for 
the vasculature (basement membrane) in glioblastoma tumor lines showed a very good 
correlation with 9F1 (endothelial cell staining) (unpublished data). Collagen IV could not be 
used as marker for the vasculature in the squamous cell carcinoma tumor lines because of a 
high amount of collagen causing non-vascular structures to be stained [4]. Monoclonal 
antibody 9F1 was preferred over MEC 7.46 because the staining intensity is higher if  9F1 is 
used [42].
If Hoechst staining is observed without vascular structures (Figure 6) this could be caused 
by the presence of vessels in the plane above or below the tumor section. Although a dose 
of 15 mg/kg Hoechst has already been shown to be vaso-active (37) it is expected that 
relative changes of tumor blood perfusion will be less influenced by the Hoechst 
concentration used.
Nicotinamide administration has been suggested to increase tumor oxygenation, probably as 
a consequence of an increased tumor blood perfusion in rodent tumors [17]. In our studies, 
nicotinamide given as a single agent showed only a moderate increase in the perfusion 
fraction in both tumor lines. An explanation for the absence of a more significant increase 
could be that the baseline perfusion fraction of these two tumor lines was already relatively 
high, certainly if  compared with glioblastoma xenografts which may have perfusion 
fractions as low as 20% [2]. Carbogen breathing significantly decreased the perfusion 
fraction in the same tumor (SCCNij3) which was responsive to nicotinamide but not in 
SCCNij19 suggesting a difference in vascular responsiveness to environmental stimuli 
between the two tumor lines.
Other investigators have also observed tumor-dependent changes in blood perfusion during 
carbogen breathing. An increase in perfusion in the RIF-tumor was reported by Honess and 
Bleehan [15]. After injection of 86RbCl a maximum increase in perfusion was observed 
after 4.5 min of breathing carbogen, which lasted for 9 min (the end of their experiment). 
Laser Doppler flow measurements in human tumors during carbogen breathing showed 
variable responses. Some tumors had a decrease in perfusion fraction, others showed no
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change and some tumors showed an increase [32]. Differential responses in tumor blood 
perfusion after carbogen or nicotinamide treatment may be related to generation, by the 
tumor cells, of endogenous vasoconstrictors (e.g. endothelin-1) and vasodilators (e.g. NO) 
as production of these factors is known to be both oxygen-dependent and tumor type 
dependent [5].
SCCNij3 showed a decrease of the hypoxic fraction despite a decrease of tumor blood 
perfusion. Similar data to this, were obtained by Van der Sanden et al. They studied 
perfusion and oxygenation in a human glioblastoma xenograft tumor model [38]. After 
treatment with carbogen the oxyhemoglobin (O2 Hb) concentration in the tumors, analyzed 
with near infra red spectroscopy (NIRS), increased. Also an increase in arterial pO2 (blood 
gas analysis) and tumor tissue oxygenation was observed (19F-NMR relaxometry). 
However, in these experiments a decrease in tumor blood perfusion occurred, as measured 
by MR-imaging with gadolinium-DTPA uptake. And finally, the bio-energetic status as 
analyzed by 31P-magnetic resonance spectroscopy was decreased after 5 min carbogen 
breathing. These observations could be explained by the so-called 'steal effect': increased 
perfusion of the tissues directly surrounding the tumor at the cost of a decrease of tumor 
perfusion. The impoverished supply of nutrients, including glucose, to the tumor cells led to 
a decrease in bio-energetic status and a reduction in proliferative activity, demonstrated in 
our work by a reduced LI (Table 1). As quiescent cells use less oxygen than proliferating 
cells [39] the effective diffusion distance of the oxygen increases, resulting in a net increase 
of the pO2 in the tumor tissue. Another explanation could be that carbogen breathing 
resulted in a decrease of the mean arterial blood pressure (MABP). This would also result in 
a reduced supply of nutrients. Both a steal effect and a decrease of the MABP could explain 
the apparent paradox of tumor line SCCNij3: a decrease in hypoxia after carbogen breathing 
despite a decrease in the perfusion fraction.
The decrease in tumor perfusion and relative vascular volume, observed in SCCNij3 only, 
after carbogen treatment was reversed when nicotinamide was added. The perfusion fraction 
increased to the level of the control tumors. The absence of a significant increase of tumor 
blood perfusion after nicotinamide treatment may be attributed to a high baseline tumor 
blood perfusion fraction that can not be further increased by nicotinamide. If, however, 
tumor blood perfusion is not at the maximum level due to carbogen treatment, nicotinamide 
can cause an increase in the perfusion fraction. The observed difference in response to 
carbogen treatment between the two tumor lines with the same histology originating from 
the same site shows the inter-tumor variability.
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Proliferation
In this study the proliferation and hypoxia markers are injected into the animals and 
therefore have to be transported with the blood stream. One might then argue that the 
availability of these markers is dependent on the blood perfusion. However, in an earlier 
study we have shown the availability of BrdUrd throughout the tumor. BrdUrd was 
observed at distances as large as 400 ^m from perfused vessels and also in the direct vicinity 
of non-perfused blood vessels [4].
We observed an increase in proliferative activity in both tumor lines with nicotinamide. In 
non-tumor systems, both in vivo and in vitro experiments showed that addition of 
nicotinamide resulted in a change of cell proliferation rate depending on the cell type that 
was investigated. An increase was found in pancreatic ß-cells [45], while a decrease was 
found in human arterial smooth muscle cells [6] and endothelial cells [11]. An increase 
could be the result of stimulation of cells in G0/1 to enter S-phase. If the LI and thus the S- 
phase fraction increases from 11% to 14% (SCCNij3) this would mean that, assuming that 
approximately 70% of cells are in G0/1, only an additional 5% of these cells enter S-phase 
by stimulation with nicotinamide. The relevance of this effect for the outcome of treatment is 
unclear at the moment.
In contrast to nicotinamide, carbogen breathing induced a significant reduction of LI in both 
SCCNij3 and SCCNij19 tumors. The decrease in LI could be due to a cell cycle delay in S- 
phase as a result of glucose and other nutrient deprivation and reduced bio-energetic status 
[38] due to the diversion of blood flow away from the tumor. Another explanation could be 
a G2 delay caused by reperfusion injury to previously poorly oxygenated cells by the overall 
increased pO2. In either case, the anti-proliferative effect of carbogen could compliment its 
radiation modifying effects on the hypoxic component of tumors by also discouraging 
proliferation of tumor cells during a course of fractionated radiotherapy. However, in one of 
the tumor models (SCCNij19) nicotinamide reversed the anti-proliferative effects of 
carbogen, suggesting that the anti-proliferative effect of carbogen may not be obtained in all 
cases with the full ARCON protocol.
Hypoxia
Diffusion distances do not appear to be limiting for NITP after i.p. injection as small islands 
of intact hypoxic cells can be stained in necrotic areas distal to any perfused blood vessels. 
Data on the diffusion distance of hypoxia markers are sparse. In a study with the 2- 
nitroimidazole AF-2, Olive showed that this marker could diffuse up to 400 |im through 
excised tumor cubes of 1-2 mm [28, 29].
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The baseline level of hypoxia showed a large variation between different tumors of the same 
tumor line. This large variation was also observed in flow cytometry studies with NITP 
labeling in murine tumors [40]. Apparently there is a large variation in hypoxic fractions 
between tumors, even within one transplant of a single tumor line.
Hodgkiss et al showed in CaNT tumors that the maximal NITP concentration was reached at 
45-60 min after injection. Fluorescence was detected by flow cytometry after 45-60 min and 
was maximal at 2 h [13]. Because of this relatively long time required for NITP to produce a 
detectable signal, in the present experiments carbogen breathing was continued for 1 h. This 
is longer than the optimal breathing time to overcome hypoxia, which is between 5 and 15 
min [26]. Timing of nicotinamide in our experiments was such that the peak plasma 
concentration occurred shortly after injection of NITP [36]. As a result in our experiments 
the hypoxic fraction may be underestimated, because only 55 min elapsed between NITP 
injection and harvesting of tumor. However, a large effect of nicotinamide on tumor 
hypoxia was observed previously with a 30 min (but not a 60 min) delay between 
administration of nicotinamide and administration of NITP [14], which is similar to the 
delay used in this work. Changes after treatment with carbogen and nicotinamide were 
nevertheless clearly observed in both tumor lines. Hypoxia, analyzed with NITP, was 
drastically reduced after carbogen treatment. Nicotinamide gave only a minor decrease of 
NITP-staining. Treatment of tumors with carbogen in combination with nicotinamide 
resulted for SCCNij3 in a hypoxic fraction that was almost undetectable with NITP. For 
SCCNij19 the combination treatment resulted in a hypoxic fraction that was not as low as 
the carbogen only group. This difference between carbogen alone and carbogen in 
combination with nicotinamide in SCCNij19 could be related to an increase in oxygen 
consumption due to an increase in proliferative activity (LI for the combination treatment is 
higher than for the carbogen only treatment only in SCCNij19).
It is difficult to analyze the effects of carbogen on the NITP metabolism. Oxygen clearly 
modifies NITP metabolism and can therefore be used as marker of hypoxia. The effect of 
nicotinamide on the NITP metabolism is unknown at this moment, however the dose used 
in in vivo experiments are low compared to doses that are used in vitro to cause DNA repair 
inhibition. It is currently under investigation if chronic or the combination of chronic and 
acute hypoxia are measured by hypoxic markers. This will depend on the half-life of the 
compound and on the time period vessels transiently open and close. If only chronic 
hypoxia is visualized by this method one would not expect to observe significant changes 
after nicotinamide treatment. Polarographic or optical pO2 [44] measurements and analysis 
with MR-techniques probably give an indication of the total amount of hypoxia at any
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moment in time. These may be better methods to demonstrate the effect on tumor hypoxia 
resulting from vaso-active agents such as nicotinamide [19].
The differences in response to nicotinamide and carbogen between the two tumor lines that 
were analyzed show that, even in tumors of the same site and histology, a pre-treatment 
analysis could be of help in selecting patients for treatments that are aiming at reducing 
tumor hypoxia. This is the ultimate goal of our study: to design an assay that can be helpful 
in selecting patients or patient categories that may benefit from novel radiotherapy treatments 
including altered fractionation schedules, oxygenation modification or hypoxia-specific 
toxins [3,18,21,24,35]. Recently we have started a study that applies most of the described 
methodology to human tumor material. Patients are injected with hypoxic markers and 
proliferation markers after which diagnostic biopsies are taken and analyzed. Initial results 
indeed show large differences between individual patients.
Conclusion
This investigation has demonstrated the value of a computer-controlled scanning method for 
analysis of microenvironmental parameters. These experiments show that in a xenografted 
human tumor improvement of the oxygenation status is achieved by treatment with 
carbogen. Carbogen breathing is very effective in reducing diffusion limited ('chronic') 
hypoxia and has an additional anti-proliferative effect. In one of the two tested tumor lines a 
reduction of tumor blood perfusion occurred after carbogen breathing which was reversed 
by nicotinamide. This shows the importance of the addition of nicotinamide in certain 
treatment schedules, especially if the tumor blood perfusion is decreased. The clinical 
implication of the effect of nicotinamide and carbogen on proliferation parameters needs 
further investigation.
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Abstract
Hypoxia has a negative effect on the outcome of radiotherapy and surgery, and hypoxia is 
also related with an increased incidence of distant metastasis.
In this study tumor pO2 measurements using a newly developed time-resolved 
luminescence-based optical sensor (OxyLite™) were compared with bio-reductive hypoxic 
marker binding (pimonidazole). Single pO2 measurements per tumor were compared with 
hypoxic marker binding in tissue sections using image analysis. Both assays were 
performed in the same tumors of three human tumor lines grown as xenografts.
Both assays demonstrated statistically significant differences in the oxygenation status of the 
three tumor lines. There was a good correlation between hypoxic marker binding and the 
pO2 measurements with the OxyLite™ device. A limitation of the OxyLite™ system is that it 
is not yet suited for sampling multiple sites in one tumor. An important strength is that 
continuous measurements can be taken from the same position and dynamic information on 
the oxygenation status of tumors can be obtained. The high spatial resolution of the hypoxic 
marker binding method can complement the limitations of the OxyLite™ system. In the 
future, a bio-reductive hypoxic cell marker for global assessment of tumor hypoxia may be 
combined with analysis of temporal changes in pO2 with the OxyLite™ to study the effects 
of oxygenation modifying treatment on an individual basis.
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Introduction
It is well known that radiotherapy under hypoxic conditions is less effective than under 
well-oxygenated conditions [14,23]. Hypoxia is currently considered to be one of the three 
most important radiation-resistance mechanisms together with intrinsic radio-resistance and 
rapid cell proliferation. The importance of tumor hypoxia for radiation treatment outcome 
has been illustrated by treatment strategies with the aim to overcome tumor hypoxia. The use 
of hyperbaric oxygen, carbogen breathing, vaso-active drugs and hypoxic cell sensitizers in 
combination with radiotherapy have shown an increase in loco-regional control and 
sometimes survival [7,17,20,27,37]. The oxygenation status of tumors is not only an 
important indicator for the outcome of radiotherapy, but for surgical treatment as well, 
which was shown for cancer of the uterine cervix [19]. Finally, hypoxia was correlated with 
an increased incidence of distant metastases in human soft tissue sarcomas [3] and 
carcinoma of the uterine cervix [33]. The negative effect of hypoxia on radiation treatment 
outcome can be explained by the mechanism of reduced free radical formation in a hypoxic 
environment. The adverse correlation with the outcome of surgical treatment and the 
increased incidence of metastases in hypoxic tumors could be the result of the expression of 
certain oncogenes, stress proteins or cytokine production stimulated by low oxygen tensions 
[34]. It was shown that hypoxia can elevate the mutation frequency in cultured cells thereby 
acting as a mechanism in tumor progression [30].
Tumor hypoxia can be analyzed in various ways. Radiobiological hypoxia can be assessed 
with the paired survival curve assay [24,35] or with the more recently developed comet 
assay [26]. Direct measurement of tumor tissue oxygenation is possible with polarographic 
needle electrodes (Eppendorf™) [18,25,36] or time-resolved luminescence-based optical 
sensors [8,40]. Other methods to study hypoxia in tissues include the use of bio-reductive 
chemical probes such as the 2-nitroimidazoles [21,22,28], electron paramagnetic resonance 
oximetry [13] and cryospectrophotometry of intra-vascular HbO2 saturation [11].
A number of studies have shown a correlation between hypoxia assessed by polarographic 
measurements (Eppendorf™) and the outcome of radiotherapy [4,12,18,25]. However, a 
disadvantage of this method is that temporal changes in oxygenation cannot be reliably 
measured because the microelectrode cannot be left in the same position within the tumor for 
prolonged periods of time. The reason for this is that, for the polarographic pO2 
measurements, small amounts of oxygen are consumed and a diffusion gradient is
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generated. The electrode therefore needs to be moved through the tissue to prevent hypoxia 
developing as an artifact of the measurements [32,39].
Recently a fiber-optic probe was developed for pO2 measurements. The pO2 measurements 
with this method are based on pO2 dependent changes in the half-life of an excited 
luminiphor at the tip of a probe. This process does not consume oxygen but relies only on 
the presence of oxygen [8,40,41]. The fiber-optic probe can be left at one position for a 
longer period of time, which makes it possible to measure temporal pO2 changes as well as 
to measure the effect of oxygenation modifying interventions over time in a tissue.
In the present study we compared tumor pO2 measurements using time-resolved 
luminescence-based optical sensors (OxyLite™) with bio-reductive hypoxic marker binding 
(pimonidazole) in tissue sections using a semi-automatic computer-controlled method for 
simultaneous multi-parameter analysis of whole tissue sections [5,6,31]. Both assays were 
performed in the same tumors of three different human tumor lines grown as xenografts in 
nude mice.
Materials and methods
Tumors
Three human xenograft tumor lines (SCCNij3, E102 and E106) with different vascular 
architecture and widely different distribution patterns of hypoxia were used for these 
experiments. Tumor line SCCNij3 was derived from a primary human squamous cell 
carcinoma of the larynx (moderately to well differentiated). Tumor lines E102 and E106 
were derived from two different primary human glioblastomas.
Viable 1 mm3 tumor pieces from resection specimens were transplanted subcutaneously in 
nude mice (Balb/c ABom nu mouse). Tumors were passaged when they reached a diameter 
of 1 cm. For the oxygen measurements, tumors were transplanted in the right hind leg. 
Calculation of tumor volume was based on the formula: (A x B x C x n) / 6, where A, B and 
C are tumor diameters measured with calipers in three perpendicular directions.
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines.
Tumor specimens were directly stored in liquid nitrogen after the pO2 measurements, until 
cut into 5 ^m frozen sections. The sections were then stored at -80 oC until staining. Tumor 
tissue sections at the largest circumference of the tumor were analyzed.
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Experimental set-up
During the measurements the animals were kept under anesthesia to minimize any artifacts 
of pO2 measurements due to movements of the animals. An acrylic distributor for the 
anesthetic gas enflurane (Ethrane™), in admixture with a continuous flow of air, was used. 
The set-up was kept at a constant temperature of 33 oC with a warm water mattress. The 
body temperature of the mice was continuously recorded during the experiments by a rectal 
probe (see below tumor pO2 measurements).
Tumor pO? measurements
The recently developed and marketed fiber-optic oxygen-sensing device, OxyLite™ (Oxford 
Optronix™, Oxford, UK) was used to measure tumor pO2. Details of the methodology of 
the fiber-optic oxygen tension measurements were described before [8,40,41]. The pO2 
measurements are based on the principle that, following optical excitation of a luminiphor, 
the half-life to return to the ground state is inversely related to the oxygen tension. The 
luminiphor used for this purpose is ruthenium chloride complex. Blue-light emitting diodes 
are used as the source of excitation light, at around 450 nm. A single optical fiber guides the 
blue-light, as well as the resultant luminescence. The luminiphor at the tip of the probe 
absorbs a proportion of the blue light. When ruthenium chloride complex returns to the 
ground state, the emitted photons have a wavelength of around 590-620 nm. The response 
of the sensor to pO2 is non-linear and therefore the probes must be pre-calibrated. The 
probes that were used in the present experiments were pre-calibrated by the manufacturers. 
The luminescence lifetime is also temperature dependent. Therefore, all measurements are 
corrected automatically for differences in temperature using a thermocouple. In these 
experiments mainly small tumors of 6-8 mm were used, the temperature probe would thus 
have been located just underneath the skin. The temperature correction of the pO2 
measurements was therefore based on the rectal temperature (using a separate 
thermocouple), since it was felt that this was a better reference than the skin temperature. It 
was found that temperature measurements in the central part of the tumor were within 0.5 
oC of the rectal temperatures, even if measured over several hours (data not shown). The 
resulting error in the pO2 measurements was less than 1 mm Hg under these conditions 
[41].
The fiber-optic probes were inserted in the tumor through a small 0.6 mm needle (23 gauge) 
and placed in the center of the tumor. Following insertion, the needle was pulled back. In 
each tumor pO2 measurements were performed in a single position, pO2-values were 
determined from the plateau that was reached within 1 to 10 min after insertion of the fiber­
optic pO2-probe. After the pO2 measurements had reached a plateau for over 5 min, the
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pO2-values were calculated as the average pO2 over the next 5 min. The oxygen tension was 
measured in a total of 35 SCCNij3 tumors, 28 E102 and 38 E106 gliomas.
Marker of hypoxia
Pimonidazole hydrochloride (1 -[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimi dazole 
hydrochloride) was used at a dose of 80 mg/kg as marker of hypoxia, injected intra­
venously, 20 min prior to the start of the pO2 measurements [10,29]. Pimonidazole is a bio- 
reductive chemical probe with an immuno-recognizable side chain. The addition of the first 
electron in bio-reductive activation is reversibly inhibited by oxygen with a half-maximal 
pO2 of inhibition of about 3 mm Hg, with complete inhibition occurring at approximately 10 
mm Hg [29]. Pimonidazole was injected in 13 of the 35 SCCNij3-bearing mice, 12 of the 
28 E102-bearing mice and 7 of the 38 E106-bearing mice.
Immunohistochemical staining
After they were thawed, sections were fixed in acetone for 10 min. Slides were then rinsed 
in phosphate buffered saline (PBS). The sections were rinsed three times for 2 min in PBS 
between all the consecutive steps of the staining procedure.
Endothelial structures and hypoxic marker pimonidazole
Sections were incubated overnight (16h) at 4 oC with undiluted 9F1 (rat monoclonal to 
mouse endothelium [38] together with rabbit anti-pimonidazole antibodies [1,2] diluted 
1:200 in undiluted 9F1. Sections were then incubated for 60 min at room temperature with 
tetramethyl rhodamine isothiocyanate (TRITC)-conjugated goat anti-rat antibodies (Jackson 
Immuno Research Laboratories, West Grove, PA, USA) diluted 1:100 together with 
biotine-conjugated donkey anti-rabbit antibodies (Jackson Immuno Research Laboratories) 
diluted 1:100 in PBS-B (PBS with 0.5% bovine serum albumin). This was followed by a 
60 min pooled incubation at room temperature with TRITC-conjugated donkey anti-goat 
antibodies (Jackson Immuno Research Laboratories) and streptavidine-Alexa-488 
(Molecular Probes Inc. Eugene, Oregon, U.S.A.) both diluted 1:100 in PBS-B.
Scanning of sections, image processing and analysis of hypoxic parameters 
The tumor sections were scanned for quantitative analysis by a computerized digital image 
processing system as described before [6,31]. A high-resolution intensified solid-state 
camera on a fluorescence microscope (Zeiss Axioskop) with a computer-controlled 
motorized stepping stage was used. Tumor cross-sections were sequentially scanned at 
100X magnification, using different filters for the TRITC and Alexa-488 signals. After each
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scan, which consisted of 36 or 64 fields (6 x 6 or 8 x 8, depending on the size of the tissue 
section) of 1.2 mm2 each, one composite binary image was reconstructed from the 
individual microscopic fields. The whole scanning procedure thus yielded two composite 
images from each tumor cross-section: one showing hypoxic areas (pimonidazole) and one 
showing vascular structures (9F1). Finally, a hematoxylin and eosin staining (H&E) of the 
tissue sections allowed a contour line to be drawn around the tumor area while excluding 
non-tumor tissue and areas of necrosis.
The pimonidazole hypoxic fraction was calculated as the total hypoxic area (pimonidazole) 
relative to the total tumor area [6].
Statistics
Linear least squares regression analysis was used for calculation of the correlation between 
the median hypoxic fraction and median pO2. For calculation of the differences in hypoxic 
fraction and pO2 between the tumor lines, ANOVA was used. The statistical analyses were 
done on a Macintosh computer using the Statistica 4.0 software package.
Results
Figure 1 shows an H&E stained tumor section of tumor line SCCNij3 with a fiber optic 
oxygen probe overlaid. This figure gives an impression of the dimensions of the probe 
relative to the tissue architecture. The pO2 that is measured, is an average of the oxygen 
tension in the ruthenium chloride at the tip of the fiber-optic probe. The measuring volume 
consists of the tissue area directly adjacent to the tip of the probe [15].
Oxygen tension and tumor size
Figure 2A is a cumulative plot of the pO2-values obtained from all individual tumors of the 3 
different tumor lines. With a median pO2 of 2 mmHg, the squamous cell carcinoma tumor 
line was the most hypoxic of the three tumor lines that were analyzed. The median pO2 of 
the two glioma tumor lines were 11 and 24 mmHg. Mean, median as well as the proportion 
of pO2-values below 2.5, 5 and 10 mmHg are shown in Table 1. The differences in pO2- 
values between the three tumor lines were statistically significant (ANOVA, p=0.002).
Most of the tumors used for these experiments had a diameter between 5.5 to 7 mm (the 
approximate volumes ranged from 80 to 200 mm3). Within this relatively narrow range of 
tumor sizes no correlation was found between tumor volume and the pO2 measurements 
from the center of the tumors in either of the three tumor lines (Figure 3).
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Figure 1. Example o f an H&E stained section o f the human squamous cell carcinoma 
xenograft tumor line SCCNij3 with a fiber-optic oxygen probe overlaid. The 
photomicrograph shows the dimensions o f the probe relative to tissue 
architecture.
Hypoxic fraction
Figure 4 shows binary images of representative examples of the three tumor lines, 
demonstrating the distribution of the stained pimonidazole adducts in the tumor section. 
Although in the SCCNij3 tumor hypoxia, staining was found throughout the tissue section, 
it was predominantly present in the center of the tumor. The arrows in Figure 4 (SCCNij3) 
indicate a necrotic area in the center of the tumor. In the binary images, necrosis can be 
recognized as a red / yellow color as the result of non-specific staining; this was confirmed 
by H&E-staining of the same tissue section. The necrotic areas were excluded from the 
calculation of the hypoxic fraction.
A cumulative plot of the hypoxic fraction obtained from the individual tumors is shown in 
Figure 2B. The median hypoxic fraction of SCCNij3 was 0.14 (mean 0.20, range 0.1-0.38, 
n=13). Glioma tumor line E102 showed hardly any pimonidazole binding and had a median
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hypoxic fraction of 0.004 (mean 0.01, range 0.001-0.05, n=12). Glioma tumor line E106 
showed a diffuse patchy pattern of pimonidazole binding without predominance in central or 
peripheral parts of the tumor. The median hypoxic fraction was 0.08 (mean 0.1, range 0.08­
0.2, n=7). In contrast to SCCNij3, this tumor line showed hardly any necrosis. If necrosis 
could be recognized in E106 at all (by means of H&E staining), this was not specifically 
located in the center of the tumor, but in small areas throughout the tumor section. The 
differences in hypoxic fraction between the three tumor lines were statistically significant 
(ANOVA, p < 0.05).
Table 1. Oxygen tension characteristics o f 3 human tumor lines
tumor
line mean median
pO2#
range n* S.E.M.
proportion of pO2-values#
< 2.5 (%) < 5 (%) < 10 (%)
SCCNij3 6.4 2 0-38 35 3.2 57 63 77
E102 22 24 0-42 28 2.9 7 7 14
E106 16 11 0.8-42 38 4.2 8 21 45
* number of tumors; # pO2 in mmHg
Oxygen tension and hypoxic fraction
The median hypoxic fraction relative to the median pO2 for the three tumor lines is shown in 
Figure 5. A strong correlation was found between the median pO2 and median hypoxic 
fraction as well as between the mean pO2 and the mean hypoxic fraction of the three tumor 
lines (linear least squares regression analysis, p=0.02 for median pO2 versus median 
hypoxic fraction).
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percentage
pO2 (mmHg)
percentage
hypoxic fraction
Figure 2. Cumulative frequency (percent) o f pÜ2 measurements by OxyLite™ (A) and 
hypoxic fraction determined by pimonidazole staining (B) o f  individual 
tumors o f the human squamous cell carcinoma tumor line SCCNij3 and o f the 
human glioblastoma tumor lines E102 and E106.
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Discussion
In this study, pO2 measurements with a recently developed optical sensor (OxyLite™) were 
compared with bio-reductive hypoxia marker binding (pimonidazole). The three different 
human tumor lines that were studied included one human head and neck squamous cell 
carcinoma and two human glioblastoma tumor lines grown as xenografts in nude mice. 
Tumor hypoxia (pimonidazole-staining) and pO2 varied significantly between these three 
tumor lines. The measurements showed a good correlation between tumor pO2 and binding 
of the bio-reductive hypoxic marker pimonidazole.
The method most commonly used for direct pO2 measurements in tissues is by 
polarographic oxygen microelectrodes (Eppendorf™). These pO2 measurements are based 
on the linear relationship between electrode currents and oxygen availability. This method 
has the advantage of a short acquisition time (fraction of a second). With the Eppendorf™ 
design the polarographic microelectrode advances through the tissue with a varying step 
size, usually in the order of 0.4 to 0.7 mm and acquires a reading at each step [25,36]. In 
this way a large number of pO2 measurements per tumor can be obtained within 10 to 15 
minutes. A disadvantage of the microelectrodes is that they cannot remain at one position for 
continuous measurements because they consume oxygen; they may then measure artificially 
low oxygen tensions after some time. Another disadvantage is that the accuracy decreases at 
lower oxygen tensions due to the weak electrical currents associated with these low oxygen 
concentrations [8]. The OxyLite™ system has overcome some of these limitations. There is 
no oxygen consumption, which allows the probe to stay in the same position for a 
prolonged time (hours). The relationship between the luminescence lifetime and the oxygen 
tension is non-linear. At low pO2 levels, where the degree of quenching is least, the lifetime 
and signal amplitudes are greatest, which results in an enhanced accuracy at low pO2 levels. 
A disadvantage of this non-linear relationship is that the probes need to be pre-calibrated and 
at higher pO2 levels the measurements become less precise [40].
At the moment, the OxyLite system is not suited for sampling multiple sites in one tumor. 
Another disadvantage of this methodology is that after insertion of the optic-fiber it can take
1 to 10 min before the pO2-value reaches a plateau. Probably this period of time is necessary 
for the tissue to restore after the mechanical damage caused by inserting the pO2-probe. It is 
unclear if this is a disadvantage only for the fiber-optic probes with a rounded tip, or if  this 
is a process also occurring with needle-type sensors with a sharp tip, such as the 
Eppendorf™. However, once the pO2-value has reached a plateau, the time to respond to a 
change in pO2, caused by for instance carbogen breathing, is within less than one min [41].
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Tumor pÜ 2 versus volume. Data points represent pÜ 2 measured at one 
position in the center o f individual tumors o f the human squamous cell 
carcinoma line SCCNij3 and o f the glioblastoma tumor lines E102 and E106.
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E102 E106
Figure 4. Pseudo-colored composite images reconstructed after scanning for the 
vascular structures (9F1, red) and hypoxia (pimonidazole, green) o f complete 
sections o f the human squamous cell carcinoma xenograft tumor line 
SCCNij3 and the human glioblastoma tumor lines E102 and E106. Necrotic 
areas were identified on the same tissue sections by means o f H&E staining 
and are indicated by arrows. The scale bar refers to all 4 images.
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This favors the hypothesis that this phenomenon of reaching a plateau is likely to be caused 
by a mechanical disruption or compression, which also occurs with other types of invasive 
pO2 measurements. As soon as a stepping device for moving the fiber-optic probe through 
tissues becomes available, a direct comparison of the two methodologies will be possible. 
The bio-reductive compound pimonidazole was used as marker of hypoxia. Initially, 
pimonidazole was used in the clinic as a hypoxic cell sensitizer. However, it failed to prove 
its effectiveness in clinical trials [9]. After development of an antibody against pimonidazole 
[1] it has been tested extensively in tumor models as a hypoxic cell marker and recently, it 
was reintroduced into the clinic for this reason. Characteristics of pimonidazole are very 
similar to misonidazole [29] with a steep increase in the reduction below a pO2 of 10 mm 
Hg [16].
median
median hypoxic fraction
Figure 5. Median tumor pO2 versus median hypoxic fraction o f the human squamous 
cell carcinoma tumor line SCCNij3 and of the human glioblastoma tumor lines 
E102 andE106 (+ SEM).
With pimonidazole as hypoxia marker the distribution pattern of hypoxic regions throughout 
a tissue section can be studied [6]. Pimonidazole staining was more centrally located in the 
squamous cell carcinoma line SCCNij3 compared with glioma line E106 (Figure 4). Since
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the pO2 was measured in the central part of the tumor, the probability of measuring in a 
hypoxic area is higher in SCCNij3 than in E106 (Figure 3A versus 3C).
Extensive necrosis in the center of the tumor was found in 5 out of the 20 tumors with pO2 
readings below 2.5 mm Hg of tumor line SCCNij3. The majority of necrotic areas were 
located in the center of this tumor and these necrotic areas were also larger in SCCNij3 
compared to E106, thus there is a probability that irrelevant measurements are being made in 
necrotic areas of the SCCNij3 tumors. In fact, this may have been the case in 5 out of 20 
tumors that showed readings below 2.5 mmHg.
Raleigh et al. [29] recently published the results of a study in which pimonidazole binding 
was compared with Eppendorf™-based pO2 measurements. Different levels of oxygenation 
were induced in the C3H mouse mammary carcinoma. Animals were treated with either 
hydralazine, the breathing of different gas mixtures such as air, carbogen and pure oxygen 
or hypoxia was induced by clamping blood supply to tumors. A good correlation was found 
between radiobiological hypoxia, analyzed with the paired survival curve method, 
pimonidazole binding and pO2 measurements (Eppendorf™) [29]. The correlation between 
pimonidazole adducts binding and Eppendorf™-based pO2 was strongest if the 
pimonidazole hypoxic fraction was compared with the percentage of pO2 readings below 10 
mm Hg. The correlation between the hypoxic fraction and the mean pO2 of each tumor was 
less strong.
For the experiments reported here, the hypoxic tumor fractions were calculated in the same 
tumors after measurement of pO2. There was a good correlation between median pO2 and 
median hypoxic fraction (Figure 5). However, extensive heterogeneity of well and poorly 
oxygenated regions within each tumor line were found with the pimonidazole binding 
method, which is illustrated in Figure 4. Although we found a good correlation between the 
results of the two methodologies, they are clearly different in nature each with specific 
strengths and weaknesses. The strength of the hypoxic marker binding method obviously is 
the high spatial resolution. The advantage of the OxyLite™ system is that absolute pO2- 
values can be obtained and, maybe most important, that continuous measurements can be 
taken from the same position over prolonged periods of time. This will give dynamic 
information on the oxygenation status of tumors with the possibility to better monitor the 
effects of oxygenation modifying treatments. Spatial information can be increased by using 
multiple probes per tumor or by adding a stepping stage on the OxyLite™ device as with the 
Eppendorf™ system. Oxygen tension measurements with Eppendorf™ in the same three 
tumor lines in combination with hypoxic marker binding has shown a correlation in the 
same range as the present data obtained with OxyLite™. With Eppendorf™ a great number
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of pO2-values per individual tumor was obtained, which explained that the correlation 
between pO2 and hypoxic fraction for individual tumor was stronger with Eppendorf™ than 
with OxyLite™ (work in progress).
In a number of studies, parameters derived from Eppendorf™-based pO2 measurements 
have been identified that can predict for treatment outcome [4,18,25]. Although statistically 
significant differences in pre-treatment characteristics have been found, it is still not possible 
to use these parameters for pre-treatment selection on an individual basis. An assay to test 
the effect of treatments modifying the oxygenation status of a tumor, such as administration 
of drugs to increase tumor blood perfusion, or carbogen breathing, in an individual patient 
has the potential of being predictive for treatment outcome. For oxygen tension 
measurements, the newly developed time-resolved fiber-optic pO2 measuring OxyLite™ 
allows the study of temporal changes in pO2, but with the restraint that only a limited 
number of measurements per tumor is possible. In the present study, a good correlation 
between time-resolved fiber-optic pO2 measurements and tumor hypoxic fraction based on 
bio-reductive chemical probe binding was found for three human tumors that varied 
significantly in their oxygenation status. Although a significant difference in pO2 and 
hypoxic fraction between the three lines was found, the results also showed a large variation 
within each tumor line. This indicates that multiple measurements per tumor or per tumor 
line are necessary for global assessment of tumor hypoxia.
Conclusion
The tumor microenvironment is a dynamic system and to better understand the biology of 
tumors it is important to quantify dynamic changes in the tumor microenvironment. The 
major strength of the OxyLite™ lies in the ability to monitor pO2 in the same tumor area for 
a prolonged period of time; this aspect is further investigated in ongoing experiments. A 
combination of a bio-reductive hypoxic cell marker, for global assessment of tumor 
hypoxia, in combination with analysis of temporal changes in pO2, with the OxyLite™, may 
be helpful to select patients on an individual basis for oxygenation modifying treatments.
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Abstract
Background and purpose. In head and neck cancer, addition of both carbogen breathing and 
nicotinamide to accelerated fractionated radiotherapy showed increased loco-regional control 
rates. An assay based on the measurement of changes in tumor pO2, in response to 
oxygenation modification could be helpful for selecting patients for these new treatment 
approaches.
Materials and methods. The fiber-optic oxygen-sensing device, OxyLite™, was used to 
measure changes in pO2, at a single position in tumors, after treatment with nicotinamide 
and carbogen in three human xenograft tumor lines with different vascular architecture and 
hypoxic patterns. Pimonidazole was used as a marker of hypoxia and was analyzed with a 
digital image processing system.
Results. At the position of pO2 measurement, half of the tumors showed a local increase in 
pO2 after nicotinamide administration. Steep increases in pO2 were measured in most 
tumors during carbogen breathing although the increase was less pronounced in tumor areas 
with a low pre-treatment pO2. A trend towards a faster local response to carbogen breathing 
for nicotinamide pre-treated tumors was found in all three lines. There were significant 
differences in hypoxic fractions, based on pimonidazole binding, between the three tumor 
lines. There was no correlation between hypoxic marker binding and the response to 
carbogen breathing.
Conclusion. Temporal changes in local pO2 can be measured with the OxyLite™. This 
system was used to quantitate the effects of oxygen modifying treatments. Rapid increases 
in pO2 during carbogen breathing were observed in most tumor areas. The locally measured 
response to nicotinamide was smaller and more variable. Bio-reductive hypoxic cell marker 
binding in combination with OxyLite™ pO2 determination gives spatial information about 
the distribution patterns of tumor hypoxia at the microscopic level together with the 
possibility to continuously measure changes in pO2 in specific tumor areas.
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Introduction
Tumor hypoxia has a negative effect on the outcome of cancer treatment. It is well known 
that the radiation dose necessary to kill hypoxic cells can be up to a threefold higher 
compared to cells under well-oxygenated conditions [20]. Several studies have shown that 
there is a correlation between tumor hypoxia and local control or survival. This was found 
for head and neck cancer as well as for carcinomas of the uterine cervix [3,18,22,23,37]. 
Several treatment modifications have been introduced in the clinic to either overcome 
hypoxia or to specifically treat hypoxic cells for instance with bio-reductive cytotoxic drugs 
such as tirapazamine [4]. Often treatment modifications were given in combination with 
radiotherapy, such as radiotherapy under hyperbaric oxygen conditions, and the use of 
hypoxic cell sensitisers (nimorazole), which have shown an increase in loco-regional tumor 
control [21,39,47].
One of the newer strategies involves the addition of carbogen and nicotinamide to 
conventional or accelerated radiotherapy. This resulted in a significant radio-sensitization in 
the mouse mammary carcinoma tumor line CaNT. In these experiments the addition of 
carbogen was used to reduce diffusion limited hypoxia and the vaso-active drug 
nicotinamide was added to reduce perfusion limited hypoxia [43]. In a phase II study in 
stage III and IV head and neck cancer, carbogen and nicotinamide were added to an 
accelerated fractionation schedule (ARCON). A high loco-regional control rate of 72% at 2 
years was observed. Particularly good results were observed for oropharynx and larynx 
carcinomas. The local control at 3 years for 78 patients with advanced larynx carcinoma was 
83% indicating that this approach offers excellent possibilities for organ preservation [30]. 
This increase in loco-regional control is accompanied by an increase in acute toxicity and 
also, despite the success of the multi-factorial approach of ARCON, still some patients fail 
treatment [7,28,29]. Therefore, a predictive assay, based on individual measurement of the 
tumor tissue oxygenation status, may be helpful in selecting patients for these new treatment 
combinations.
There are various methods to measure tumor hypoxia. Direct in-situ measurement of tumor 
tissue pO2 is possible with polarographic needle electrodes (Eppendorf™) [37,46]. Another 
approach to study hypoxia is with the use of bio-reductive chemical markers such as the 2- 
nitroimidazoles [12,32,34,40,41]. Other methods for the analysis of tissue oxygenation 
include the comet assay [38], electron paramagnetic resonance (EPR) oximetry [19] and 
cryospectrophotometry of intra-vascular HbO2 saturation profiles [15].
Each of these methods has specific advantages and disadvantages, but the disadvantage of 
most of these methods is that they only give static information of the tissue oxygenation
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status. Temporal changes cannot be monitored and therefore the results are not necessarily 
indicative of the effectiveness of an oxygenation-modifying intervention.
Several methods are now under investigation to analyze changes in the oxygenation status 
over time. These include the use of double hypoxia markers detected by 
immunohistochemical techniques or detected after labeling with radioisotopes [27,44]. Non­
invasive or minimally invasive methods include MR-based techniques exploring changes in 
perfusion [45]. Also, MR techniques that are modified to allow direct measurements of pO2 
[36] and EPR oximetry [17,19] are being developed.
Recently, a fiber-optic probe was developed for continuous pO2 measurements [9,52,53]. 
The fiber-optic probe can be left in the same position in the tissue for a prolonged period of 
time because there is no oxygen consumption during the pO2 measurements. This makes it 
possible to directly measure temporal changes in pO2 as well as the effects of oxygenation 
modifying interventions over time in a tissue. Like the Eppendorf™ pO2-histograph, the 
response time of this oxygen-sensing device, which is based on time-resolved luminescence 
techniques, is very short [53]. The commercial version was marketed in 1998 (OxyLite™).
The aim of the present study was to measure the changes in pO2 induced by carbogen 
breathing and nicotinamide administration. Tumor pO2 was continuously monitored during 
these interventions with the fiber-optic pO2 probes. Three human xenograft tumor lines with 
different vascular architecture and widely different distribution patterns of hypoxia were 
used for these experiments.
Materials and methods
Tumors
The three tumor lines used for this study included two human glioblastoma xenograft lines. 
One has a homogeneous distribution pattern of hypoxic areas throughout the tumor (E106) 
as shown by pimonidazole staining. The other one has only a minimal detectable amount of 
hypoxia (E102). The third xenograft line that was analyzed originated from a human 
squamous cell carcinoma of the larynx (moderately to well-differentiated) with extensive 
hypoxia and necrosis localized predominantly in the center of the tumor (SCCNij3).
Viable 1 mm3 tumor pieces from resection specimens were transplanted subcutaneously in 
nude mice (Balb/c ABom nu mouse). Tumors were passaged when they reached a diameter 
of 1 cm.
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For the fiber-optic pO2 measurements tumors were transplanted in the right hind leg. 
Calculation of tumor volume was based on the formula:
(A x B x C x n) / 6, where A, B and C are tumor sizes measured with calipers in three 
perpendicular directions. Tumors within a size range of 60 to 270 mm3 were used, which 
corresponds with a diameter of 5 to 8 mm. Within this range there was no effect of tumor 
volume on tumor pO2 in these three human xenograft tumor lines [8].
Animals were kept in a specific pathogen-free unit in accordance with institutional 
guidelines.
After the pO2 measurements, the tumor specimens were directly stored in liquid nitrogen, 
until cut into 5 ^m frozen sections. The sections were then stored at -80 oC until staining. 
Tumor tissue sections at the largest circumference of the tumor were analyzed. Sections 
were stained with hematoxylin and eosin staining (H&E) to detect necrosis in the tumors.
Experimental set-up and carbogen breathing
During the measurements the animals were kept under anesthesia to minimize artifacts of 
pO2 measurements due to movements of the animals. An acrylic distributor for the 
anaesthetic gas enflurane (Ethrane™), in admixture with a continuous flow of air or 
carbogen (95% O2, 5% CO2), was used. The set-up was kept at a constant temperature of 
33 oC with a warm water mattress and a plastic plate on top of it to reduce artifacts due to 
temperature fluctuations. The body temperature was continuously recorded during the 
experiments by a rectal probe (see below tumor pO2 measurements).
Nicotinamide
After initiation of the anesthesia and before the pO2 measurements started, a needle was 
inserted intra-peritoneally (i.p.) to allow injection of nicotinamide during the pO2 
measurements without movement of the animal. Nicotinamide (Sigma) was dissolved in 
saline and injected i.p. at a concentration of 500 mg/kg. Nicotinamide was injected after 
equilibration of the pO2 and 20 min after this administration the carrier gas mixture was 
switched from air to carbogen.
Tumor pO? measurements
The recently developed and marketed fiber-optic oxygen-sensing device, OxyLite™ (Oxford 
Optronix™, Oxford, UK) was used to measure tumor pO2. Details of the methodology of 
the fiber-optic oxygen tension measurements were described before [9,52,53]. The pO2 
measurements are based on the principle that, following optical excitation of a luminiphor, 
the half-life to return to the ground state is inversely related to the oxygen tension. The
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luminiphor used for this purpose is ruthenium chloride complex. Blue-light emitting diodes 
are used as the source of excitation light, at around 450 nm. A single optical fiber guides the 
blue-light, as well as the resultant luminescence. The luminiphor at the tip of the probe 
absorbs (a proportion of) the blue light. When ruthenium chloride complex returns to the 
ground state, the emitted photons have a wavelength of around 590-620 nm. The probes 
used in the present experiments were pre-calibrated by the manufacturers because the 
response of the sensor to pO2 is non-linear.
The luminescence lifetime is also temperature dependent. Therefore, all measurements are 
corrected automatically for differences in temperature measured by a thermocouple in the 
mouse rectum. The temperature in the central part of the tumor was measured and was 
within 0.5 oC of the rectal temperatures. The resulting error in the pO2 measurements under 
these conditions is less than 1 mm Hg [53].
The fiber-optic probes were inserted in the tumor through a small 0.6 mm needle (23 gauge) 
and placed in the center of the tumor. Following insertion, the needle was pulled back.
A response to carbogen breathing or nicotinamide administration was, based on fluctuations 
in pO2 observed in previous experiments, defined as an increase in locally measured tumor 
pO2 of at least 10% relative to the pre-treatment pO2. The oxygen sensor was not moved 
during the pO2 measurements and thus the pO2 changes registrated pertain only to the area 
of the tumor where the probe was positioned.
The oxygen tension was measured in a total of 36 SCCNij3 tumors, 17 E102 and 21 E106 
tumors with sizes ranging from 60 to 270 mm3. Five of the 36 SCCNij3 had only a 
marginal viable rim of tumor tissue with massive necrosis in the center of the tumor (based 
on H&E staining). Approximately half of the tumors were treated with carbogen breathing 
only and the other half was treated with nicotinamide followed by carbogen breathing.
Marker of hypoxia, immunohistochemical staining and scanning
As marker of hypoxia pimonidazole (1-[(2-hydroxy-3-piperidinyl)propyl]-2-nitroimidazole 
hydrochloride) was administered i.p. at a dose of 100 mg/kg, 15 min before the pO2 
measurements started (J.A. Raleigh, Department of Radiation Oncology, University of 
North Carolina, School of Medicine, Chapel Hill, NC, USA) [1,2].
Tumor specimens were directly stored in liquid nitrogen until frozen sections of 5 |im 
thickness were cut, which were then stored at -80 oC until staining.
The tissue sections were scanned and analyzed with an image processing system after 
immunohistochemical staining for hypoxia (pimonidazole) and vasculature (rat monoclonal 
to mouse endothelium, 9F1 [49]) [5,6,42]. A high-resolution intensified solid-state camera 
on a fluorescence microscope (Zeiss Axioskop) with a computer-controlled motorized
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stepping stage was used. A detailed description of the scanning method has been given by 
Rijken et al. [42].
Statistics
Linear least squares regression analysis was used for calculation of the correlation between 
hypoxic fraction and pre-treatment pO2, pre-treatment pO2 and response to nicotinamide, 
and pre-treatment pO2 and response to carbogen breathing. For calculation of the differences 
in hypoxic fraction and pO2 between the tumor lines, ANOVA was used. The t-test was 
used to calculate the statistical differences between the pO2 of carbogen responding versus 
non-responding tumors and for the differences in time to reach a maximum pO2 during 
carbogen breathing with or without nicotinamide treatment. The statistical analyses were 
done on a Macintosh computer using the Statistica 4.0 software package.
Results
Figure 6 shows binary images of representative examples of the three tumor lines that were 
used in the current experiments. The images illustrate the differences in distribution patterns 
of vascular architecture and hypoxia between the three tumor lines. Almost no hypoxia was 
detectable in glioblastoma xenograft line E102. Glioblastoma xenograft line E106 shows 
patches of hypoxia distributed evenly throughout the tumor. Although in the squamous cell 
carcinoma line SCCNij3 hypoxia staining was found throughout the tissue section, it was 
predominantly present in the center of the tumor surrounding necrotic areas (solid arrows), 
which were identified by H&E-staining of the same tissue section. The part of the section 
covered with normal skin is clearly visible due to its hypoxic staining (dotted arrows).
Carbogen only
Figure 1 shows an example of 3 tumors of squamous cell carcinoma line SCCNij3 
measured simultaneously, during repeated exposures of carbogen breathing. Two out of 
these 3 tumors showed a local increase in pO2 during carbogen breathing. In one of the 3 
tumors there was no measurable local response to carbogen.
In all tumors of both glioblastoma xenograft lines a strong local increase in tumor pO2 in 
response to carbogen breathing was found. In glioblastoma line E102 the mean pO2 
increased from 27 to 74 mmHg (Table I, Figure 2) and in glioblastoma line E106 the mean 
pO2 increased from 21 to 67 mmHg (Table II, Figure 3).
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In 9 out of the 17 SCCNij3 tumors an increase in local pO2 during carbogen breathing was 
found. The mean pO2 of tumors without a locally measured increase in pO2 (< 10%) was 
significantly lower than the mean pO2 of tumors with a local increase in pO2 (> 10%), 0.8 
mmHg versus 9.1 mmHg, respectively (t-test, p<0.05). The mean pO2 of the tumor areas 
showing a response (>10%) increased from 9.1 to 51 mmHg (Table III, Figure 4).
Table I. Results of pO2 measurements in glioblastoma xenograft tumor line E102.
n volume*
(range)
2 
g
pO2 after 
NAM# 
(range)
pO2 during 
carbogen# 
(range)
time to reach max. 
pO2 after start of 
carbogen@ (range)
nicotinamide, 2 173 20 21 69 3.8
non­
responders (157-189) (8.7-31) (9.1-33) (56-83) (2.2-5.3)
nicotinamide,
responders
8 135
(63-201)
23
(0.4-37)
31
(2.1-45)
55
(11-87)
2.5
(0.8-6.5)
carbogen only 7 129 27 -- 74 3.9
(63-176) (13.8-38) (25-100) (0.8-14)
mean 137 24 29 64 3.2
* mean volume in mm3; t  mean pre-treatment pO2 in mmHg; # mean pO2 in mmHg; @ time 
in min.
Nicotinamide
In 8 out of 10 treated tumors of the least hypoxic glioblastoma xenograft line E102, a local 
increase in pO2 of more than 10% was found in response to nicotinamide. The mean local 
pO2 in tumors with a measurable response showed an increase from 23 to 31 mmHg. Only 
5 of the 19 tumors of the most hypoxic tumor line of the three lines studied, the squamous 
cell carcinoma line SCCNij3, showed a locally measurable response to nicotinamide 
treatment. The mean local pO2 of the tumors, where a response was measured, increased 
from 11.1 to 15.5 mmHg. Of glioblastoma xenograft line E106, 5 out of 10 tumors showed 
a local increase in mean pO2 from 15.7 to 25 mmHg. No significant difference in pre­
treatment local pO2 of tumors with or without an increase in pO2 was found in the 
glioblastoma lines. However, in the SCCNij3 line, the pre-treatment pO2 was significantly 
lower in the tumor areas showing no increase in pO2 as compared to the tumors where an 
increase in pO2 was measured (t-test, p<0.05) (Tables I, II and III).
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Table II. Results o f pO2 measurements in glioblastoma xenograft tumor line E106.
n volume*
(range) ra
p
n
O 2
)
pO2 after 
NAM# 
(range)
pO2 during 
carbogen# 
(range)
time to reach max. 
pO2 after start of 
carbogen@ (range)
nicotinamide, 5 139 16.0 17.3 58 2.7
non­
responders (105-169) (2.3-34) (2.2-38) (13-100) (1.0-5.5)
nicotinamide, 5 140 15.7 25 78 2.2
responders (110-226) (2.9-30) (7.2-36) (45-100) (1.5-2.7)
carbogen only 11 166 21 -- 67 3.6
(63-262) (2.7-49) (22-100) (0.7-16)
mean 153 18.5 21.2 67 3.0
* mean volume in mm3; K mean pre-treatment pO2 in mmHg; # mean pO2 in mmHg; @ time 
in min.
Table III. Results o f pO2 measurements in the human squamous cell xenograft tumor line 
SCCNij3.
n volume*
(range) ra
p
n
O 2
)
pO2 after 
NAM# 
(range)
pO2 during 
carbogen# 
(range)
time to reach max. 
pO2 after start of 
carbogen@ (range)
nicotinamide, 14 157 2.4 2.4 6.0 4.1
non­
responders (92-234) (0-21) (0-21) (0-63) (2.2-6.0)
nicotinamide,
responders.
5 128
(79-205)
11.1
(2-27)
15.5
(2-40)
50
(12-100)
3.6
(1.3-5.0)
carbogen 
only, non­
responders
8 165
(113-220)
0.8
(0-3)
0.8
(0-3.2)
carbogen 9 160 9.1 -- 51 8.1
only,
responders (73-264) (0-29) (2.5-100) (3-16)
mean 156 4.9 5.8 22 5.4
* mean volume in mm3; T mean pre-treatment pO2 in mmHg; # mean pO2 in mmHg; @ time 
in min.
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Figure 1. Examples o f  continuous pO2 measurements versus time in 3 different human 
xenografts o f  tumor line SCCNij3 (A, B, C) and the locally measured 
response to multiple exposures o f carbogen breathing. The start o f each 
carbogen breathing period is indicated by a solid arrow; switching back from  
carbogen to air breathing is indicated by a dashed arrow.
Nicotinamide plus carbogen
Figure 5 shows the changes over time in local tumor pO2 after injection of nicotinamide 
followed by carbogen breathing in 3 tumors of the squamous cell carcinoma line. In these 
examples one tumor did not show a local response to nicotinamide but in this tumor a steep 
increase during carbogen breathing was found (1). One tumor showed an increase of more 
than 10% in local pO2 after nicotinamide treatment and also during carbogen breathing (2) 
and in the third SCCNij3 tumor the pO2 increased neither after nicotinamide administration 
nor during carbogen breathing (3).
For both glioblastoma xenograft lines the effect of nicotinamide on pO2 was overwhelmed 
by the effect of carbogen breathing on tumor pO2. There was no significant difference in 
local response to carbogen after pre-treatment with nicotinamide (Figure 2 and 3). The 
tumors that showed no local response to nicotinamide all showed a response to carbogen. 
This was different for the squamous cell carcinoma line SCCNij3. Thirteen of the 16 tumors
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of this tumor line that did not show a local response to nicotinamide also did not show a 
response to carbogen breathing (Figure 4).
p O2
(m m H g)
w ith
carbogen
pO2 (mmHg)
Figure 2. Pre-treatment local tumor pO2 versus pO2 after carbogen breathing o f the 
human glioblastoma xenograft line E102. All points represent the plateau-value 
o f a single measurement in different individual tumors. The lines that are 
shown do not represent curve fitting for the actual data, but are drawn to 
indicate the slopes in case o f no change, a three-fold or a five-fold increase in 
locally measured tumor pO 2.
Pre-treatment pO 2 versus response to carbogen breathing
The increase in pO2 during carbogen breathing measured locally in the tumors was for all 
tumor lines, irrespective of the response to nicotinamide, correlated with the pre-treatment 
pO2. The increase in pO2 for glioblastoma E102 was by a factor of 2.5 (multiple regression 
analysis, p=0.0006), for glioblastoma E106 this was 2.9 (p=0.0005) and for squamous cell 
carcinoma line SCCNij3 this was 3.8 (p<0.0001), Figures 3, 4 and 5.
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Time to reach the maximum pO2
After nicotinamide was injected (i.p.), before carbogen breathing started, the maximum 
increase in locally measured pO2 was found at approximately 20 min. As soon as the carrier 
gas mixture of ethrane was switched from air to carbogen, the response to carbogen was 
very rapid. Of the tumors of the SCCNij3 line that showed a local response to carbogen, 9 
out of 17 carbogen only tumors plus 8 out of 19 nicotinamide pretreated tumors, the mean 
time to reach the maximum pO2 was 4.1 min (range 1.3-16 min). Although it took 16 min 
for the slowest responding tumor to reach the maximum pO2 level (32 mmHg), pO2 had 
already increased from 0.5 to 13.5 mmHg within 5 min. Only 2 out of the 17 tumors of this 
tumor line that showed an increase in pO2 during carbogen breathing the maximum pO2- 
value remained below 5 mmHg and for 2 additional tumors the maximum local increase in 
pO2 remained below 10 mmHg. No significant differences between nicotinamide pre-treated 
and non-nicotinamide pre-treated tumors were found (t-test, p>0.05). However, a trend 
towards a faster increase in pO2 during carbogen breathing was found for tumors where a 
local response to nicotinamide was measured in all three tumor lines (Tables I, II and III).
p°2
(m m H g)
w ith
carbogen
pO2 (m m H g)
Figure 3. Pre-treatment local tumor pO2 versus pO2 after carbogen breathing o f the 
human xenograft tumor line E106. All points represent a measurement in 
different individual tumors. For details see figure 2.
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Hypoxic marker binding
The hypoxic fraction, based on pimonidazole adducts binding, was significantly different 
for the three tumor lines. For glioblastoma E106 the hypoxic fraction was 0.11 [0.03-0.19] 
for E102 this was 0.01 [< 0.01- 0.05] and the hypoxic fraction of SCCNij3 was 0.21 
[0.10-0.38] (ANOVA, p<0.05). A trend was found for a correlation between the proportion 
of tumors responding to nicotinamide and the mean hypoxic fraction of the three tumor lines 
(multiple regression analysis, R=0.99, p=0.08) (Tables I, II and III).
p°2
(m m H g)
w ith
carbogen
100
80
60
40
20
20 40 60 
pO (mmHg)
a NAM, non-responders
▲ NAM, responders
o Carbogen, non-responders
•  Carbogen, responders
80 100
Figure 4. Pre-treatment local tumor pO2 versus pO2 after carbogen breathing o f the 
human xenograft tumor line SCCNij3. All points represent a measurement in 
different individual tumors. The insert shows an enlargement o f the same 
graph for pO 2-values below 8 mmHg. For details see figure 2.
0
0
Discussion
This paper describes the application of the recently developed pO2 measuring device 
OxyLite™. Tumor pO2 was locally measured in three human xenograft tumor lines that 
showed large differences in hypoxic profile based on bio-reductive hypoxic marker binding 
(pimonidazole). The pO2-dependent changes in half-life of an excited luminiphor at the tip
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of a fiber-optic probe are exploited to perform continuous pO2 measurements at a single 
position in tumor xenografts. Changes in local tumor pO2 after treatment with the vaso­
active drug nicotinamide, carbogen breathing and the combination of both were quantitated. 
Two human glioblastomas and one squamous cell carcinoma from the larynx all grown as 
xenografts in nude mice were analyzed. The results showed that the effect of carbogen 
breathing on tumor pO2 was dependent on the pre-treatment pO2, being least in tumor areas 
with low pre-treatment pO2-values. The effect of nicotinamide on locally measured tumor 
pO2 was less, but a trend for a reduction in time to respond to carbogen breathing after 
nicotinamide treatment was observed.
p°2
(m m H g)
Figure 5. Examples o f  continuous local pO2 measurements versus time in 3 different 
human tumor xenografts (1,2,3) o f line SCCNij3. The dotted arrow indicates 
the injection time of nicotinamide. The start o f the carbogen breathing periods 
is indicated by a solid arrow, switching back from carbogen breathing to air 
breathing is indicated by dashed arrows. The time o f death o f animal #1 is 
indicated by #.
pO 2 values and tissue sections
Previously a correlation was described between pO2 measured with the Eppendorf™ or the
OxyLite™ system and the hypoxic fraction determined by pimonidazole adducts binding
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[8,41]. These studies showed large variations within one tumor line for pO2 measurements 
[8] as well as for hypoxic marker binding [6,41]. After H&E staining of the tissue sections 
necrotic areas were detectable.
E102 SCCNij3
* %
K ÌA " '' v *
'Î ' -V- /  F J  », ■ -  , .
-»'s»
E106
Figure 6. Pseudo-colored composite binary images o f representative tissue sections, 
reconstructed after scanning for the vascular structures (9F1, red) and 
hypoxia (pimonidazole, green), o f the human squamous cell carcinoma tumor 
line SCCNij3 and the human glioblastoma xenograft lines E102 and E106. 
Necrotic areas were identified on the same tissue sections by means o f H&E 
staining and are indicated by solid arrows. The dotted arrows indicate normal 
(hypoxic) mouse skin.
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In 5 out of 36 SCCNij3 tumors viable tumor tissue was only present at the margins of the 
tumor with necrosis present in such a degree that the pO2-values obtained from these tumors 
could only originate from necrotic areas. These 5 tumors did not show any response to 
nicotinamide and/or carbogen. These findings illustrate the importance of tissue section 
analysis of the tumor areas where pO2 was measured.
There are several methods available to measure the oxygenation status of tissues. The 
majority of these methods can not be used to directly measure temporal changes in the 
oxygenation status of tissues. Methods to study absolute changes in tumor pO2 include 
electron paramagnetic resonance (EPR) oxymetry [17,19] and spin-lattice relaxation of 
fluorinated MR agents [33,36]. A disadvantage of these measurements is the necessity to 
inject markers, i.e. fluorocarbon in the case of spin-lattice relaxometry or ESR agents into 
the tumor area in the case of EPR-oxymetry. Another disadvantage is the low spatial 
resolution of these techniques.
Information on pO2 changes with a high spatial resolution can be obtained when two bio- 
reductive hypoxia markers are used, which are injected consecutively. This method was 
recently developed. Changes in the hypoxic pattern, induced by carbogen breathing 
(reduction of hypoxia) and by hydralazine injection (increase of hypoxia), were successfully 
quantitated [44].
In the present study, a luminiphor at the tip of an optic fiber was used to measure local 
changes in pO2. A disadvantage of this method is that the number of measurements per 
tumor is limited. A maximum of 4 measurements per tumor is possible because this is the 
currently available number of channels for the OxyLite™ system. This is a disadvantage of 
OxyLite™ compared with Eppendorf™ where a large number of pO2-measurements per 
tumor provide a profile of the tumor oxygenation status [46]. Currently, a stepping mode, 
similar to the Eppendorf™ pilgrim-step-device, is being developed for the OxyLite™ 
system. The limitation of polarographic pO2 measurements is that, due to the oxygen 
consumption during the pO2 measurements, the probe needs to be moved through the 
tissue. Therefore, investigation of temporal pO2-changes induced by oxygenation modifying 
treatment with Eppendorf™, is difficult to perform. By combining the double hypoxia 
marker technique with optic fiber-based pO2 measurements, spatial information on 
oxygenation changes of a whole tissue section can be complemented with continuous on­
line measurements in certain areas of interest.
Effect o f nicotinamide on pO 2 measurements
Nicotinamide is a vaso-active drug and is used to reduce perfusion-limited hypoxia [24-26]. 
The effect of nicotinamide on local tumor pO2 was limited compared to the large effect of
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carbogen breathing. Furthermore, only part of the tumor areas showed a response to 
nicotinamide. This was especially the case for the squamous cell carcinoma xenograft line 
SCCNij3. Of this tumor the pre-treatment pO2 was significantly lower in the non­
responding tumor areas as compared to the locally responding tumors. The mean pre­
treatment pO2 for the 5 tumors showing a local response to nicotinamide was 11.1 mmHg 
versus 2.4 mmHg for the 14 tumors that did not show a local response after nicotinamide 
administration. This may indicate that severely hypoxic areas and necrotic areas may be too 
distant from blood vessels and therefore are not affected by vaso-active stimuli. 
Alternatively, if  (non-functional) vessels are situated in these severely hypoxic areas, they 
may not be responsive to nicotinamide.
Nevertheless, Rojas et al. found that the TCD-50 in the CaNT mouse mammary carcinoma 
was significantly lower if nicotinamide was added to a conventional fractionated or an 
accelerated fractionated irradiation schedule [43]. This was explained by the ability of 
nicotinamide to reduce the amount of perfusion limited hypoxia. There are several possible 
explanations why nicotinamide does not induce a measurable increase in pO2 in every tumor 
area. First, an increase in pO2 is only expected in those areas of the tumor where tumor 
blood perfusion is indeed impaired. Second, when tumor blood perfusion is increased this 
does not necessarily mean that pO2 will increase, for example when an increased perfusion 
is accompanied by an increase in oxygen consumption. Third, the presence of perfusion- 
limited hypoxia is related to the fraction of transiently opening and closing vessels in a 
tumor, which very likely differs between tumors and tumor lines. Another important 
mechanism, with respect to the combined treatment of radiotherapy, carbogen and 
nicotinamide, could be that nicotinamide counteracts impaired tumor blood perfusion that 
may be induced by carbogen breathing. This effect of carbogen was observed in a number 
of experimental tumors including squamous cell carcinoma tumor line SCCNij3 and KHT 
murine fibrosarcomas [6,16].
Carbogen and time to response
Improved tumor oxygenation during carbogen breathing was described previously, also in 
humans [14,35]. Martin et al. used polarographic pO2 measurements to study pO2 changes 
in metastatic neck nodes during carbogen breathing. In 16 out of 20 patients an increase in 
median pO2 was found and also the frequency of low pO2 readings (proportion of pO2- 
values below 2 or 10 mmHg) was drastically reduced. Within 1 to 6 min after air breathing 
was changed to carbogen breathing, the maximal effect on pO2 was reached. These 
polarographic measurements indicate an overall shift towards higher pO2-values in the 
tumor. However, the pO2 changes at specific positions can not be monitored. The data
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presented here and other experimental studies [36] as well as a clinical study by Falk et al. 
[14] demonstrated that especially tumor areas with very low pO2-values might not show an 
increase in pO2 during carbogen breathing. The impact of these very poorly oxygenated 
regions on the outcome of radiotherapy might be limited. By mathematical modeling of 
experimental data it was suggested that severely chronically hypoxic cells, which are also 
nutritionally deprived, might not be the radio-resistant cells that are relevant for treatment 
outcome. These cells are presumably on the edge of dying even without treatment. A more 
important contribution to the radio-resistant cell population in terms of treatment outcome 
may come from the cells at intermediate hypoxia and the acutely hypoxic cells. These cells 
only lack availability of oxygen, which makes them radio-resistant, but with enough 
nutritional supplies they will be able to efficiently repair radiation-induced DNA damage 
[10,11,51].
Clinical studies have been initiated to study the distribution of hypoxia at the microscopic 
level with EF5 or pimonidazole as bio-reductive hypoxic cell markers [13,31,50]. When 
pimonidazole was used as hypoxic cell marker for head and neck tumors, different patterns 
in the distribution of hypoxia could be recognized with a large variation among tumors that 
originate from the same anatomical sites [50].
Conclusion
Fiber-optic pO2 measurements can be used to study temporal changes in pO2. These 
measurements were used to quantitate the effects of oxygen modifying treatment locally in 
three different human tumor lines. With this methodology an almost universal, rapid 
increase in pO2 during carbogen breathing was observed with the exception of severely 
hypoxic areas. The effect of nicotinamide on tumor pO2 measured locally, was smaller and 
more variable, which may be explained by various amounts of perfusion limited hypoxia 
present in the tumors that were studied.
In the future, the combination of hypoxic cell markers and continuous pO2 measurements 
with the OxyLite™ system in patients, will enable us to further quantitate the effects of 
oxygenation modifying treatments such as nicotinamide administration and carbogen 
breathing. Information about the distribution pattern of tumor hypoxia at the microscopic 
level, together with the measurement of absolute changes in local tumor pO2, may allow a 
better selection of patients for these new treatment approaches.
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A bstract
The effect of irradiation depends on the oxygenation status of the tissue, while irradiation 
itself also changes the oxygenation and perfusion status of tissues. A better understanding 
of the changes of tumor oxygenation and perfusion over time after irradiation will allow a 
better planning of fractionated radiotherapy in combination with modifiers of blood flow and 
oxygenation.
Vascular architecture (endothelial marker), perfusion (Hoechst 33342) and oxygenation 
(pimonidazole) were studied in a human laryngeal squamous cell carcinoma tumor line 
grown as xenografts in nude mice. The effect of a single dose of 10 Gy X-rays on these 
parameters was evaluated from 2 h to 11 days after irradiation.
Shortly after irradiation there was an 8% increase in perfused blood vessels (from 57% to 
65%) followed by a significant decrease with a minimum value of 42% at 26 h after 
irradiation and a subsequent increase to control levels at 7 to 11 days after irradiation. The 
hypoxic fraction showed a decrease at 7 h after treatment from 13% to 5% with an increase 
to 19% at 11 days after irradiation.
These experiments show that irradiation causes rapid changes in oxygenation and perfusion 
which may have consequences for the optimal timing of radiotherapy schedules employing 
multiple fractions per day and the introduction of oxygenation- and perfusion-modifying 
drugs.
- 140 -
Oxygenation and perfusion after radiotherapy
In troduction
It has been demonstrated that the effect of irradiation depends on the oxygenation status of 
the tissue that is treated [18,29]. For single doses in the clinical dose range, this relationship 
is a fairly simple one and is independent of tissue type. However, the issue becomes more 
complicated with fractionated irradiation, because irradiation by itself changes the 
oxygenation status of tissues [22,40]. There have been several investigations of changes in 
hypoxia after radiotherapy. In most studies, the hypoxic cell fraction is calculated as the 
radiobiologically hypoxic fraction by the paired survival curve method. In this assay, 
tumors are irradiated in vivo under both well-oxygenated and anoxic conditions. The 
survival curves of the in vitro clonogenic assay are then calculated separately for the well- 
oxygenated and hypoxic tumors. From these curves, the radiobiological hypoxic fraction is 
calculated. This assay was first described by Van Putten [43] and has been reviewed 
extensively by Moulder and Rockwell [30]. Analysis of the radiobiologically hypoxic 
fraction after radiotherapy showed a change over time. In the murine SCC VII tumor an 
increase of the radiobiological hypoxic fraction up to 80% to 100% was found immediately 
after irradiation [25,26]. This was followed by a decrease in the radiobiologically hypoxic 
fraction, with a minimum value of 2% at 6 h after irradiation. This decrease was followed 
by an increase to 6%, the level of the untreated tumor [25].
Another and more recent method to assess oxygenation at the cellular level is the comet 
assay. In SCC VII tumors, a decrease in hypoxic fraction from 18% in untreated tumors to 
6% at 6 h after a single fraction of 10 Gy was found [31].
Other methods to measure the hypoxic fraction include electron paramagnetic resonance 
oximetry [16], polarographic and time-resolved luminescence pO2 measurements 
[19,32,49], markers of hypoxia [28,33,35] and cryospectrophotometry of intra-vascular 
HbO2 saturation profiles [15]. These measurements give an indication of the degree of 
hypoxia in a tumor, which is not necessarily correlated with the radiobiological hypoxic 
fraction [14].
In recent years, bio-reductive chemical probes of hypoxia have been used to estimate 
hypoxic fractions in animal and human tumors. Nitroimidazole hypoxia markers have 
proven to be particularly useful for in vivo studies [10]. The introduction of 
immunohistochemical detection of nitroimidazole binding provided a non-radioactive 
method for detecting hypoxia at the cellular level in tissues [28,33]. After injection and 
staining for the markers, labeled cells can be analyzed by flow cytometry [45,46] or 
visualized in formalin-fixed or frozen tissue sections [8,24,34,44]. Analysis of whole-tissue
- 141 -
Chapter 7
sections allows calculation and interpretation of the distribution of hypoxic areas at the 
microscopic level throughout a tumor [8,35].
In the present study, we analyzed the changes over time and the spatial distribution of 
hypoxia and blood perfusion in a human squamous cell carcinoma tumor model of the 
larynx after irradiation. The previously described semi-automatic computer-controlled 
method for simultaneous multi-parameter quantitative analysis of whole-tissue sections was 
used [6,8,37].
M aterials and methods
Tumors
Tumor line SCCNij3 was derived from a primary human squamous cell carcinoma of the 
larynx (moderately to well differentiated). Viable 1 mm3 tumor pieces from a resection 
specimen were transplanted subcutaneously in nude mice (Balb/c ABom nu mouse). 
Tumors were passaged when they reached a diameter of 1 cm. For the present experiments, 
tumors from passage 10 and 11 were transplanted in the hind leg of Balb/c ABom nu mice. 
Animals were kept in a special pathogen-free unit in accordance with institutional guidelines. 
Assessment of the human characteristics of the tumor was done by in situ hybridisation of 
chromosome 1. Approval of the local ethical committee for animal use was given for these 
experiments.
Markers of perfusion and hypoxia
As a marker of perfusion, the fluorescent dye Hoechst 33342 (Serva, Heidelberg, 
Germany) was given intra-venously via one of the tail veins at a dose of 25 mg/kg. As a 
marker of hypoxia, pimonidazole hydrochloride (1-[(2-hydroxy-3-piperidinyl)propyl]-2- 
nitroimidazole hydrochloride) was used at a dose of 100 mg/kg, also injected intra-venously 
[12,35]. Pimonidazole is a bio-reductive chemical probe with an immuno recognizable side 
chain. The addition of the first electron in bio-reductive activation is reversibly inhibited by 
oxygen with a half maximal pO2 of inhibition of about 3 mm Hg with complete inhibition 
occurring at about 10 mm Hg [35].
Pimonidazole was injected 60 min and Hoechst 33342 one min prior to killing the animals 
(Figure 1).
Tumor specimens were directly stored in liquid nitrogen until they were cut into 5 ^m frozen 
sections. The sections were then stored at -80 oC until stained. One tissue section per tumor
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was analyzed. Tumor tissue sections at the largest circumference of the tumor were 
analyzed.
Irradiation (10 Gy single dose) Pimonidazole Hoechst
-2, -7 or -26 h, -1 h -1 min 0
-3, -7 or -11 d
Figure 1. Treatment schedule and experimental design. See text for details.
Irradiations
Tumors were irradiated when they reached a diameter of 0.6 to 0.8 cm. The experimental 
set-up was adapted from Ang et al. [1] and Stüben et al. [41] and consisted of a central 
acrylic distributor for mixing and distributing the anesthetic gas, enflurane (Ethrane™), in 
admixture with air. The animals were positioned around the distributor; this allowed for the 
simultaneous irradiation of ten mice. Animals were irradiated with a 16 MV photon beam at 
a dose rate of 2 Gy/min to a total dose of 10 Gy. The animals and their tumors were covered 
with a 2 cm thick perspex layer, which served as build-up material for the irradiation and as 
an insulator to prevent hypothermia of the animals and tumors during the anesthesia. In 
addition, heaters were used to increase the air temperature. A 10 cm thick Cerrobend™ 
metal shielding block was used to protect the bodies of the animals. Ten rectangular holes 
were made in the block so that the tumor in the hind leg of each mouse was in an irradiation 
field of 3 x 2 cm2. The system was calibrated using film dosimetry. Tumors were harvested 
at 2, 7 and 26 h and 3, 7 and 11 days after irradiation (Figure 1). Control animals were 
injected with pimonidazole and Hoechst and kept under ambient conditions.
Immunohistochemical staining
After they were thawed, sections were fixed in acetone for 10 min. Slides were then rinsed 
and mounted in phosphate-buffered saline (PBS) for scanning of the Hoechst signal prior to 
immunohistochemical staining of the other markers. Details of the scanning procedure are 
given below.
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Between each of the consecutive steps of the staining procedure, the sections were rinsed 
three times for 2 min in PBS.
26 h 11 d
Figure 2. Pseudo-colored composite images reconstructed after scanning for the 
Hoechst signal (perfusion, blue), vascular structures (9F1, red) and hypoxia 
(pimonidazole, green) o f  cross sections o f the human squamous cell 
carcinoma xenograft tumor line SCCNij3. Examples are given o f a control 
tumor and at different times after irradiation. Necrotic areas, which were 
identified on the same tissue sections by means o f H&E staining, are 
indicated by arrows.
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Endothelial structures
After being scanned for the Hoechst signal (tumor blood perfusion), sections were 
incubated for 45 min at room temperature with undiluted 9F1 (rat monoclonal to mouse 
endothelium [47], Department of Pathology, University Hospital Nijmegen, The 
Netherlands). Sections were then incubated for 30 min at room temperature with tetramethyl 
rhodamine isothiocyanate (TRITC)-conjugated goat anti-rat antibodies (Jackson Immuno 
Research Laboratories, West Grove, PA, USA) diluted 1:50 in PBS-B (PBS with 0.5% 
bovine serum albumin). This was followed by 30 min incubation at room temperature with 
TRITC-conjugated donkey anti-goat antibodies (Jackson Immuno Research Laboratories) 
diluted 1:50 in PBS-B.
Pimonidazole
For staining of pimonidazole adducts, the tissue sections were incubated overnight with 
rabbit anti-pimonidazole antibodies [2,3] diluted 1:200 in PBS-B, followed by a 2 h 
incubation with FITC-conjugated donkey anti-rabbit antibodies (Jackson Immuno Research 
Laboratories) at room temperature.
Scanning of tumor sections and image processing
The tumor sections were scanned for quantitative analysis by a computerized digital image­
processing system as described previously [8,37]. A high-resolution intensified solid-state 
camera on a fluorescence microscope (Zeiss Axioskop) with a computer-controlled 
motorized stepping stage was used. Tumor cross sections were sequentially scanned three 
times at 100X magnification, using different filters for the Hoechst, TRITC, and FITC 
signals. After each scan, which consisted of 36 or 64 fields (6 x 6 or 8 x 8, depending on 
the size of the tissue section) of 1.2 mm2 each, one composite binary image was 
reconstructed from the individual microscopic fields. The whole scanning procedure thus 
yielded three composite images from each tumor cross-section: one showing the perfused 
areas (Hoechst), one showing hypoxic areas (pimonidazole) and one showing vascular 
structures (9F1). Finally, a hematoxylin and eosin staining (H&E) on the tissue sections 
allowed a contour line to be drawn around the tumor area while excluding non-tumor tissue 
and areas of necrosis. The necrotic and non-tumor tissue areas were excluded from the 
analysis of tumor blood perfusion and tumor hypoxia.
Analysis of vascular and hypoxic parameters
Quantitative analysis of perfusion was derived from the Hoechst and 9F1 images. When 
these two images were combined, the overlapping structures represented those vascular
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structures that were perfused at the time of Hoechst injection. Vascular structures that had 
no adjacent zone of Hoechst-stained nuclei represented non-perfused vessels. The area of 
perfused vascular structures divided by the total vascular area of the tissue section yielded 
the perfusion fraction [6,37].
The hypoxic fraction was calculated as the total hypoxic area (pimonidazole) relative to the 
total tumor area [8].
Statistics
For analysis of the differences in the relative amount of hypoxia and tumor blood perfusion 
at different times after irradiation, the t-test was applied. The average and standard error of 
the mean (SEM) for 4 to 8 animals per time point are given. The statistical analyses were 
done on a Macintosh computer using the Statistica 4.0 software package.
R esu lts
Images
Figure 2 shows the pseudo-colored composite images reconstructed after scanning at 
different times after irradiation. These images illustrate a decrease in the hypoxic fraction 
with a minimum amount of pimonidazole staining (hypoxia, green) at 7 h after irradiation. 
This was followed by an increase of the hypoxic fraction as shown in the example 11 days 
after irradiation. Secondly, the images show a decrease in perfusion status (Hoechst, blue) 
with a minimum tumor blood perfusion 26 h after irradiation. The tumor blood perfusion 
then increased again at later times. At 11 days after irradiation, enlarged necrotic areas 
appeared in the tumor, which are indicated by arrows. The necrotic areas were identified in 
the same tissue sections by H&E staining. An increase in the necrotic fraction was observed 
after three days. For control tumors and tumors up to 26 h after irradiations the mean 
necrotic fraction was 0 to 7%; at 3 days the necrotic fraction was 13% and at 11 days it was 
16.5%.
Vascular structures and perfusion
The baseline perfusion fraction for SCCNij3 tumors was 57%. Shortly after irradiation, 
there was an increase, with a maximum of 65% at 2 to 7 h after irradiation. This increase 
was followed by a significant decrease, with a minimum value of 42% at 26 h after 
irradiation (p < 0.05). Subsequently a slow but steady increase to near the level of the
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untreated tumors occurred which persisted for at least 11 days, the final time examined in 
this experiment (Figure 3).
Hypoxia
The hypoxic fraction showed a significant decrease after irradiation, with a minimum value 
at 7 h after treatment. In this period, the hypoxic fraction decreased significantly from 13% 
to 5% (p < 0.05). Afterward, a slow but steady increase occurred that continued until the 
end of the experiment at 11 days. At 11 days the hypoxic fraction had increased to 19%, 
which was significantly higher than the hypoxic fraction at 2 to 96 h (p < 0.05) (Figure 4).
time after irradiation (h)
Figure 3. Perfusion fraction as a function o f time after irradiation with a single dose 
of 10 Gy. Each data point represents the mean o f 4 to 8 tumors (+ SEM).
D iscussion
The oxygenation status of tissues and the response to irradiation are closely connected. 
Radiotherapy is less effective under hypoxic conditions and irradiation by itself changes the 
oxygenation status of tissues. Because hypoxic cells can be three times more radio-resistant 
than normoxic cells [18], changes of the oxygenation status of a tumor during the course of 
irradiation are relevant for treatment outcome.
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We have used a semi-automatic method for quantitative analysis of tumor perfusion, 
vasculature and hypoxia [6,8,37]. This system allows to study architectural patterns of 
vascularization and oxygenation of tumors with a high spatial resolution. The method can be 
used only if  a clear discrimination between stained and non-stained areas is obtained with a 
high signal-to-noise ratio. Although setting of the threshold is a subjective procedure, 
Rijken et al. [37] showed that there was only a small variation in outcome of the analysis of 
the perfusion fraction if the threshold was changed. Because a steep gradient is found for 
the staining intensity of pimonidazole, changes in the hypoxic fraction due to changes in the 
threshold of the hypoxic fraction are also small (Rijken et al. submitted for publication).
The results of the present study show that changes in oxygenation and blood perfusion in a 
human squamous cell carcinoma xenograft tumor line occur over a period of 11 days after 
irradiation with a dose of 10 Gy, which has clear implications for fractionated radiation 
treatments.
time after irradiation (h)
Figure 4. The hypoxic fraction o f whole tumor tissue sections as a function o f time 
after irradiation with a single dose o f 10 Gy. Each data point represents the 
mean o f 4 to 8 tumors (+ SEM).
Perfusion
The perfusion fraction decreased after irradiation, reaching a minimum at 26 h after 
treatment. At later times there was a recovery of tumor perfusion to the level of the untreated
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animals between 7 and 11 days after irradiation. Goda et al [17], using MR-imaging with 
gadolinium-DTPA uptake, also found a decrease in perfusion status after radiotherapy. This 
decrease was maximal at 6 h after irradiation in the MTG-B tumor and at 24 h in the RIF 
tumor. Olive used two fluorescent perfusion markers (Hoechst 33342 and DiOC7) injected 
at 20 min intervals ('double dye method') to analyze variability in tumor blood perfusion 
[31]. After a single dose of 10 Gy X-rays, SCC VII tumors showed an increase in the 
fraction of perfused vessels (decrease in mismatches of the two perfusion markers) over a 
period of 7 h. At 30 h after treatment, a decrease of the fraction of perfused vessels occurred 
(increase in mismatches). This is in good agreement with our results, which also showed an 
increase followed by a decrease in perfusion during the first 26 h after irradiation. An early 
decrease in tumor blood perfusion has been attributed to radiation-induced edema, 
thrombosis [13] and an increase in damaged capillaries through the direct effect of radiation 
[42].
An increase in tumor blood perfusion at later time points after irradiation may be attributed to 
a decrease of the interstitial fluid pressure (IFP) of the tumor. A decrease in IFP can result in 
a redistribution of blood between the systemic circulation and the tumor and there can be a 
filling of previously collapsed, non-functioning tumor vessels [4,42]. Another explanation 
for an increase in tumor blood perfusion could be new vessel formation by (neo-) 
angiogenesis. It has been reported that endothelial cells can proliferate 20-2000 times faster 
than endothelial cells in normal tissue [36]. After a single dose of 5 Gy, Dewhirst et al. 
found an increase in vascular density at 24 and 72 h after treatment [11].
Hypoxia
Explanations for early reoxygenation after radiotherapy include a decrease of the number of 
respiring cells, inhibition of cellular respiration and improvement of tumor blood supply 
[23]. An additional mechanism that may be involved is the induction of apoptosis by 
irradiation.
Changes in hypoxic fraction after irradiation were analyzed by immuno-histochemical 
analysis of binding of markers of hypoxia. With this method, the hypoxic tumor cell 
fraction is given relative to all tumor cells, excluding only necrotic areas and non-tumor 
tissue areas. After irradiation, however, a certain percentage of the tumor cells are destined 
to die, the so-called 'doomed' cells. Presumably these cells will die after a limited number of 
divisions and thus be unable to form macro-colonies in a clonogenic assay [5]. Calculation 
of the hypoxic fraction using markers of hypoxia as well as other methods such as oxygen 
electrodes and the comet assay are based on total cell numbers. Doomed cells cannot be 
discriminated from clonogenic cells based on their morphology or their location in a tumor.
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Only fluorescence-activated cell sorting [12] or the in vivo-in vitro paired survival curve 
method can correct for doomed cells and provide the hypoxic fraction for clonogenic cells 
only. It can be expected that at increasing times after irradiation the methods that are based 
on total cell numbers correspond better with the clonogenic assay, because doomed cells 
will be eliminated with time. Using the comet assay to analyze hypoxic fractions, Olive [31] 
found that the hypoxic fraction in murine SCC VII tumors decreased from 18% in untreated 
animals to 6% at 6 hours after a single dose of 10 Gy. Using the paired survival curve 
method, Kim and Brown [25] found an increase in hypoxic fraction from a baseline of 
approximately 6% to 80% in SCC VII tumors immediately after a single dose of 10 Gy, 
which decreased again to approximately 2% at 6 h after irradiation. The differences in 
hypoxic fraction of untreated tumors indicate that the presence of doomed cells is not the 
only explanation for the differences in outcome. The decrease in the hypoxic fraction from 
13% to 5% and 7% at 6 h and 26 h, respectively, after a single dose of 10 Gy in our study 
is consistent with the previous studies. The reduction in tumor hypoxia of 30 to 40% 
relative to the control tumors at 6 h after irradiation was found in SCC VII tumors with 
comet and paired survival curve assays and in xenograft tumors with the hypoxic marker 
pimonidazole.
In the KHT murine sarcoma tumor model, Fenton [15] studied changes in oxygenation 
status with cryospectrophotometry of intra-vascular HbO2 saturation profiles. After a single 
dose of 10 Gy, he also found a maximum increase in the tumor oxygenation status 
approximately 6 h after irradiation, mainly in the outer zones of the tumors.
This is in contrast with the experiments of Goda et al. [17], in which pO2 was measured by 
electron paramagnetic resonance oximetry. A reduction in pO2 values was found after 
irradiation with a single dose of 20 Gy in MTG-B and RIF tumors. This decrease in pO2 
was found at the same time of minimal tumor perfusion analyzed with gadolinium-DTPA 
uptake.
The advantage of analysis of hypoxia with markers of hypoxia in combination with 
immunohistochemical staining of tissue sections is that hypoxia can be studied in relation to 
the vascular architecture at the microscopic level. This allows non-tumor tissue to be 
excluded from the analysis, with a high spatial resolution. The disadvantage of an analysis 
with the use of such markers is that hypoxia needs to last long enough to allow distribution 
and reduction of the marker. Therefore, the longer-lasting diffusion-limited ('chronic') 
hypoxia will be detected more accurately than shorter periods of perfusion-limited ('acute') 
hypoxia. Detection of hypoxia with polarographic probes as well as electron paramagnetic 
resonance oximetry has a low spatial resolution. The comet assay will include both
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diffusion- and perfusion-limited hypoxia to a certain extent, but discrimination of tumor and 
non-tumor cells is difficult. With cryospectrophotometry of intra-vascular HbO2 saturation, 
only vessels containing red blood cells can be analyzed, and provides only an indirect 
indication of tissue oxygenation.
Analysis of the oxygen diffusion distance in irradiated tumors by Olive [31] showed a 
decrease in oxygen consumption that could explain the decrease in tumor hypoxia. This 
indicates that a decrease in oxygen consumption could be relatively more important than a 
change in tumor blood perfusion with respect to the occurrence of hypoxia after irradiation, 
as also reported by Secomb et al. [38]. The discrepancy between perfusion and hypoxia 
after 26 h in our experiments also suggests that changes in tumor blood perfusion may be 
less important than changes in oxygen consumption. The increase in hypoxia at later times 
may be due to an increase in oxygen consumption as a result of a recovery of cellular 
respiration and an increase of the number of respiring cells.
In preliminary experiments, we also found pimonidazole staining after irradiation occurring 
at greater distance from blood vessels compared to untreated tumors. Further development 
of the image analysis method is needed to include the measurement of staining intensities, 
which allows a further quantification of changes in tumor hypoxia near blood vessels.
Clinical studies have also shown changes in oxygenation status after radiotherapy. 
Comparison of polarographic oxygen measurements (Eppendorf™) before irradiation with 
measurements two weeks after the start of radiotherapy for head and neck tumors showed 
an increase in the median pO2 from 12 mm Hg to 26 mm Hg [27]. In a study by Stadler et 
al. [39], a decrease in tumor pO2 was measured after doses of 30 to 70 Gy in combination 
with 5 FU and mitomycin-C. Finally, a study by Brizel et al. [7] showed that the 
combination of hyperthermia and radiotherapy caused an increase in pO2 in human soft 
tissue sarcomas. Because there are changes over time after irradiation and because these 
temporal changes in hypoxia will depend on fraction size as well as number of fractions 
given, it is difficult to draw conclusions from these clinical studies in relation to the 
experimental studies. However, in the study of Lartigau et al. [27], in which pO2 was 
measured at a fixed time after irradiation (4 h) in head and neck tumors, the results were 
comparable with our experimental findings in a human squamous cell carcinoma xenograft 
model from a larynx tumor.
The observed changes in tumor hypoxia after irradiation with a maximal decrease in tumor 
hypoxia 7 h after irradiation could be important in a complementary way for accelerated
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irradiation schedules. Accelerated fractionation counteracts accelerated repopulation during 
radiotherapy [48]. Although the differences were not statistically significant, a minimal 
increase in oxygenation status in the outer zones of tumors after only 2.5 Gy of X-rays was 
observed by Fenton using KHT tumors [15]. Whether the same changes in oxygenation 
occur after multiple fractions to the same extent and at the same time is unclear. However, if 
the single-dose experiments with 10 Gy could be extrapolated to fractionated irradiation, an 
unanticipated benefit of these schedules with inter-fraction intervals of 6 to 8 h might be that 
the second fraction is given at the time when the tumor oxygenation status could be at a 
maximum level.
Our experiments also showed that radiation-induced decreases in tumor blood perfusion 
occur. In on-going experiments we will analyze whether this can be reversed by vaso-active 
drugs, such as nicotinamide, as it does in carbogen-induced decreases in blood perfusion 
[8]. If this is true, it may give an additional explanation for the increase in loco-regional 
tumor control that is achieved if radiotherapy is given in combination with carbogen 
breathing and nicotinamide [9,20,21].
Conclusion
These experiments showed that irradiation can cause a rapid change in oxygenation and 
perfusion status in a human squamous cell carcinoma xenograft. This may have 
consequences for the optimal timing of irradiation treatment schedules employing multiple 
fractions per day combined with interventions for modification of oxygenation.
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Chapter 8
Sum m ary 
C hapter 1
Introduction
The three most important mechanisms for local failure after radiotherapy are intrinsic radio­
resistance, rapid tumor cell proliferation and tumor cell hypoxia.
Intrinsic radio-resistance refers to the differences in clonogenic responses that were found 
between tumors of different histology and within tumors of similar histology after 
irradiation. Differentiation between tumor types is mainly based on clonogenic cell survival 
assays. To reduce the effect of intrinsic radio-resistance on treatment outcome the local 
irradiation dose itself or the efficacy of the irradiation has to be increased. This can be 
achieved with for example dose escalation by hyperfractionated radiotherapy or intensity 
modulated radiotherapy, or the use of radiosensitizers.
The second mechanism, rapid tumor cell proliferation, refers to the loss of effectiveness of 
radiotherapy if the overall treatment time is prolonged. Several studies have shown an 
improvement in loco-regional tumor control if the total treatment time was reduced. Assays 
to study the proliferation rate of tumor cells are based on determination of specifically 
labeled proliferating cells with microscopic or flow cytometry techniques.
The third mechanism, tumor cell hypoxia, refers to the observation that hypoxic cells are 
more resistant to irradiation than normoxic cells. Reducing tumor cell hypoxia or the use of 
hypoxic cell sensitizers have shown an increase in loco-regional tumor control. Tumor cell 
hypoxia can be studied with various techniques such as the use of bio-reductive chemical 
markers, MR-based methods and polarographic or fiber-optic pO2 measurements.
Chapter 2
Clinical results of accelerated radiotherapy with carbogen and nicotinamide 
Experimental studies showed an almost twofold increase in effectiveness when accelerated 
radiotherapy combined with carbogen and nicotinamide (ARCON) was compared with 
standard radiotherapy. This combination was chosen to overcome repopulation of 
clonogenic tumor cells during radiotherapy by reducing the total treatment time from 7 to 5.5 
weeks and to minimize radio-resistance due to tumor hypoxia by adding nicotinamide to 
reduce perfusion limited hypoxia and by adding carbogen breathing to reduce diffusion 
limited hypoxia.
A total of 124 patients with stage III or IV head and neck squamous cell carcinomas received 
the ARCON treatment. Loco-regional control for larynx carcinomas was 85%, for 
hypopharynx carcinomas 50% and for oral cavity and oropharynx carcinomas 65%.
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C hapter 3
Development of a system for multi-parameter analysis of vasculature, perfusion and 
proliferation in human tumor xenografts
Despite the high loco-regional control rates with ARCON, still some patients fail after 
treatment. This in combination with an increase of toxicity indicates the need for optimal 
selection of patients for this type of treatment intensification. This has led to the 
development and the standardization of a multi-parameter assay for the analysis of tumor 
vascular architecture, tumor blood perfusion and tumor cell proliferation.
Whole tumor cross-sections of human larynx carcinoma and glioblastoma xenografts were 
studied. Hoechst 33342 and BrdUrd were used as perfusion and proliferation markers and 
an anti-endothelial antibody (9F1) was used to delineate vascular structures. The tissue 
sections were analyzed by a multi-step immune-staining and computer-controlled 
microscope scanning method. The various vascular and proliferation parameters were 
quantitated and related by analysis of the computerized images.
The BrdUrd labeling index (LI) based on manual counting and flow cytometry both were in 
good agreement with the LI based on surface analysis obtained with the computer-controlled 
method. LI decreased at increasing distance from its nearest vessel. In the vicinity of 
perfused vessels the LI was 30-70% higher compared to non-perfused vessels.
C hapter 4
Vascular architecture and microenvironmental parameters in human squamous cell 
carcinoma xenografts: effects of carbogen and nicotinamide
For studying the results of oxygenation modifying treatment, the staining and scanning 
protocol was expanded to include the analysis of tumor cell hypoxia with a bio-reductive 
hypoxic cell marker (NITP). The effects of carbogen breathing and nicotinamide in two 
human laryngeal squamous cell carcinoma xenograft lines were analyzed.
The decrease of the number of perfused blood vessels in one of the two tumor lines during 
carbogen breathing was reversed by nicotinamide. In both tumor lines the LI decreased after 
treatment with carbogen and both tumor lines showed a drastic reduction of hypoxia by 
carbogen breathing alone and also when carbogen breathing was combined with 
nicotinamide.
Thus, differences in response to nicotinamide and carbogen were observed in two tumors 
with similar histology and from the same head and neck site indicating that there is a need 
for an assay to select patients for oxygenation modifying treatment.
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C hapter 5
Optical sensor based oxygen tension measurements correspond with hypoxic marker 
binding in three human tumor xenograft lines
To add information about temporal changes in pO2, hypoxic cell marker binding was 
compared with fiber-optic pO2 measurements. The newly developed fiber-optic oxygen 
sensing device, OxyLite™, was further standardized. Local tumor pO2 measurements were 
compared with bio-reductive hypoxic marker binding (pimonidazole) in three human tumor 
xenograft lines.
The strong correlation between hypoxic marker binding and pO2 indicates the validity of the 
OxyLite™ pO2 measurements. The two methods are complementary and the combination of 
a bio-reductive hypoxic cell marker, for global assessment of tumor hypoxia and analysis of 
temporal changes in pO2, with the OxyLite™ may be helpful to select patients on an 
individual basis for oxygenation modifying treatments.
C hapter 6.
The effect of nicotinamide and carbogen on tumor oxygenation in xenografts measured with 
a time-resolved luminescence-based optical sensor
Temporal changes in pO2 resulting from carbogen breathing and nicotinamide were further 
analyzed in three human xenograft tumor lines with the OxyLite™ system.
Half of the tumors showed an increase in pO2 after nicotinamide administration. Increase in 
pO2 during carbogen breathing was less pronounced at tumor positions where low pO2- 
values were measured. After pre-treatment with nicotinamide a trend towards a faster 
response to carbogen breathing was found in all three lines. The combination of continuous 
pO2 measurements and bio-reductive hypoxia marker binding makes it possible to quantitate 
absolute changes in tumor pO2 together with analysis of hypoxia at the microscopic level of 
oxygenation modifying treatments in tumors.
C hapter 7
Changes in blood perfusion and hypoxia after irradiation of a human squamous cell 
carcinoma xenograft tumor line
Vasculature, perfusion and hypoxia were studied in a human laryngeal squamous cell 
carcinoma xenograft line after a single dose of 10 Gy X-rays.
An initial increase in the percentage of perfused blood vessels was followed by a significant 
decrease at 26 h after irradiation with a subsequent increase again to control levels after 7 to
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11 days. The hypoxic fraction showed a decrease at 7 h after treatment followed by a 
gradual increase over the subsequent 11 days.
These experiments showed that irradiation causes rapid changes in tumor hypoxia and tumor 
blood perfusion, which may have consequences for the optimal timing of radiotherapy 
schedules employing multiple fractions per day and the introduction of oxygenation and 
perfusion modifying drugs.
C onclusion
An experimental treatment combining accelerated radiotherapy with carbogen breathing and 
nicotinamide was successfully explored in head and neck cancer patients. This therapy is 
aiming to reduce the negative effect of tumor cell repopulation during radiotherapy and to 
reduce radio-resistance caused by tumor cell hypoxia. Assays were developed and tested to 
quantitate the effects of this treatment strategy on the tumor microenvironment in relation to 
tumor tissue architecture. Human tumors transplanted as xenografts in nude mice were used 
as tumor models. Bio-reductive hypoxic cell markers were used to analyze changes in the 
hypoxic fraction. BrdUrd was used to analyze the tumor cell proliferation status and tumor 
blood perfusion was studied with the perfusion marker Hoechst 33342. The 
microenvironmental effects of carbogen breathing, nicotinamide administration and 
irradiation were quantitated. A newly developed oxygen sensor was used to quantitate 
temporal changes in tumor pO2 . Differences in microenvironmental responses with respect 
to the various parameters between the tumor lines were described. The combination of 
parameters based on hypoxic cell markers, proliferation markers and perfusion markers 
analyzed with an image analysis system and pO2 measurements with the OxyLite™ may be 
helpful to select patients for treatment intensification. Future work will be directed towards 
the clinical application of the techniques that were described in this thesis.
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H oofdstuk 1
Inleiding
De drie belangrijkste mechanismen die ervoor kunnen zorgen dat radiotherapie faalt zijn 
intrinsieke stralenresistentie, snelle tumorcelproliferatie en tumorcelhypoxie.
Intrinsieke stralenresistentie doelt op de verschillen die bestaan tussen tumoren van 
verschillende histologische categorieën en binnen verschillende histologische categorieën 
met betrekking tot clonogeniciteit na bestraling. Het onderscheid tussen deze tumorgroepen 
is voornamelijk gebaseerd op celoverlevingsonderzoek na bestraling. Om het negatieve 
effect van intrinsieke stralenresistentie op lokale en regionale tumorcontrole te beperken, 
moet het effect van bestraling worden versterkt. Dit kan worden bereikt door gebruik te 
maken van dosisescalatie in combinatie met bijvoorbeeld hyperfractionering of door gebruik 
te maken van stoffen die het effect van radiotherapie versterken (radiosensitiserende 
stoffen).
Het tweede mechanisme: snelle tumorcelproliferatie, verwijst naar het verlies van effectiviteit 
van radiotherapie naarmate de totale behandelingstijd toeneemt. Het is in verschillende 
studies aangetoond dat de lokale en regionale tumorcontrole toeneemt als de totale 
behandelingstijd afneemt. De proliferatiesnelheid kan worden onderzocht door gebruik te 
maken van het aankleuren van delende cellen met bijvoorbeeld bromodeoxyuridine 
(BrdUrd). De fractie delende cellen kan worden bepaald met behulp van microscopie of 
flowcytometrie. Uit de fractie delende cellen kan vervolgens de proliferatiesnelheid worden 
berekend.
Tumorcelhypoxie, het derde mechanisme, heeft betrekking op het verschijnsel dat 
hypoxische cellen ongevoeliger zijn voor bestraling dan goed geoxygeneerde cellen. 
Modificaties van de behandeling met als doel de invloed van tumorcelhypoxie te 
verminderen, hebben een toename van de lokale en regionale tumorcontrole laten zien. Het 
effect van radioresistentie door tumorcelhypoxie kan op meerdere manieren worden 
gereduceerd. Reductie van het aantal hypoxische cellen kan worden bereikt door het 
toedienen van stoffen die hypoxische cellen gevoeliger maken voor radiotherapie ('hypoxic 
cell sensitisers'), door het verbeteren van de doorbloeding van tumoren met vaso-actieve 
stoffen of door het aanbieden van zuurstofverrijkte gasmengsels. Er zijn diverse methoden 
beschikbaar om tumorcelhypoxie te meten. Dit kan bijvoorbeeld met behulp van bio- 
reduceerbare chemische stoffen, magnetische resonantie (MR) technieken en polarografische 
meting van de zuurstofspanning dan wel door middel van meting van de zuurstofspanning 
met behulp van glasvezelsensoren.
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H oofdstuk 2
Klinische resultaten van versneld gefractioneerde radiotherapie in combinatie met het 
ademen van carbogeen en inname van nicotinamide
Dierexperimentele studies hebben een bijna tweevoudige toename van de lokale 
tumorcontrole aangetoond als versneld gefractioneerde radiotherapie werd gegeven in 
combinatie met het ademen van carbogeen (95% O2, 5% CO2) en inname van nicotinamide 
in vergelijking met conventionele radiotherapie. Bij de klinische toepassing van deze 
behandeling wordt repopulatie van clonogene tumorcellen tijdens de bestraling tegengegaan 
door de totale behandelingstijd te verkorten van 7 naar 5.5 week. Tumorcelhypoxie wordt 
verminderd door enerzijds inname van nicotinamide om hypoxie door verminderde perfusie 
te bestrijden en anderzijds door het ademen van carbogeen ter beperking van diffusie 
gelimiteerde hypoxie (ARCON, accellerated radiotherapy met carbogeen en nicotinamide).
In deze klinisch studie werden in totaal 124 patiënten met een stadium III of IV 
plaveiselcelcarcinoom van het hoofd- en halsgebied volgens deze strategie behandeld. Voor 
larynxcarcinomen was de lokale en regionale controle 85%, voor hypofarynxcarcinomen 
was dit 50% en voor mondholte- en orofarynxcarcinomen 65%.
H oofdstuk 3
Ontwikkeling van een systeem voor het gelijktijdig analyseren van vasculatuur, perfusie en 
proliferatie in humane tumorlijnen
Ondanks de goede lokale en regionale tumorcontrole die werd bereikt in de ARCON-studie 
waren er toch nog patiënten die een lokaal en/of regionaal tumorrecidief ontwikkelden. Dit, 
tezamen met de toegenomen acute toxiciteit, gaf de aanzet tot de ontwikkeling en 
standaardisatie van een onderzoeksmethode voor selectie van patiënten voor deze 
combinatiebehandeling. Bij deze onderzoeksmethode werd in weefselcoupes gelijktijdig de 
vaatarchitectuur, de bloeddoorstroming en de tumorcelproliferatie onderzocht.
Weefselcoupes van humane larynxcarcinomen en glioblastomen, getransplanteerd in 
athymische muizen, werden in zijn geheel geanalyseerd. Injectie van Hoechst 33342 werd 
gebruikt om de geperfundeerde bloedvaten aan te kleuren en BrdUrd werd gebruikt om de 
prolifererende cellen te markeren. Tenslotte werd een antilichaam gericht tegen 
muizenendotheel (9F1) gebruikt om de bloedvaten zichtbaar te maken.
De coupes werden geanalyseerd met behulp van een meerstaps immunohistochemische 
kleuring in combinatie met een beeldanalysesysteem voor bestudering van microscopische 
coupes. De analyse van de proliferatie is gebaseerd op de fractie van het totale
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tumorcelkernoppervlak dat positief is voor BrdUrd. Vergelijking van het handmatig tellen 
van BrdUrd-positieve cellen onder de microscoop met deze analyse en vergelijking van op 
flowcytometrie gebaseerde proliferatie partamers met genoemde analyse lieten beide een 
goede correlatie zien. De aldus bepaalde proliferatie-index nam af bij toenemende afstand 
van het meest nabij gelegen bloedvat. In de nabijheid van geperfundeerde bloedvaten was de 
proliferatie-index 30% tot 70% hoger dan in de nabijheid van niet geperfundeerde 
bloedvaten.
H oofdstuk 4
Vaatarchitectuur en het micromilieu van tumorlijnen afkomstig van humane 
plaveiselcelcarcinomen: effecten van het ademen van carbogeen en toediening van 
nicotinamide
Het protocol, genoemd in hoofdstuk 3, werd uitgebreid om ook de invloed van 
zuurstofmodificatie te bestuderen. Tumorcelhypoxie werd aangetoond met behulp van een 
stof die alleen onder hypoxische condities biochemisch kan worden gereduceerd (NITP). 
Het effect van carbogeen en nicotinamide werd in twee verschillende tumorlijnen 
bestudeerd. Deze tumorlijnen waren afkomstig van humane larynxcarcinomen en werden 
getransplanteerd in athymische muizen. In één van de twee lijnen nam de bloeddoorstroming 
onder invloed van carbogeen af. Dit kon echter weer worden tegengegaan door nicotinamide 
toediening. Beide tumorlijnen lieten een afname van de tumorcelproliferatie zien na 
carbogeen. Bij beide tumorlijnen werd een drastische afname van de hypoxie gevonden na 
het ademen van carbogeen alleen en ook na carbogeenademen in combinatie met 
nicotinamide toediening.
Het feit dat er duidelijke verschillen werden gevonden in het micromilieu van twee 
tumorlijnen met vergelijkbare histologie en herkomst, onder invloed van carbogeen en 
nicotinamide, vormt de basis voor de verdere ontwikkeling van methoden om ook bij 
individuele patiënten het effect van hypoxie reducerende behandelingen te testen.
H oofdstuk 5
Meting van zuurstofspanning met behulp van een optische sensor komt overeen met 
hypoxische merkstofbinding in drie humane tumorlijnen
Door het gebruik van een optische sensor kunnen absolute veranderingen in de 
zuurstofspanning (pO2) worden gemeten. Deze methode werd vergeleken met hypoxische 
merkstofbinding (pimonidazol). De recent ontwikkelde zuurstofsensor OxyLite™ werd 
vergeleken met pimonidazolbinding in drie humane tumorlijnen getransplanteerd in 
athymische muizen.
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Er werd een sterke correlatie gevonden tussen de twee methoden hetgeen de validiteit van de 
OxyLite™-methode aangeeft. De twee gebruikte methoden voor het bepalen van de 
oxygenatiegraad van tumoren zijn duidelijk complementair. De hypoxische merkstoffen 
kunnen worden gebruikt voor globale analyse van hypoxie binnen tumoren. Veranderingen 
van de pO2 in de tijd kunnen daarentegen worden gemeten met de OxyLite™.
H oofdstuk 6
Het effect van het ademen van carbogeen en toediening van nicotinamide op de 
zuurstofspanning van humane tumorlijnen gemeten met op luminiscentie gebaseerde 
zuurstofsensoren
Veranderingen in pO2-waarden, veroorzaakt door carbogeen en nicotinamide, werden 
geanalyseerd in drie humane tumorlijnen met behulp van de OxyLite™. Bij de helft van de 
tumoren was er een lokaal meetbare toename van de pO2 na toediening van nicotinamide. Na 
het starten van carbogeen werd er een zeer snelle en sterke toename van de pO2 gevonden. 
De toename van de pO2 tijdens carbogeen was echter minder uitgesproken in tumorgebieden 
met initieel lage pO2-waarden. Er werd een trend gevonden die liet zien dat de stijging van 
de pO2 in reactie op het ademen van carbogeen sneller optrad wanneer dit werd 
voorafgegaan door nicotinamide toediening. De combinatie van continue pO2-meting en het 
gebruik van hypoxische merkstoffen maakt het mogelijk om het effect van 
zuurstofmodificerende behandelingen op de pO2 in tumorweefsel te kwantificeren tezamen 
met analyse van hypoxie op microscopisch niveau.
H oofdstuk 7
Verandering in doorbloeding en hypoxie na bestraling van een tumorlijn afkomstig van een 
humaan plaveiselcelcarcinoom
Het effect van bestraling hangt af van de oxygenatiegraad van het weefsel dat wordt 
bestraald terwijl radiotherapie zelf ook veranderingen in oxygenatie en doorbloeding van 
weefsels induceert.
Vaatarchitectuur, doorbloeding en hypoxie werden bestudeerd in een tumorlijn afkomstig 
van een humaan plaveiselcelcarcinoom van de larynx na een eenmalige bestraling met 10 Gy 
röntgenstraling.
Binnen enkele uren na de bestraling werd er een toename van geperfundeerde bloedvaten 
gevonden. Dit werd gevolgd door een significante daling 26 uur na de bestraling, 
vervolgens was er weer een geleidelijke toename van de geperfundeerde vaten. Zeven tot elf 
dagen na de bestraling was de doorbloeding weer gestegen tot het niveau van onbehandelde 
tumoren. Ook de fractie hypoxische tumorcellen nam af na bestraling waarbij al na 7 uur de
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laagste hoeveelheid hypoxie werd gemeten. Dit werd echter weer gevolgd door een toename 
van de hypoxie. Bij de laatste meting, 11 dagen na de bestraling, was de hypoxie gestegen 
tot boven het uitgangsniveau.
Deze experimenten laten zien dat bestraling snelle veranderingen in oxygenatie en 
doorbloeding in tumoren kan veroorzaken. Dit heeft mogelijk consequenties voor optimale 
planning van bestralingsschemata die gebruik maken van meerdere bestralingsfracties per 
dag. Daarnaast kunnen de uitkomsten van deze experimenten consequenties hebben voor het 
optimaliseren van behandelingen die gericht zijn op het reduceren van tumorcelhypoxie en 
het stimuleren van de tumordoorbloeding met name indien dit wordt toegepast in combinatie 
met radiotherapie.
C onclusie
In dit proefschrift zijn de resultaten getoond van een klinische studie die een zeer goede 
lokale en regionale tumorcontrole liet zien na behandeling met de combinatie van versneld 
gegeven radiotherapie, het ademen van carbogeen en inname van nicotinamide bij patiënten 
met een hoofd- en halstumor. Deze behandeling is gericht op het tegengaan van 
tumorcelrepopulatie tijdens de bestraling en het reduceren van tumorcelhypoxie. Er werden 
methoden ontwikkeld om de effecten van het ademen van carbogeen en toediening van 
nicotinamide in tumoren te kwantificeren. Humane tumoren, getransplanteerd in athymische 
muizen, werden gebruikt als tumormodel. Met behulp van merkstoffen en 
immunohistochemische technieken werd de vaatarchitectuur in combinatie met de 
tumordoorbloeding, hypoxische celfractie en tumorcelproliferatie op microscopisch niveau 
geanalyseerd met een beeldverwerkingssysteem. Een nieuw type zuurstofsensor werd 
gebruikt om absolute verandering van de tumor-pO2 te meten. Na behandeling met 
nicotinamide en het ademen van carbogeen was er niet alleen sprake van een zeer sterke 
afname van de tumorcelhypoxie, maar er waren ook effecten op de tumorcelproliferatie en 
op de bloeddoorstroming van de tumoren. Deze veranderingen in het micromilieu in reactie 
op bestraling, het ademen van carbogeen en inname van nicotinamide zijn in dit proefschrift 
beschreven.
Ter bestudering van het micromilieu van tumoren kan een combinatie van parameters 
gebruikt worden die gebaseerd is op tumorcelhypoxie, tumorcelproliferatie en 
tumordoorbloeding tezamen met directe pO2-metingen. In de toekomst kan het 
gebruikmaken van deze combinatie hulp bieden bij de selectie van patiënten voor nieuwe 
behandelingsstrategieën.
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